STOCK TITAN

VSee Health has $41.7K cash, flags going-concern doubt

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
10-Q

Rhea-AI Filing Summary

VSee Health, Inc. (VSEE), which provides telehealth physician services through iDoc, reported nine-month continuing-operations revenue of $4.94 million, versus $4.57 million a year earlier. Cost of revenue rose to $3.69 million from $2.01 million, and the continuing-operations net loss widened to $7.19 million from $5.59 million. Third-quarter revenue was $1.50 million, down from $2.32 million, and quarterly net loss was $2.85 million versus $289,745.

Cash was $41,666 at September 30, while operating cash outflow from continuing operations was $3.00 million for the nine months. Management said liquidity and historical losses raise substantial doubt about the company’s ability to continue as a going concern for at least one year after issuance of the statements. It is negotiating additional financing, but said there is no assurance its plans will succeed.

VSee Health sold VSee Lab on May 31, 2026, to Milton Chen, its former co-CEO and chairman, and recorded a $4.17 million gain on the discontinued operation. It also reported three notes in default for late payment, with balances of $1.50 million, $33,000 and $64,000.

2 points · 1 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

3 major · 4 points

How the balance works

Positive

  • Major pointVSee Lab sale generated a $4.17 million gain on discontinued operations.
  • Moderate pointNine-month continuing-operations revenue rose to $4.94 million from $4.57 million.

Negative

  • Major pointManagement disclosed substantial doubt about continuing as a going concern for at least one year.
  • Major pointNine-month continuing-operations loss widened to $7.19 million from $5.59 million.
  • Major pointThree notes with balances of $1.50 million, $33,000 and $64,000 were in default for late payment.
  • Moderate pointThird-quarter revenue fell to $1.50 million from $2.32 million.

Filing Explained

VSee Health agreed to acquire about 10% of GoMyRx for $2 million and had funded $749,800 by September 30, 2026, including $100,000 in cash and 22,500 newly issued shares; issuing those shares increases the share count and reduces existing holders’ percentage ownership.

Continuing-operations revenue $4.94 million Nine months ended September 30, 2026; $4.57 million in 2025
Third-quarter revenue $1.50 million Three months ended September 30, 2026; $2.32 million in 2025
Continuing-operations loss $7.19 million Nine months ended September 30, 2026; $5.59 million in 2025
Net loss $4.60 million Nine months ended September 30, 2026; $6.86 million in 2025
Cash $41,666 September 30, 2026
Operating cash used by continuing operations $2.997 million Nine months ended September 30, 2026; $1.125 million in 2025
Gain on sale of discontinued operations $4.169 million Nine months ended September 30, 2026
Balances of notes in default for late payment $1.50 million, $33,000 and $64,000 As of September 30, 2026
going concern financial
"substantial doubt about the Company’s ability to continue as a going concern"
Going concern is the accounting assumption that a company will keep operating and meeting its obligations for the foreseeable future. The phrase matters most when a company or its auditors disclose substantial doubt about it, a formal warning that the business may not have enough resources to continue without raising money, restructuring, or selling assets. That language in a filing or press release signals elevated financial risk.
discontinued operations financial
"presented as discontinued operations in the accompanying condensed consolidated financial statements"
Discontinued operations are parts of a company that it has decided to sell or shut down, and no longer plans to run in the future. This matters to investors because it helps them understand which parts of the business are ongoing and which are being phased out, providing a clearer picture of the company’s current performance and future prospects. Think of it like a store closing a department—it no longer contributes to sales or profits.
allowance for credit losses financial
"allowance for credit losses was $1,902,156"
Allowance for credit losses is a reserve set aside by a financial institution to cover potential losses from borrowers who may not repay their loans. It acts like a safety net, helping the institution prepare for loans that might turn sour. For investors, it signals how cautious the institution is about the quality of its loans and potential risks to its financial health.
original issue discount financial
"10.00% original issue discount promissory note"
Original issue discount (OID) is the difference between a debt security’s face value and the lower price at which it is first sold, treated as additional interest that accrues over the life of the instrument. For investors it matters because OID raises the effective yield and changes taxable income and the holding’s cost basis over time — think of buying a $100 voucher for $90 and recognizing the $10 gain as earned interest as the voucher approaches maturity.
SEPA liability financial
"June 2026 SEPA liability"
reverse stock split financial
"implemented a 1-for-80 reverse split on outstanding shares of common stock"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much revenue did VSEE report for the first nine months of 2026?

VSee Health reported $4.94 million of continuing-operations revenue for the nine months ended September 30, 2026, compared with $4.57 million in the 2025 period. The 2026 total included $2.09 million in patient fees and $2.85 million in telehealth fees.

Which VSEE notes were in default for late payment?

VSee Health reported three notes in default for late payment: a $1,500,600 note issued by iDoc in December 2021, and notes with balances of $33,000 and $64,000 issued in August 2023. The two August 2023 notes were classified as current liabilities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 10-Q

 

 

 

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2026

 

or

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from to

 

Commission File Number: 001-41015

 

VSee Health, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware 86-2970927
(State or other jurisdiction of
incorporation or organization)
 (I.R.S. Employer
Identification Number)

 

980 N Federal Hwy

Suite 304

Boca Raton, FL 33432

(Address of Principal Executive Offices)

 

(754) 231-1688

(Registrant’s telephone number)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class Trading symbol Name of Exchange on which registered
Common Stock, par value $0.0001 per share VSEE OTC
     
Warrants, which entitles the holder to purchase one (1) share of common stock at a price of $920.00 per whole share VSEEW OTC

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large, accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large, accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large, accelerated filer☐Accelerated filer☐  
      
Non-accelerated filer☒Smaller reporting company☒Emerging growth company☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

As of November 15, 2026, there were 876,837 of the registrant’s common stock outstanding.

 

 

 

 

 

TABLE OF CONTENTS

   Page
    
Part IFinancial Information 1
    
Item 1.Financial Statements 1
    
 Condensed Consolidated Balance Sheets as of September 30, 2026 (Unaudited) and December 31, 2025 1
    
 Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2026 and 2025 (Unaudited) 2
    
 Condensed Consolidated Statements of Stockholders’ Equity (Deficit) for the three and nine months ended September 30, 2026 and 2025 (Unaudited) 3
    
 Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2026 and 2025 (Unaudited) 5
    
 Notes to Condensed Consolidated Financial Statements (Unaudited) 6
    
Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations 43
    
Item 3.Quantitative and Qualitative Disclosures about Market Risk 50
    
Item 4.Controls and Procedures 50
    
Part IIOther Information 52
    
Item 1.Legal Proceedings 52
    
Item 1A.Risk Factors 52
    
Item 2.Unregistered Sales of Equity Securities and Use of Proceeds 52
    
Item 3.Defaults Upon Senior Securities 53
    
Item 4.Mine Safety Disclosures 53
    
Item 5.Other Information 53
    
Item 6.Exhibits 53
    
Exhibit Index 53
    
Signatures 54

i

Table of Contents

  

As used in this Quarterly Report on Form 10-Q, unless otherwise indicated, VSee Health, Inc., together with its consolidated subsidiaries, is hereinafter referred to as “VSee Health,” the “Registrant,” “us,” “we,” “our” or the “Company.”

Cautionary Note on Forward-Looking Statements

This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements appear in a number of places in this Form 10-Q including, without limitation, in the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations”. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. Forward-looking statements are typically identified by words such as “plan,” “believe,” “expect,” “anticipate,” “intend,” “outlook,” “estimate,” “forecast,” “project,” “continue,” “could,” “may,” “might,” “possible,” “potential,” “predict,” “should,” “would” and other similar words and expressions, but the absence of these words does not mean that a statement is not forward-looking.

The forward-looking statements are based on the current expectations of our management and are inherently subject to uncertainties and changes in circumstances and their potential effects and speak only as of the date of such statement. There can be no assurance that future developments will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties or other assumptions that may These risks and uncertainties include, but are not limited to, those factors described in “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, filed by us with the Securities and Exchange Commission (“SEC”).

These and other factors could cause actual results to differ from those implied by the forward-looking statements. Forward-looking statements are not guarantees of performance and speak only as of the date hereof. The forward-looking statements are based on the current and reasonable expectations of our management but are inherently subject to uncertainties and changes in circumstances and their potential effects and speak only as of the date of such statements. There can be no assurance that future developments will be those that have been anticipated or that we will achieve or realize these plans, intentions or expectations.

All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing cautionary statements. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

In addition, statements of belief and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this filing, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to unduly rely upon these statements.

ii

Table of Contents

  

PART I —FINANCIAL INFORMATION

Item 1. Financial Statements

VSEE HEALTH, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

   September 30,
2026
   December 31,
2025
 
   (Unaudited)     
ASSETS        
Current assets        
Cash  $41,666   $5,051,445 
Accounts receivable, net of allowance for credit losses of $1,902,156 and $835,007 as of September 30, 2026, and December 31, 2025, respectively   2,174,188    2,241,247 
Due from related party   319,690    304,614 
Prepaids and other current assets   279,768    141,203 
Current assets from discontinued operations   -    626,898 
Total current assets   2,815,312    8,365,407 
           
Non-current assets          
Long-term investments   749,800    - 
Right-of-use assets, net   5,690    13,304 
Intangible assets, net   7,127,506    8,785,000 
Goodwill   4,916,694    4,916,694 
Fixed assets, net   91,170    294,987 
Non-Current assets from discontinued operations   -    37,627 
Total assets  $15,706,172   $22,413,019 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current liabilities          
Accounts payable and accrued liabilities  $7,429,784   $9,330,442 
Due to related party   51,900    51,900 
Operating lease liabilities   5,690    10,394 
Financing lease liabilities   -    131,062 
Encompass Purchase Liability   400,000    650,000 
Convertible notes   1,429,660    713,128 
Loan payable, related party, net of discount   141,651    141,651 
Line of credit   -    456,097 
Notes payable, net of discount   125,758    880,175 
Common stock issuance obligation   1,440    18,941 
Current liabilities from discontinued operations   -    3,860,818 
Total current liabilities   9,585,883    16,244,608 
           
Non-current liabilities          
Notes payable, less current portion, net of discount   781,581    593,941 
SEPA liability   206,663    - 
Operating lease liabilities, less current portion   -    2,910 
Deferred tax liabilities, net   119,192    119,192 
Total liabilities  $10,693,319   $16,960,651 
           
Commitments and Contingencies (Note 11)          
           
STOCKHOLDERS' EQUITY          
Preferred stock, par value $0.0001; authorized 10,000,000 shares:   
 
    
 
 
Series A Preferred stock, $0.0001 par value, 6,500 shares designated; 122 and 1,788 shares issued and outstanding as of September 30, 2026, and December 31, 2025, respectively   1    1 
Series B Preferred stock, $0.0001 par value, 2,000 shares designated; 0 shares issued and outstanding as of September 30, 2026, and December 31, 2025, respectively   -    - 
Common stock, $0.0001 par value; 100,000,000 shares authorized; 806,078 and 414,995 shares issued and outstanding as of September 30, 2026, and December 31, 2025, respectively   81    42 
Additional paid-in capital   92,031,184    87,869,048 
Accumulated deficit   (87,018,413)   (82,416,723)
Total stockholders' equity   5,012,853    5,452,368 
Total liabilities and stockholders’ equity  $15,706,172   $22,413,019 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

1

Table of Contents

 

VSEE HEALTH, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2026, AND 2025 (UNAUDITED)

   For the Three Months Ended   For the Nine Months Ended 
   September 30,   September 30, 
   2026   2025   2026   2025 
Revenues                
Patient fees  $604,464   $882,529   $2,086,896   $2,069,565 
Telehealth fees   892,315    1,436,393    2,851,060    2,499,662 
Institutional fees   -    -    -    2,500 
Total revenues   1,496,779    2,318,922    4,937,956    4,571,727 
Cost of revenues   1,186,100    1,187,296    3,693,712    2,014,819 
Gross margin   310,679    1,131,626    1,244,244    2,556,908 
                     
Operating expenses                    
Compensation and related benefits   447,350    416,528    1,345,866    1,357,571 
General and administrative   2,033,147    2,535,231    6,425,055    6,122,603 
Total operating expenses   2,480,497    2,951,759    7,770,921    7,480,174 
                     
Net operating loss   (2,169,818)   (1,820,133)   (6,526,677)   (4,923,266)
                     
Other income (expense)                    
Interest expense   (67,503)   (745,965)   (240,146)   (1,662,939)
Other income (expense), net   -    (5)   -    172,709 
Change in fair value of financial instruments   (150,403)   2,828,647    (182,504)   1,412,351 
(Loss)/Gain on extinguishment of financial liabilities   (296,689)   -    71,120    (126,125)
Loss on issuance of financial instruments   (164,288)   (305,000)   (309,462)   (443,020)
Total other income (expense), net   (678,883)   1,777,677    (660,992)   (647,024)
                     
Loss from continuing operations before provision for income taxes   (2,848,701)   (42,456)   (7,187,669)   (5,570,290)
                     
Provision for income taxes for continuing operations   -    -    (5,260)   (15,233)
                     
Loss from continuing operations, net of tax  $(2,848,701)  $(42,456)  $(7,192,929)  $(5,585,523)
                     
(Loss) income from discontinued operations before provision for income taxes   -    (247,289)   2,594,574    (1,274,189)
                     
Provision for income taxes for discontinuing operations   -    -    (3,335)   (2,756)
                     
(Loss) income from discontinued operations, net of tax  $-   $(247,289)  $2,591,239   $(1,276,945)
                     
Net loss  $(2,848,701)  $(289,745)  $(4,601,690)  $(6,862,468)
                     
Basic and diluted loss per common share- continuing operations  $(3.88)  $(0.21)  $(10.68)  $(27.20)
Basic and diluted loss per common share  $(3.88)  $(1.40)  $(6.83)  $(33.42)
                     
Weighted average number of common shares outstanding, basic and diluted - continuing operations *   734,931    206,867    673,496    205,369 
Weighted average number of common shares outstanding, basic and diluted   734,931    206,867    673,496    205,369 

 

*Shares outstanding have been restated for the 1-for-80 reverse stock split effective September 22, 2026. See Note 2 – “Summary of Significant Accounting Policies”.

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

2

Table of Contents

 

VSEE HEALTH, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT) *

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2026

   Series A Preferred Stock   Series B Preferred Stock   Common Stock   Additional Paid-   Accumulated   Total Stockholders' 
   Shares   Amount   Shares   Amount   Shares   Amount   In Capital   Deficit   Equity 
Balance - December 31, 2025   1,788   $1    -   $-    414,995   $42   $87,869,048   $(82,416,723)  $5,452,368 
Net loss for the three months ended March 31, 2026- Continuing operations   -    -    -    -    -    -    -    (1,263,786)   (1,263,786)
Net loss for the three months ended March 31, 2026- Discontinued operations   -    -    -    -    -    -    -    (1,336,476)   (1,336,476)
Shares issued on the exercise of pre-funded warrants   -    -    -    -    64,213    6    508    -    514 
Shares issued on conversion of preferred stock   (1,366)   -    -    -    8,539    1    (1)   -    - 
Shares issued as part of stock grants to vendors   -    -    2,000    1    37,500    4    1,573,795    -    1,573,800 
Stock based compensation   -    -    -    -    32,761    3    945,502    -    945,505 
Shares issued during the period   -    -    -    -    33,315    3    949,142    -    949,145 
Balance - March 31, 2026   422   $1    2,000   $1    591,323   $59   $91,337,994   $(85,016,985)  $6,321,070 
                                              
Net loss for the three months ended June 30, 2026- Continuing operations   -    -    -    -    -    -    -    (3,080,442)   (3,080,442)
Net income for the three months ended June 30, 2026- Discontinued operations   -    -    -    -    -    -    -    3,927,715    3,927,715 
Shares issued on conversion of Series A preferred stock   (300)   -    -    -    1,875    -    -    -    - 
Shares issued on conversion of Series B preferred stock   -    -    (2,000)   (1)   16,250    2    (1)   -    - 
Repurchase of common stock in connection with sale of VSee Labs (Refer Note 3)   -    -    -    -    (35,876)   (4)   (545,309)   -    (545,313)
Shares issued on conversion of Quantum loan   -    -    -    -    34,324    3    521,718    -    521,721 
Shares issued on exercise of pre - funded warrants   -    -    -    -    58,738    6    464    -    470 
Stock based compensation   -    -    -    -    29,444    3    447,551    -    447,554 
Balance - June 30, 2026   122   $1    -   $-    696,078   $69   $91,762,417   $(84,169,712)  $7,592,775 
                                              
Net loss for the three months ended September 30, 2026- Continuing operations   -    -    -    -    -    -    -    (2,848,701)   (2,848,701)
Shares issued on settlement of ADI convertible note   -    -    -    -    6,250    1    45,499    -    45,500 
Shares issued on settlement of M2B convertible note   -    -    -    -    6,250    1    45,499    -    45,500 
Shares issued as commitment fees to Strata SEPA liability (Refer Note 9)   -    -    -    -    40,000    4    67,996    -    68,000 
Shares issued to vendor   -    -    -    -    57,500    6    109,773    -    109,779 
Balance - September 30, 2026   122   $1    -   $-    806,078   $81   $92,031,184   $(87,018,413)  $5,012,853 

 

*Shares outstanding have been restated for the 1-for-80 reverse stock split effective September 22, 2026. See Note 2 – “Summary of Significant Accounting Policies”.

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 

3

Table of Contents

 

VSEE HEALTH, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT) *

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2025

   Series A Preferred Stock   Series B Preferred Stock   Common Stock   Additional Paid-   Accumulated   Total Stockholders' 
   Shares   Amount   Shares   Amount   Shares*   Amount   In Capital   Deficit   Deficit 
Balance - December 31, 2024   6,158   $1    -   $-    203,715   $20   $67,685,364   $(67,703,873)  $(18,488)
Net loss for the three months ended March 31, 2025- Continuing operations   -    -    -    -    -    -    -    (3,639,134)   (3,639,134)
Net loss for the three months ended March 31, 2025- Discontinued operations   -    -    -    -    -    -    -    (320,306)   (320,306)
Payment to shareholder   -    -    -    -    -    -    (10,000)   -    (10,000)
Issuance during the period   -    -    -    -    1,563    -    90,634    -    90,634 
Share based compensation   -    -    -    -    -    -    400,297    -    400,297 
Balance - March 31, 2025   6,158   $1    -   $-    205,278   $20   $68,166,295   $(71,663,313)  $(3,496,997)
                                              
Net loss for the three months ended June 30, 2025- Continuing operations   -    -    -    -    -    -    -    (1,903,933)   (1,903,933)
Net loss for the three months ended June 30, 2025- Discontinued operations   -    -    -    -    -    -    -    (709,350)   (709,350)
Issuance during the period   -    -    -    -    6    -    -    -    - 
Share based compensation   -    -    -    -    -    -    373,977    -    373,977 
Balance - June 30, 2025   6,158   $1    -   $-    205,284   $20   $68,540,272   $(74,276,596)  $(5,736,303)
                                              
Net loss for the three months ended September 30, 2025- Continuing operations   -    -    -    -    -    -    -    (42,456)   (42,456)
Net loss for the three months ended September 30, 2025- Discontinued operations   -    -    -    -    -    -    -    (247,289)   (247,289)
Issuance during the period   -    -    -    -    7,500    1    450,549    -    450,550 
Balance - September 30, 2025   6,158   $1    -   $-    212,784   $21   $68,990,821   $(74,566,341)  $(5,575,498)

 

*Shares outstanding have been restated for the 1-for-80 reverse stock split effective September 22, 2026. See Note 2 – “Summary of Significant Accounting Policies”.

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

4

Table of Contents

 

VSEE HEALTH, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2026

   For the Nine Months Ended 
   September 30, 
   2026   2025 
CASH FLOWS FROM OPERATING ACTIVITIES:        
Net loss  $(4,601,690)  $(6,862,468)
Less: Net (income)/loss from discontinued operations   (2,591,239)   1,276,945 
Net loss from continuing operations  $(7,192,929)  $(5,585,523)
           
Adjustments to reconcile net loss from continuing operations to net cash used in operating activities:          
Allowance for expected credit losses   1,132,043    521,098 
Depreciation and amortization   1,863,599    1,933,764 
Stock-based compensation   643,861    764,036 
Amortization of right-of-use assets   7,614    63,906 
Loss on issuance of financial instruments   309,462    443,020 
Change in fair value of financial instruments   182,504    (1,412,351)
(Gain)/Loss on extinguishment of financial liabilities   (71,120)   126,125 
Changes in operating assets and liabilities:          
Accounts receivable   (1,064,984)   (2,055,815)
Due from related party   (15,076)   247,042 
Prepaids and other current assets   (138,565)   74,940 
Accounts payable and accrued liabilities   1,354,531    3,807,829 
Operating lease liabilities   (7,614)   (52,910)
Net cash used in operating activities - continuing operations   (2,996,674)   (1,124,839)
Net cash used in operating activities - discontinued operations   (1,067,080)   (394,793)
Net cash used in operating activities  $(4,063,754)  $(1,519,632)
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
Purchase of fixed assets   (2,288)   - 
Purchase of long-term investments   (100,000)   - 
Net cash used in investing activities - continuing operations   (102,288)   - 
Net cash used in investing activities - discontinued operations   (83,287)   (22,776)
Net cash used in investing activities  $(185,575)  $(22,776)
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Repayment of notes payable   (969,864)   (668,092)
Proceeds from notes issued during the period   157,500    1,907,791 
Payments on factoring payable   -    (56,787)
Payment to shareholder   -    (10,000)
Proceeds from issuance of common stock   -    541,184 
Proceeds from pre-funded warrants, net of issuance costs   984    - 
Proceeds from convertible notes issued during the period   1,041,000    - 
Payments due on acquisition purchase   -    (44)
Payments on financing lease liability   (591,118)   (25,000)
Payments on Encompass Purchase liability   (50,000)   - 
Repayment of line of credit   (348,952)   - 
Net cash (used in) provided by financing activities- continuing operations   (760,450)   1,689,052 
Net cash used in financing activities- discontinued operations   -    - 
Net cash (used in) provided by financing activities  $(760,450)  $1,689,052 
           
NET CHANGE IN CASH   (5,009,779)   146,644 
Cash, Beginning of Period   5,051,445    326,115 
CASH, END OF THE PERIOD  $41,666   $472,759 
           
Supplemental disclosure of cash flow information:          
Cash paid for interest expense  $127,084   $282,281 
Cash paid for income taxes  $-   $- 
Non-cash investing and financing activities:          
Common stock issued on conversion of May 2025 Convertible Note  $299,348   $- 
Common stock issued on conversion of Quantum note  $521,721   $- 
Common stock issued to settle directors’ compensation payable  $60,762   $- 
Common stock issued to settle executives’ compensation payable  $555,457   $- 
Common stock issued to settle employees and consultants’ compensation payable  $776,842   $- 
Common stock issued as consideration for investment in GoMyRx Inc.  $649,800   $- 
Common and preferred stock issued to settle accounts payable  $1,683,579   $- 
Common stock issued to ADI under the settlement agreement  $45,500   $- 
Common stock issued to M2B under the settlement agreement  $45,500   $- 
Promissory note issued to ADI under the settlement agreement  $50,000   $- 
Promissory note issued to M2B under the settlement agreement  $125,000   $- 
Common stock issued to settle commitment fees of Strata SEPA liability  $68,000   $- 
Repurchase and cancellation of common stock on disposal of subsidiary  $545,313   $- 
Assignment of loan to settle Encompass Purchase Liability  $200,000   $- 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

5

Table of Contents

 

VSEE HEALTH, INC.  

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(all amounts in USD, except number of shares and per share data)

Note 1 Organization and Description of Business

VSee Health, Inc., (formerly known as Digital Health Acquisition Corp., a Delaware Corporation) (the “Company”, “we”, “our”, “VSee Health” or “us”) is a Delaware-based telehealth software company that provides tele-critical care and tele-neurology physician services to hospital systems, long-term acute care (LTAC) facilities, correctional facilities and other customers through its wholly owned subsidiary, iDoc Virtual Telehealth Solutions, Inc. ("iDoc"), using iDoc's internally developed telehealth technology platform. The Company earns revenue from telehealth fees and patient fees and operates as one reportable segment, Telehealth Services.

The Company was formed in Delaware on March 30, 2021, under the name Digital Health Acquisition Corp. (“DHAC”) as a “blank check company” for the purpose of acquiring, through a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, recapitalization or other similar business transaction, one or more operating businesses or assets. On June 24, 2024 (the “Closing Date”), the parties consummated the business combination by and among DHAC, DHAC Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of DHAC (“Merger Sub I”), DHAC Merger Sub II, Inc., a Texas corporation and a direct, wholly owned subsidiary of DHAC (“Merger Sub II”), VSee Lab Inc., a Delaware corporation (“VSee Lab”), and iDoc Virtual Telehealth Solutions, Inc., a Texas corporation (“iDoc”), (the “Business Combination”). In connection with the Business Combination, DHAC changed its name from Digital Health Acquisition Corp. to VSee Health, Inc. Furthermore, unless otherwise stated or unless the context otherwise requires, references to “DHAC” refer to Digital Health Acquisition Corp., a Delaware corporation, prior to the Closing Date. The transaction was accounted for as a reverse recapitalization, with VSee Lab, Inc. identified as the accounting acquirer.

iDoc, provides high-acuity patient care solutions through elite physician services in ICUs using a proprietary technology platform. It delivers neuro-critical care and tele-critical care services to a wide range of customers, including hospital systems, LTACs, and correctional facilities. Staffed by board-certified intensivists, neurointensivists, neurologists, and advanced practice providers, iDoc offers 24/7 care for acute neurological conditions and supports multidisciplinary treatment plans. Its services include teleneurocritical care, teleneurology, epileptology, and advanced monitoring such as intracranial pressure, cerebral hemodynamics, brain oximetry, microdialysis, and continuous EEG.

VSee Lab, was a telehealth software platform offering a scalable, API-driven solution for virtual healthcare delivery. Its proprietary, modular system enables plug-and-play telehealth services with end-to-end encrypted video, integrated with medical devices, EMRs, and other sensitive data (See Note 3 – Discontinued Operations).

For financial reporting purposes, historical financial data prior to June 24, 2024, reflects the operations of VSee Lab, Inc. The acquisition of iDoc Virtual Telehealth Solutions, Inc. was treated as a business combination under Accounting Standards Codification 805, Business Combinations, with the excess purchase consideration recorded as goodwill.

On May 31, 2026, the Company divested VSee Lab by selling 100% of its ownership interest to Milton Chen, the Company’s former co-Chief Executive Officer. Following the divestiture, VSee Lab became an independent standalone business and is no longer a subsidiary of VSee Health. Accordingly, VSee Lab has been classified and presented as discontinued operations in the consolidated financial statements retrospectively for all periods presented, where applicable (See Note 3 – Discontinued Operations). Mr. Chen also resigned as the Company’s co-Chief Executive Officer and Chairman of the Board of Directors in connection therewith.

Going Concern

Management has determined that principal conditions including the Company’s liquidity condition and historical operating losses raise substantial doubt about the Company’s ability to continue as a going concern for a period of time of at least one year after the date that the accompanying consolidated financial statements are issued.

The Company has incurred multiple years of losses resulting in an accumulated deficit of $87,018,413 as of September 30, 2026, and further losses are anticipated in the development of its business. Further, the Company had operating cash outflows from continuing operations of $2,996,674 for the nine months ended September 30, 2026. For the three months ended and nine months ended September 30, 2026, the Company had a loss from continuing operations of $2,848,701 and $7,192,929 respectively. The Company’s operations have been funded principally through the issuance of debt and equity. These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year from the issuance of these financial statements. 

Management has undertaken a series of measures to address these concerns, which include:

●Revenue Enhancement Strategies: The Company won new contracts with larger hospitals and entered new markets, demonstrating the Company’s ability to generate positive revenue growth from its robust pipeline.
   
●Additional Financing: The Company is in negotiations with an investor for additional financing, which is expected to support its working capital needs and fund its growth initiatives.

 

There is no assurance that the Company’s plans to alleviate such concerns will be successful within one year after the date the condensed consolidated financial statements are issued. The accompanying condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

6

Table of Contents

 

Note 2 Summary of Significant Accounting Policies

Basis of Presentation and Consolidation

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). Certain information or footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.

The unaudited condensed consolidated financial statements include the accounts of VSee Health, Inc. and its wholly owned subsidiary, iDoc Virtual Telehealth Solutions, Inc. ("iDoc"). In addition, the consolidation includes Encompass Healthcare Billing, LLC, a wholly owned subsidiary of iDoc. All intercompany balances and transactions have been eliminated in consolidation. On May 31, 2026, the Company divested VSee Lab, Inc. through the sale of its entire ownership interest. As a result, VSee Lab and its subsidiary, This American Doc, Inc., are no longer included in the Company’s consolidated financial statements subsequent to the divestiture date. Prior to June 24, 2024, the historical financial statements reflected the accounts of VSee Lab, Inc. and its 53.8% owned subsidiary, This American Doc, Inc., as VSee Lab was the accounting acquirer in the reverse recapitalization.

The interim results for the three and nine months ended September 30, 2026, are not necessarily indicative of the results to be expected for the year ending December 31, 2026, or for any future interim periods. These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC. The significant accounting policies and estimates used in preparing these unaudited condensed consolidated financial statements were applied on a basis consistent with those used in the audited consolidated financial statements for the year ended December 31, 2025.

The results of operations, cash flows, and assets and liabilities of VSee Lab for prior periods have been recast and presented as discontinued operations (see Note 3 – Discontinued Operations). This presentation change did not impact the Company's consolidated net loss, consolidated cash flows, total assets, total liabilities or total stockholders' equity. 

Segments

The Company identifies its operating segments in accordance with ASC 280, Segment Reporting ("ASC 280"), based on how its chief operating decision maker ("CODM") reviews financial information to assess performance and allocate resources.

Management has determined that the Company has one operating and reportable segment. The Company's segment reflects the manner in which its Chief Executive Officer, who serves as the Chief Operating Decision Maker ("CODM"), reviews results and allocates resources.

The Company’s operating and reporting segment is Telehealth Services (“Telehealth”). iDoc Virtual Telehealth Solutions, Inc. is included in Telehealth. Prior to the divestiture of VSee Lab on May 31, 2026, the Company's operations included a Healthcare Technology business. Following the disposition of VSee Lab, the Company no longer conducts Healthcare Technology operations, and the results of continuing operations is reported through the Telehealth segment.

Use of Estimates

The preparation of the Company’s condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts stated in the condensed consolidated financial statements and accompanying notes. These judgments, estimates, and assumptions are used for, but not limited to, the determination of estimated provision for contractual adjustments from third-party payors in the recognition of patient fee contracts, revenue, cost of revenues, goodwill and intangible asset impairment analysis, allowance for credit losses, ADI Promissory Note, M2B Promissory Note, the ADI Funding Convertible Note, ClearThink Convertible Note, Labrys Convertible Promissory Note (each of these instruments are defined in Note 8 Convertible notes), June 2026 SEPA liability, Strata SEPA liability (each of these are defined in Note 9 SEPA liability), stock-based compensation, incremental borrowing rate determination, useful life of intangibles, reserve for income tax uncertainties and other contingencies, and valuation of deferred tax asset.

The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. However, future events are subject to change and best estimates and judgments routinely require adjustment. Actual results could differ from those estimates.

Reverse Stock Split

On September 22, 2026, the Company implemented a 1-for-80 reverse split on outstanding shares of common stock. All share and per share data throughout these consolidated financial statements have been retroactively adjusted to reflect the reverse stock split. The total number of authorized shares of common stock and the par value per share of the Company's common stock did not change as a result of the reverse stock split. As a result of the reverse stock split, an amount equal to the decreased value of the common stock was reclassified from “common stock” to “additional paid-in capital.” In addition, the conversion prices of the outstanding convertible notes and certain series of preferred stock, as well as the exercise prices or number of shares issuable upon exercise of outstanding warrants, were adjusted to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. All fractional shares were rounded up.

Income Taxes

The Company applies ASC 740-10, Accounting for Income Taxes (“ASC 740-10”), which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax basis and operating loss, capital loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

7

Table of Contents

 

The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest and penalties related to unrecognized tax benefits as a component of general and administrative expenses. The Company’s federal tax return and any state tax returns are not currently under examination.

Revenue Recognition

The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers (“ASC 606”). ASC 606 establishes a principle for recognizing revenue upon the transfer of promised goods or services to customers in an amount that reflects the expected consideration received in exchange for those goods or services. The core principle of ASC 606 is to recognize revenue to depict the transfer of promised goods or services to clients in an amount that reflects the consideration the entity expects to be entitled in exchange for those goods or services. 

The Company derives revenue from business services associated with direct tele-physician provider patient fee services, telehealth services and institutional services provided to our clients.

The Company determines revenue recognition in accordance with ASC 606, through the following five steps:

1) Identify the contract with a customer

The Company considers the terms and conditions of its contracts and the Company’s customary business practices in identifying its contracts under ASC 606. The Company determines it has a contract with a customer when the contract has been approved by both parties, it can identify each party’s rights regarding the services to be transferred and the payment terms for the services, it has determined the customer to have the ability and intent to pay, and the contract has commercial substance. The Company applies judgment in determining the customer’s ability and intent to pay, which is based on a variety of factors, including the customer’s payment history or, in the case of a new customer, credit and financial information pertaining to the customer.

The Company also has service contracts with hospitals or hospital systems, physician practice groups, and other users. These customer contracts typically range from two to three years, with an automatic renewal process. The Company either invoices these customers for the monthly fixed fee in advance or at the end of the month, depending on the contract terms.

The contracts typically contain cancellation clauses with advance notice; therefore, the Company does not believe that it has any material outstanding commitment for future revenues beyond one year from the end of a reporting period.

2) Identify the performance obligations in the contract

Performance obligations promised in a contract are identified based on the services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the service either on its own or together with other resources that are readily available, and are distinct in the context of the contract, whereby the transfer of the services is separately identifiable from other promises in the contract. The Company’s contracts typically contain cancellation clauses with advance notice; therefore, the Company does not believe that they have any material outstanding commitments for future revenues beyond one year from the end of the reporting period.

3) Determine the transaction price

The total transaction price is based on the amount to which the Company is entitled to based on the contracts with its customers. The Company believes the quoted transaction prices in the customer contracts represent the stand-alone selling prices for each of the separate performance obligations which are distinct and priced separately within the contract. The transaction price for each service provided is independent and established in the contract and based on the duration of service provided or for a rate for service provided. Fees are established based on the service transferred to the client.

4) Allocate the transaction price to performance obligations in the contract

If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation based on a relative stand-alone selling price (“SSP”). The determination of a SSP for each distinct performance obligation requires judgment. The Company believes the quoted transaction prices in the customer contracts represent the standalone selling prices for each of the separate performance obligations that are distinct and priced separately within the contract.

5) Recognize revenue when or as the Company satisfies a performance obligation

Revenue is recognized when or as control of the promised goods or service is transferred to the customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services.

Patient Fees Services and Performance Obligation

Patient Fee Services

Patient fees represent a series of distinct services because performance obligations are met when the Company’s physicians provide professional medical services to patients at the client site. The patient benefits from professional services when care is rendered by the Company’s medical professionals. Revenue recognition commences when the Company satisfies its performance obligation to provide professional medical services to patients.

The Company acts as the principal in these arrangements because it controls the medical services before they are transferred to the patient. This control is evidenced by the Company’s primary responsibility for fulfilling the service and its direct authority over the affiliated physicians, including the right to direct their clinical activities and administrative protocols.

8

Table of Contents

 

Patient Fee Contracts Involving Third-Party Payors

The Company receives payments from patients, third-party payors, and others for patient fee services. Third-party payors reimburse based on contracted rates or billed charges, which are generally lower than billed amounts. The Company determines the transaction price on patient fees based on standard charges for services provided, reduced by adjustments provided to third-party payors, and implicit price concessions provided to uninsured patients. The Company monitors its revenue and receivables from third-party payors and records an estimated contractual allowance to properly account for the differences between billed and collected amounts.

Revenue from third-party payors is presented net of an estimated provision for contractual adjustments. Patient revenues are net of service credits and service adjustments, and implicit price concessions. These adjustments and implicit price concessions represent the difference between the amount billed and the estimated consideration the Company expects to receive, based on historical collection experience, market conditions and other factors. Although the Company believes that its approach to estimates and judgments as described herein is reasonable, actual results could differ, from estimated amounts and such difference could be material.

All of the Company’s telemedicine contracts for patient reimbursement fees are directly billed to the payors by the Company. The Company earns patient fees by providing high acuity patient care solutions. For patient fees, performance obligations are met when the Company’s physicians provide professional medical services to patients at the client site as this is deemed as transfer of goods and services to respective patients. The patient benefits from the professional services when care is rendered by the Company’s medical professionals. The revenue is determined based on the telemedicine billing code(s) associated with the respective professional service rendered to patients.

The Company earns primarily from reimbursement from the following third-party payors:

Medicare

The Company’s affiliated provider network is reimbursed by the Medicare Part B and Part C programs for certain of the telemedicine services it provides to Medicare beneficiaries. Medicare coverage for telemedicine services is treated distinctly from other types of professional medical services and is limited by federal statute and subject to specific conditions of participation and payment pursuant to Medicare regulations, policies and guidelines, including the location of the patient, the type of service, and the modality for delivering the telemedicine service, among others.

Medicaid

Medicaid programs are funded jointly by the federal government and the states and are administered by states (or the state’s designated managed care or other similar organizations) under approved plans. Our affiliated provider network is reimbursed by certain State Medicaid programs for certain of the telemedicine services it provides to Medicaid beneficiaries. Medicaid coverage for telemedicine services varies by state and is subject to specific conditions of participation and payment.

Commercial Insurance Providers

The Company is reimbursed by commercial insurance carriers. The basis for payment to the commercial insurance providers is consistent with Medicare reimbursement fee structure guidelines and the Company is in-network or out-of-network with the commercial insurance carriers based on state and insurer requirements.

Telehealth Fees Service Contracts and Performance Obligation

Contract For Telemedicine Care Services

Performance obligations in the contract for telemedicine care are based on services provided via the use of hardware and software integration that includes multi-participant video conferencing, and electronic communication for 24 hours per day, seven days per week for the duration of the contract. The Company provides administrative support for the tele-physician services and coordinates the services of its clinicians’ network through administrative support, hardware support, and software support and provider coverage availability. The Company provides coverage availability of its physician services ranging from 12 to 24 hours per day. Performance obligations in the contract for these services transferred to the customer are distinct in the context of the contract, whereby the transfer of the services is separately identifiable from patient services and institutional services obligations. Performance obligations are met when the Company provides administrative, business, and medical records and reports related to their professional services rendered pursuant to the agreement in such format and upon such interval as hospitals may require. Revenue from telemedicine care services is included in telehealth fees in the condensed consolidated financial statements.

The Company recognizes revenue for variable consideration when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. The Company estimates the amount of revenue to be recognized on variable consideration, using the expected value or the most likely amount method, whichever is expected to better predict the amount. The Company’s estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on assessments of legal enforceability, performance, and all information that is reasonably available to the Company. The determination of the amount of revenue the Company can recognize each accounting period requires management to make estimates and judgments on the estimated expected customer life or expected performance period.

The Company commences revenue recognition when the Company satisfies its performance obligation to provide the contractual tele-physician hours services. Prior to the commencement of services, customers generally make initial start-up nonrefundable payments to the Company when contracting for Company training, hardware and software installation and integration, which includes a onetime setup of software security, API interfaces, and compatibility between existing hospital equipment and hardware and software. The start-up fees do not significantly modify or customize the other goods in the contract. As the start-up service primarily covers initial administrative services for which the Company’s clients can cancel future services upon completion, management considers it to be separable from the ongoing business services, and the Company records start-up fees as revenue when the start-up service is completed over time, using the input method to measure progress each financial period. 

9

Table of Contents

 

Institutional Fees Service Contracts and Performance Obligation

Contract For Electroencephalogram (“EEG”) Professional Interpretation Services

Performance obligations in the contract for EEG professional interpretation services are based on the number of professional services EEG interpretation the Company provides. The performance obligation in the contract for these services transferred to the customer is distinct in the context of the contract, whereby the transfer of the services is separately identifiable from other promises in the contract. To facilitate the delivery of the EEG professional interpretation services, the Company’s physicians use EEG telemedicine equipment provided by the Company. The performance obligation is satisfied based on the number of EEG professional interpretations performed by the Company’s physicians. The number of professional interpretations is traced monthly by both parties and used to determine the revenue earned based on established contractual rates and is included in institutional fees in the condensed consolidated financial statements.

Under most of the Company’s contracts, including contracts with its two top customers, the customer pays fixed monthly fees for telemedicine consultation services, EEG professional interpretation services, platform software services, and hardware fees. The fixed monthly fee provides for a predetermined number of daily, monthly, or annual physician hours of coverage and agreed-upon rates for interpretation and software services. To facilitate the delivery of the consultation services, the facilities use telemedicine equipment and the Company’s virtual healthcare platform, which is provided and installed by the Company. The Company also provides the hospitals with user training, maintenance and support services for the telemedicine equipment used to perform the consultation services.

The Company commences revenue recognition on EEG professional interpretation services when the Company satisfies its performance obligation to provide professional interpretation monthly.

Disaggregation of revenue

The following table provides information about disaggregated revenue from continuing operations by timing of revenue recognition:

   For the three months ended   For the nine months ended 
   September 30,   September 30,   September 30,   September 30, 
   2026   2025   2026   2025 
Timing of revenue recognition                
Products and services transferred over time  $-   $-   $-   $- 
Products and services transferred at a point in time   1,496,779    2,318,922    4,937,956    4,571,727 
Total Revenue  $1,496,779   $2,318,922   $4,937,956   $4,571,727 

Net Loss Per Common Share

The Company computes income (loss) per common share, in accordance with ASC Topic 260, Earnings Per Share, which requires dual presentation of basic and diluted earnings per share. Basic income or loss per common share is computed by dividing net income or loss by the weighted average number of common shares outstanding during the period. No potential diluted common shares are included in the computation of any diluted per share amount when a loss is reported. Diluted income or loss per common share is computed by dividing net income or loss by the weighted average number of common shares outstanding, adjusted for the effect of potentially dilutive securities, using the treasury stock method and the if-converted method, as applicable.

The following table presents basic and diluted earnings per share attributable to continuing operations for the three and nine months ended September 30, 2026, and 2025.

   For Three months ended   For the Nine Months Ended 
   September 30,
2026
   September 30,
2025
   September 30,
2026
   September 30,
2025
 
Net loss from continuing operations - basic and diluted  $(2,848,701)  $(42,456)  $(7,192,929)  $(5,585,523)
Weighted average shares outstanding – basic and diluted   734,931    206,867    673,496    205,369 
Net loss per share from continuing operations – basic and diluted  $(3.88)  $(0.21)  $(10.68)  $(27.20)
Excluded securities: (1) *                    
Public Warrants   123,468    143,750    123,468    143,750 
Private Warrants   6,963    6,963    6,963    6,963 
Bridge Warrants   2,174    2,174    2,174    2,174 
Extension Warrants   326    326    326    326 
September 2024 Warrants   9,259    9,259    9,259    9,259 
Quantum Convertible Note, related party (2)   -    23,281    -    23,281 
Exchange Note (2)   -    10,342    -    10,342 
September 2024 Convertible Note (3)   -    15,734    -    15,734 
Series A Preferred stock common stock equivalents (4)   761    38,488    761    38,488 
Stock options granted   10,046    10,046    10,046    10,046 
Common stock issuance obligation   640    640    640    640 
March 2025 Convertible Note (5)   -    771    -    554 
May 2025 Convertible Note (6)   -    2,454    -    1,118 
Common Stock Warrants   245,902    -    245,902    - 
ClearThink Convertible Note (7)   92,033    -    24,179    - 
Labrys Convertible Promissory Note (8)   127,441    
-
    33,481    
-
 

 

*Shares outstanding have been restated for the 1-for-80 reverse stock split effective September 22, 2026. See Note 2 – “Summary of Significant Accounting Policies”.

 

10

Table of Contents

 

(1)The Company’s diluted shares have not been included in the computation of diluted net loss per share from continuing operations for the three and nine months ending September 30, 2026, and 2025, as the result would be anti-dilutive.
 
(2)Includes the interest amount thereon and assumes the floor conversion price of $160.00.

 

(3)Includes the principal and interest amount thereon and calculated based on the initial fixed conversion price of $160.00.
  
(4)Assumes the maximum conversion thereon at the floor conversion price of $160.00.
  
(5)Includes the interest amount thereon and assumes the floor conversion price of $160.00.
  
(6)Includes the interest amount thereon and assumes the closing price as of the reporting date.
  
(7)Includes the interest amount thereon and assumes the average closing price for the reporting period.
  
(8)Includes the interest amount thereon and assumes the average closing price for the reporting period.

 

The following table presents basic and diluted earnings (loss) per share attributable to discontinued operations for the three and nine months ended September 30, 2026, and 2025.

   For Three months ended   For the Nine Months Ended 
   September 30,
2026
   September 30,
2025
   September 30,
2026
   September 30,
2025
 
Net (loss) income from discontinued operations – basic and diluted  $-   $(247,289)  $2,591,239   $(1,276,945)
Weighted average shares outstanding – basic and diluted   734,931    206,867    673,496    205,369 
Net (loss) income per share from discontinued operations – basic and diluted  $-   $(1.20)  $3.85   $(6.22)
Excluded securities: (1) *                    
Public Warrants   123,468    143,750    123,468    143,750 
Private Warrants   6,963    6,963    6,963    6,963 
Bridge Warrants   2,174    2,174    2,174    2,174 
Extension Warrants   326    326    326    326 
September 2024 Warrants   9,259    9,259    9,259    9,259 
Quantum Convertible Note, related party (2)   -    23,281    -    23,281 
Exchange Note (2)   -    10,342    -    10,342 
September 2024 Convertible Note (3)   -    15,734    -    15,734 
Series A Preferred stock common stock equivalents (4)   761    38,488    761    38,488 
Stock options granted   10,046    10,046    10,046    10,046 
Common stock issuance obligation   640    640    640    640 
March 2025 Convertible Note (5)   -    771    -    554 
May 2025 Convertible Note (6)   -    2,454    -    1,118 
Common Stock Warrants   245,902    -    245,902    - 

 

*Shares outstanding have been restated for the 1-for-80 reverse stock split effective September 22, 2026. See Note 2 - Summary of Significant Accounting Policies.
(1)The Company’s diluted shares have not been included in the computation of diluted net loss per share from discontinued operations for the three and nine months ended September 30, 2026, and 2025, as the result would be anti-dilutive.
  
(2)Includes the interest amount thereon and assumes the floor conversion price of $160.00.
  
(3)Includes the principal and interest amount thereon and calculated based on the initial fixed conversion price of $160.00.
  
(4)Assumes the maximum conversion thereon at the floor conversion price of $160.00.
  
(5)Includes the interest amount thereon and assumes the floor conversion price of $160.00.
  
(6)Includes the interest amount thereon and assumes the closing price as of the reporting date.

 

Cash

The Company considers all highly liquid investments with maturities of three months or less at the time of acquisition to be cash equivalents. The Company had no cash equivalents as of September 30, 2026, and December 31, 2025, respectively.

Periodically, the Company may carry cash balances at financial institutions more than the federally insured limit of $250,000 per institution. The amount in excess of federally insured limit as of September 30, 2026, and December 31, 2025, was approximately $0 and $4,449,913, respectively. The Company has not experienced losses on account balances and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these deposits is not significant.

11

Table of Contents

 

Accounts Receivable and Credit losses

The Company carries its accounts receivable at net realizable value. The Company maintains an allowance for credit losses for the estimated losses resulting from the inability of the Company’s clients to pay their invoices. Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-13, Credit Losses - Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), which requires entities to use a forward-looking approach based on current expected credit losses (“CECL”) to estimate credit losses on certain types of financial instruments, including trade receivables.

As of September 30, 2026, and December 31, 2025, respectively, the allowance for credit losses was $1,902,156 and $835,007 respectively. For the three months ended September 30, 2026, and 2025, the Company recognized $259,922 and $274,214 of credit loss expense within general and administrative expense on the condensed consolidated statements of operations. For the nine months ended September 30, 2026, and 2025, the Company recognized $1,132,043 and $521,098 of credit loss expense within general and administrative expense on the condensed consolidated statements of operations.

The following table presents the Company’s allowance for credit losses on September 30, 2026, and December 31, 2025:

   September 30,
2026
   December 31,
2025
 
         
Beginning allowance for credit losses  $835,007   $2,393,033 
Add: Credit loss expense   1,132,043    1,029,317 
Less: Accounts receivable write-off included in allowance for credit losses above   (64,894)   (2,587,343)
Ending allowance for credit losses  $1,902,156   $835,007 

Leases

The Company accounts for leases under ASC 842, Leases. The Company determines whether an arrangement is or contains a lease at inception. Operating leases are recorded as right-of-use (ROU) assets, current operating lease liabilities, and non-current operating lease liabilities on the Company’s condensed consolidated balance sheets. Finance leases are included in fixed assets and finance lease liabilities on the Company’s condensed consolidated balance sheets. Operating and finance lease right-of-use assets and liabilities are initially recognized based on the present value of lease payments over the lease term calculated using our incremental borrowing rate generally applicable to the location of the lease right-of-use asset, unless an implicit rate is readily determinable. As most of our leases do not provide an implicit rate, we generally use our incremental borrowing rate based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at commencement date. As we do not have any outstanding public debt, we estimated the incremental borrowing rate based on our estimated credit rating and available market information. The incremental borrowing rate is subsequently reassessed upon a modification to the lease agreement.

As permitted under ASC 842, the Company has made an accounting policy election not to apply the recognition provisions of ASC 842 to short-term leases (leases with a lease term of 12 months or less that do not include an option to purchase the underlying asset that the lessee is reasonably certain to exercise); instead, the Company will recognize the lease payments for short-term leases on a straight-line basis over the lease term.

Stock-based Compensation

The Company accounts for stock-based compensation in accordance with ASC 718, Compensation-Stock Compensation. Under the fair value recognition provisions, stock-based compensation cost is measured at the grant date based on the fair value of the award. For employee awards, cost is recognized on a straight-line basis over the requisite service period. For nonemployee awards, cost is recognized in the same period and in the same manner as if the Company had paid cash for the services; fully vested, nonforfeitable shares granted to nonemployees are recognized when granted. The fair value of stock awards, including shares of common stock granted to employees and consultants, is based on the closing price of the Company's common stock on the grant date. The Company estimates the fair value of share options using the Black-Scholes option-pricing model, utilizing assumptions related to the contractual term of the instruments, estimated volatility of the price of the Common Stock, and current interest rates. The Company accounts for forfeitures as they occur.

Fair Value of Financial Instruments

“Fair value” is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. ASC 820 establishes a fair value hierarchy that prioritizes and ranks the level of observability of inputs used to measure investments at fair value. The observability of inputs is impacted by a number of factors, including the type of investment, characteristics specific to the investment, market conditions and other factors. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). Investments with readily available quoted prices or for which fair value can be measured from quoted prices in active markets will typically have a higher degree of input observability and a lesser degree of judgment applied in determining fair value.

The carrying amounts are reflected in the accompanying balance sheets for cash, accounts receivable, due from/to related party, debt measured at amortized cost, accounts payable and accrued liabilities approximate fair value due to their short-term nature. The three levels of the fair value hierarchy under ASC 820 are as follows:

●“Level 1”, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;
   
●“Level 2”, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and
   
●“Level 3”, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

 

12

Table of Contents

 

In some cases, the inputs used to measure fair value might fall within different levels of the fair value hierarchy. In such cases, the level in the fair value hierarchy within which the investment is categorized in its entirety is determined based on the lowest level input that is significant to the investment. Assessing the significance of a particular input to the valuation of an investment in its entirety requires judgment and considers factors specific to the investment. The categorization of an investment within the hierarchy is based upon the pricing transparency of the investment and does not necessarily correspond to the perceived risk of that investment.

See Note 16 - Fair Value Measurements for additional information on assets and liabilities measured at fair value.

Derivative Financial Instruments

The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC 815, Derivatives and Hedging. Derivative instruments are recorded at fair value on the grant date and re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations. Derivative assets and liabilities are classified in the consolidated balance sheets as current or non-current based on whether or not net cash settlement or conversion of the instrument could be required within 12 months of the consolidated balance sheet date.

Warrant Instruments

The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in ASC 480, Distinguishing Liabilities from Equity and ASC 815 (Derivatives and Hedging). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common stock, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. 

For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. The Company has determined that its Public warrants, Private warrants, Bridge warrants, September 2024 warrants, Pre-funded warrants, Common Stock warrants and Extension warrants are freestanding and meet equity classification under ASC 815 (Derivatives and Hedging) and are therefore classified in equity.

Long – term Investments

For equity investments that do not have readily determinable fair values, the Company measures the equity investment at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investments of the Company. The Company periodically evaluates the carrying value of the equity investment, or when events and circumstances indicate that the carrying amount of an asset may not be recovered. On a quarterly basis, the Company reviews their equity investments without readily determinable fair values for impairment and considers several qualitative factors such as whether there is a significant deterioration in earnings performance, credit rating, asset quality, or business prospects of the investee in determining if impairment exists. If the investment is considered impaired, an impairment loss equal to the amount by which the carrying value exceeds its fair value is recorded through a charge to earnings. The impairment loss may be reversed in a subsequent period if there are observable transactions for the identical or similar investment of the same issuer at a higher amount than the carrying amount that was established when the impairment was recognized.

On January 16, 2026, the Company entered into a Stock Purchase Agreement with GoMyRx, Inc., a Wyoming corporation (“GoMyRx”), and Go Biz Holdings, LLC, a Wyoming limited liability company (“GBiz”), pursuant to which the Company agreed to acquire an approximately 10% ownership interest in GoMyRx for a total purchase consideration of $2,000,000.

As of the reporting date, the Company has funded $749,800 of the total committed investment, of which $100,000 was funded in cash and the remaining amount was satisfied through the issuance of 22,500 shares of the Company’s common stock.

The Company does not have the ability to exercise significant influence over GoMyRx and, accordingly, this investment is not accounted for under the equity method. The investment is accounted for as an equity investment in a private company, measured at cost, less impairment, with adjustments for observable price changes, if any.

Fixed Assets

Fixed assets are recorded at historical cost, less accumulated depreciation. The Company expenses fixed assets purchased that are less than $1,000. Depreciation is calculated on the straight-line method over the estimated useful lives of the respective assets. Repair and maintenance costs are charged to expenses as incurred. Fixed assets are depreciated using the straight-line method over the estimated useful lives of the assets as follows:

  Estimated Useful Life
Office equipment 3-5 years
Medical equipment 3-10 years
Furniture 3-7 years
Leased equipment Shorter of lease term or estimated useful life
Leasehold improvements 3-7 years

 

13

Table of Contents

 

Goodwill

Goodwill represents the excess of purchase price in a business combination over the fair value of the net identifiable assets acquired. We evaluate goodwill for impairment at the reporting unit level by assessing whether it is more likely than not that the fair value of a reporting unit exceeds it carrying value. If this assessment concludes that it is more likely than not that the fair value of a reporting unit exceeds its carrying value, then goodwill is not considered impaired and no further impairment testing is required. Conversely, if the assessment concludes that it is more likely than not that the fair value of a reporting unit is less than it carrying value, a goodwill impairment test is performed to compare the fair value of the reporting unit to its carrying value. The Company determines fair value of the reporting unit using both income and market-based models. Our models contain significant assumptions and accounting estimates about discount rates, future cash flows, and terminal values that could materially affect our operating results or financial position if they were to change significantly in the future and could result in an impairment. We perform our goodwill impairment assessment whenever events or changes in facts or circumstances indicate that impairment may exist and during the fourth quarter each year. The cash flow estimates and discount rates incorporate management’s best estimates, using appropriate and customary assumptions and projections at the date of evaluation. For the three and nine months ended September 30, 2026, the Company performed qualitative analysis by assessing that no adverse economic, industry, operational, or regulatory indicators were identified that would suggest impairment. Based on the qualitative assessment of relevant factors, the Company concludes that no impairment indicators or triggering events were identified that required the Company to perform a quantitative analysis.

Intangible Assets

Intangible assets are presented at their historical costs, net of amortization. Historical cost of intangible assets acquired in a business combination represents the fair value at acquisition. The fair value at acquisition is determined based on the appraised value of the asset. Intangible assets are comprised of developed technology and customer relationships. Developed technology and customer relationships are amortized using the straight-line method over the five-year and ten-year estimated useful lives of the assets, respectively. Identifiable intangible assets subject to amortization consist of the following:

   Estimated  September 30,   December 31, 
   Useful Life  2026   2025 
Customer relationships  10 years   2,100,000    2,100,000 
Developed technology  5 years   10,000,000    10,000,000 
Accumulated amortization      (4,972,494)   (3,315,000)
Intangible assets, net     $7,127,506   $8,785,000 

Expected amortization expense is as follows:

Year ending December 31, 2026 (remaining 3 months)   552,506 
Year ending December 31, 2027   2,210,000 
Year ending December 31, 2028   2,210,000 
Year ending December 31, 2029   1,210,000 
Year ending December 31, 2030   210,000 
Thereafter   735,000 
Total  $7,127,506 

For the three months ended September 30, 2026, and September 30, 2025, the Company recorded amortization expense of $552,498 and $552,498, respectively, within general and administrative expenses in the condensed consolidated statements of operations. For the nine months ended September 30, 2026, and September 30, 2025, the Company recorded amortization expense of $1,657,494 and $1,657,496, respectively, within general and administrative expenses in the condensed consolidated statements of operations.

Impairment of Long-lived and Intangible Assets Other than Goodwill

In accordance with ASC 360-10, the Company, on a regular basis, reviews the carrying amount of long-lived assets, including fixed assets, right-of-use assets and intangible assets, for the existence of facts or circumstances, both internally and externally, that suggest impairment. The Company determines if the carrying amount of a long-lived asset is impaired based on anticipated undiscounted cash flows, before interest, from the use of the asset. In the event of impairment, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the asset. Fair value is determined based on the appraised value of the assets or the anticipated cash flows from the use of the asset, discounted at a rate commensurate with the risk involved. 

Original Issue Discount on Debt

When the Company issues notes payable with a face value higher than the proceeds it receives, it records the difference as a debt discount and amortizes the discount as interest expense over the life of the underlying note payable.

Loss Contingencies and Litigation

The Company records reserve for loss contingencies if (a) information available prior to issuance of the condensed consolidated financial statements indicates that it is probable that an asset had been impaired or a liability had been incurred at the date of the condensed consolidated financial statements and (b) the amount of loss can be reasonably estimated. If one or both criteria for accrual are not met, but there is at least a reasonable possibility that a material loss will occur, the Company does not record and reserve for a loss contingency but describes the contingency within a note and provides detail, when possible, of the estimated potential loss or range of loss. If an estimate cannot be made, a statement to that effect is made.

Recent Accounting Pronouncements

Recent Accounting Standards Adopted by the Company

ASU 2024-04: In November 2024, the FASB issued ASU 2024-04, Debt—Debt with Conversion and Other Options (Subtopic 470-20)—Induced Conversions of Convertible Debt Instruments. The ASU clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion. The standard is effective for annual periods beginning after December 15, 2025, and interim periods within those annual periods, with early adoption permitted for all entities that have adopted the amendments in ASU 2020-06. We adopted this standard during the first quarter of 2026 on a prospective basis. The adoption did not have a material impact on the Company’s condensed consolidated financial statements presented.

14

Table of Contents

 

ASU 2025-05: In July 2025, the FASB issued ASU 2025-05, Financial Instruments—Credit Losses (Topic 326): Measurements of Credit Losses for Accounts Receivable and Contract Assets (ASU 2025-05). The amendments in this update provide a practical expedient related to the estimation of expected credit losses for current accounts receivable and current contract assets that arise from transactions accounted for under ASC 606. Under ASU 2025-05, an entity is required to disclose whether it has elected to use the practical expedient. An entity that makes the accounting policy election is required to disclose the date through which subsequent cash collections are evaluated. The standard is effective for annual periods beginning after December 15, 2025, and interim periods within those annual periods, with early adoption permitted. The Company adopted this standard during the first quarter of 2026 on a prospective basis and did not elect the practical expedient. The adoption did not have a material impact on the Company’s condensed consolidated financial statements presented.

Accounting Pronouncements Not Yet Effective 

ASU 2024-03: In November 2024, the FASB issued ASU No. 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (“ASU 2024-03”), which requires disaggregated disclosure of income statement expenses for public business entities. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of ASU 2024-03 on its disclosures in the condensed consolidated financial statements.

ASU 2025-03: In May 2025, the FASB issued Accounting Standards Update No. 2025-03, Business Combinations (Topic 805), and Consolidation (Topic 810): Determining the Accounting Acquirer in the Acquisition of a Variable Interest Entity (“ASU 2025-03”). ASU 2025-03 changes how companies determine the accounting acquirer in certain business combinations involving variable interest entities. The new guidance requires considering the factors used for other acquisition transactions to assess which party is the accounting acquirer. ASU 2025-03 is effective for the Company’s annual reporting periods beginning on January 1, 2027. Early adoption is permitted. The Company is currently evaluating the impact of adopting this new accounting guidance on its condensed financial statements and related disclosures.

ASU 2025-04: In May 2025, the FASB issued Accounting Standards Update No. 2025-04, Compensation – Stock Compensation (Topic 718) and Revenue from Contracts with Customers (Topic 606): Clarifications to Share-Based Consideration Payable to a Customer (“ASU 2025-04”). ASU 2025-04 revises the definition of a performance condition, eliminates the forfeiture policy election for service conditions, and clarifies that the variable consideration constraint in Topic 606 does not apply to share-based consideration payable to customers. The new guidance requires entities to consistently account for share-based awards granted to customers by clarifying the treatment of vesting conditions and ensuring alignment with Topic 606 and Topic 718. ASU 2025-04 is effective for fiscal years beginning after December 15, 2026, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of adopting this new accounting guidance on its condensed financial statements and related disclosures.

ASU 2025-06: In September 2025, the FASB issued ASU 2025-06- Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software (ASU 2025-06), which is intended to simplify the capitalization guidance for internal-use software by removing references to project stages and clarifying when the capitalizing of eligible costs is required. ASU 2025-06 is effective for annual periods beginning after December 15, 2027, and interim periods within those fiscal years. Early adoption is permitted. The Company is in the process of evaluating the impact of this new guidance on its disclosures in the condensed consolidated financial statements.

ASU 2025-11: In December 2025, the FASB issued ASU No. 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements, which clarifies the guidance in Topic 270 to improve the consistency of interim financial reporting. The ASU provides a comprehensive list of required interim disclosures and introduces a disclosure principle requiring entities to disclose events since the end of the last annual reporting period that have a material impact on the entity. ASU 2025-11 is effective for fiscal years beginning after December 15, 2027, including interim periods within those fiscal years, with early adoption permitted. The Company is in the process of evaluating the impact of this new guidance on its disclosures in the condensed consolidated financial statements.

ASU 2025-12: In December 2025, the FASB issued ASU No. 2025-12, Codification Improvements. The ASU addresses thirty-three items, representing the changes to the Codification that (1) clarify, (2) correct errors, or (3) make minor improvements. Generally, the amendments in this Update are not intended to result in significant changes for most entities. The ASU is effective for interim reporting periods within annual reporting periods beginning after December 15, 2026. The adoption method of this ASU may vary, on an issue-by-issue basis. Early adoption is permitted. The Company is in the process of evaluating the impact of this new guidance on its disclosures in the condensed consolidated financial statements.

Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s condensed consolidated financial statements.

The Company continues to evaluate the impact of new accounting pronouncements, including enhanced disclosure requirements, on its business processes, controls and systems.

Note 3 Discontinued Operations

On May 31, 2026, the Company entered into and consummated a Stock Purchase Agreement with Milton Chen, the Company's then co-Chief Executive Officer, Chairman of the Board, and Chief Executive Officer of VSee Lab, pursuant to which the Company sold all of its equity interests in VSee Lab, to Milton Chen. The divestiture was part of a strategic decision to focus the Company's operations and resources on the physician services business conducted through iDoc. As consideration for the transaction and the mutual release of certain liabilities under the agreement, Milton Chen transferred to the Company 35,876 shares of the Company's common stock owned by him. In conjunction with the sale, Milton Chen assumed responsibility for certain VSee Lab obligations following the closing, while the Company retained specified pre-closing liabilities, and the Company relinquished control of VSee Lab and deconsolidated the subsidiary. Accordingly, the operating results of VSee Lab have been presented as discontinued operations in the accompanying condensed consolidated financial statements.

The Company accounted for the 35,876 shares of its common stock received from Milton Chen as a repurchase and cancellation of its common stock at a value of $545,313. The carrying value of net assets disposed as at the date of sale amounted to $(3,623,565). The Company recognized a gain on sale of discontinued operations of $4,168,878 in connection with the transaction.

15

Table of Contents

 

No assets or liabilities were classified as held for sale as of September 30, 2026, as the sale of VSee Lab was completed on May 31, 2026. The revenues and expenses of VSee Lab have been separately presented as discontinued operations in the accompanying condensed consolidated financial statements.

The following table represents the major components of assets and liabilities from discontinued operations as of December 31, 2025:

Balance sheet - Discontinued operations  December 31,
2025
 
     
ASSETS    
Current assets:    
Cash  $214,841 
Accounts receivable, net of allowance for credit losses of $64,895   279,597 
Prepaids and other current assets   132,460 
Current assets from discontinued operations   626,898 
      
Non-current assets:     
Fixed assets, net   37,627 
Non-current assets from discontinued operations   37,627 
      
Total assets from discontinued operations  $664,525 
      
LIABILITIES     
Accounts payable and accrued liabilities  $2,206,332 
Deferred revenue   1,324,486 
Loan payable, related party   330,000 
Total liabilities from discontinued operations  $3,860,818 

The following table represents the major components of the results of discontinued operations for the three and nine months ended September 30, 2026, and 2025:

   For the Three Months Ended   For the Nine Months Ended 
Discontinued operations - net income (loss)  September 30,
2026
   September 30,
2025
   September 30,
2026
   September 30,
2025
 
Revenue                
Subscription fees  $       -   $894,514   $1,020,900   $2,602,186 
Professional services and other fees   -    603,696    887,406    2,524,853 
Technical engineering fees   -    163,523    127,291    993,493 
Total revenue from discontinued operations  $-   $1,661,733   $2,035,597   $6,120,532 
                     
Expenses:                    
Cost of revenues   -    720,063    1,226,622    3,155,681 
Compensation and related benefits   -    797,153    1,805,631    3,185,565 
General and administrative   -    381,905    556,493    999,599 
Interest expense   -    9,901    21,155    64,171 
Other income (expense), net   -    -    -    (10,295)
Gain on sale of discontinuing operations   -    -    (4,168,878)   - 
                     
(Loss) income from discontinued before provision for income taxes   -    (247,289)   2,594,574    (1,274,189)
                     
Provision for income taxes   -    -    (3,335)   (2,756)
                     
Net (loss) income from discontinued operations  $-   $(247,289)  $2,591,239   $(1,276,945)

Note 4 Leases

Operating Leases

The Company has an operating lease for real estate. Operating lease right-of-use assets are summarized below.

   September 30,
2026
   December 31,
2025
 
Office lease  $133,112   $133,112 
Less: Accumulated amortization   (127,422)   (119,808)
Right-of-use assets, net  $5,690   $13,304 

 

16

Table of Contents

 

Operating lease liabilities are summarized below:

   September 30,
2026
   December 31,
2025
 
Office lease  $5,690   $13,304 
Less: current portion   (5,690)   (10,394)
Long term portion  $-   $2,910 

Future minimum rent payments under the operating lease are as follows:

   Total 
Year ending December 31, 2026 (remaining 3 months)   3,000 
Year ending December 31, 2027   3,000 
Total future minimum lease payments   6,000 
Less: Imputed interest   (310)
Present value of payments  $5,690 

Expenses incurred with respect to the Company’s operating leases during the three and nine months ended September 30, 2026, which are included in general and administrative expenses on the condensed consolidated statements of operations are set forth below.

   For the Three Months Ended 
   September 30,
2026
   September 30,
2025
 
Operating lease expense  $3,000   $35,635 
Total operating lease expense  $3,000   $35,635 

   For the Nine Months Ended 
   September 30,
2026
   September 30,
2025
 
Operating lease expense  $9,000   $112,116 
Total operating lease expense  $9,000   $112,116 

The weighted average remaining lease term and the weighted average discount rate on the operating leases are set forth below.

   September 30,
2026
   December 31,
2025
 
Weighted average remaining lease term (years)   0.5    1.3 
Weighted average discount rate   18.50%   18.50%

Finance Leases

Pursuant to a settlement agreement, the Company paid $1,197,891 to a bank on January 15, 2026, in exchange for the release of certain judgment liens. Of the total amount due on that date, $772,620 related to finance lease liabilities, which was settled through a cash payment of $591,118 and a gain on extinguishment amounting to $181,501, which was recorded within ‘Gain on extinguishment of financial liabilities’ in the condensed consolidated statements of operations.

Accordingly, the finance lease liabilities have been fully settled as of September 30, 2026.

  September 30,
2026
   December 31,
2025
 
Equipment lease $736,624   $736,624 
Less: Accumulated amortization  (736,624)   (544,575)
Leased equipment, net $-   $192,049 

Finance lease liabilities are summarized below:

  September 30,
2026
  December 31,
2025
 
Equipment lease $     -  $131,062 
Less: current portion  -   (131,062)
Long-term portion $-  $- 

Total finance lease cash payments made during the three and nine months ended September 30, 2026, were $0 and $591,118 respectively. For the corresponding three and nine months ended September 30, 2025, total cash payments related to finance leases were $0 and $25,000 respectively. As of September 30, 2026, and December 31, 2025, $0 and $641,558, respectively, of the Company’s financing lease liabilities are included in accounts payable and accrued liabilities on the condensed consolidated balance sheets.

Expenses incurred with respect to the Company’s finance leases during the three and nine months ended September 30, 2026, and September 30, 2025, which are included in the condensed consolidated statements of operations are set forth below.

 

   For the Three Months Ended 
   September 30,
2026
   September 30,
2025
 
Amortization expense  $20,077   $85,986 
Interest expense   -    10,373 
Total finance lease expense  $20,077   $96,359 

 

17

Table of Contents

 

   For the Nine Months Ended 
   September 30,
2026
   September 30,
2025
 
Amortization expense  $192,049   $257,957 
Interest expense   -    38,091 
Total finance lease expense  $192,049   $296,048 

The weighted average remaining lease term and the weighted average discount rate on the finance leases are set forth below.

   September 30,
2026
   December 31,
2025
 
Weighted average remaining lease term (years)*   
           -
    0.6 
Weighted average discount rate*   -%   19.30%

 

*The finance leases obligations of the Company have been fully settled as of September 30, 2026.

 

Note 5 Accounts Payable and Accrued Liabilities

The components of accounts payable and accrued liabilities are summarized as follows:

   September 30,
2026
   December 31,
2025
 
Accounts payable  $4,507,652   $5,312,678 
Accrued compensation and benefits   1,595,084    1,981,452 
Accrued interest   363,077    366,279 
Accrued financing lease   -    641,558 
Other accrued liabilities   963,971    1,028,475 
   $7,429,784   $9,330,442 

 

Silverback Capital Settlement Agreement

 

On October 14, 2026, the Company entered into a Settlement Agreement and Stipulation with Silverback Capital Corporation (“SCC”) to settle bona fide outstanding liabilities and obligations acquired by SCC from certain of the Company’s creditors. Pursuant to the agreement, claims with an aggregate claim amount of approximately $2.6 million were settled through the issuance of shares of the Company’s common stock under Section 3(a)(10) of the Securities Act of 1933, subject to approval by the Circuit Court within the Twelfth Judicial Circuit of Florida. The Company also agreed to issue additional settlement shares with a value of $150,000 as consideration under the agreement.

 

Under the terms of the settlement agreement, settlement shares are issuable from time to time upon request by SCC and are priced based on the Closing Price of the Company’s common stock immediately preceding the settlement date. If the market price declines below the Closing Price, the purchase price is adjusted to the lower of (i) the Closing Price or (ii) 78% of the average of the three lowest traded prices during the applicable valuation period, subject to a minimum price floor of $0.005 per share. The agreement further provides that SCC’s beneficial ownership may not exceed 4.99% of the Company’s outstanding common stock, unless increased to 9.99% upon prior notice to the Company.

 

Following court approval on August 5, 2026, approving the Settlement Agreement pursuant to Section 3(a)(10) of the Securities Act, the Company commenced settlement of the claims through the issuance of common stock to Silverback Capital Corporation in accordance with the terms of the agreement. During the three months ended September 30, 2026, the Company issued 57,500 shares of common stock with an aggregate fair value of $109,779, which was recorded as a reduction of accounts payable.

 

Note 6 Factoring Payable

 

iDoc previously entered into three Future Receipts Sale Agreements (dated June 21, 2023, June 28, 2023, and October 13, 2023), under which it sold future receipts of $299,000, $140,000 and $186,250 for net purchase prices of $207,639, $100,000 and $125,000, respectively. The agreements carried no stated interest rate and had no fixed collection period, because the weekly remittances varied with future receipts. During the year ended December 31, 2025, all three agreements were fully repaid or settled. As of September 30, 2026, and December 31, 2025, the Company had no factoring payable outstanding.

Note 7 Line of Credit and Notes Payable, net of discount

The following is a summary of the notes payable as of September 30, 2026, and December 31, 2025:

Notes Payable September 30,
2026
   December 31,
2025
 
Note payable issued November 29, 2021 $-   $336,983 
Note payable issued December 1, 2021  1,500,600    1,500,600 
Note payable issued August 18, 2023  64,000    64,000 
Note payable issued August 3, 2023  33,000    33,000 
September 2025 Promissory Note  -    446,192 
Encompass SBA loan  200,000    - 
First Insurance Funding loan  16,398    - 
Total notes payable  1,813,998    2,380,775 
Less: Current portion  (125,758)   (880,175)
Less: Fair value adjustment for debt  (906,659)   (906,659)
Total notes payable, net of current portion $781,581   $593,941 

Required principal payments under the Company’s notes payable are as follows:

Year Ending December 31, 2026 (Remaining 3 months)  $147,589 
Year Ending December 31, 2027   50,080 
Year Ending December 31, 2028   51,368 
Year ending December 31, 2029   53,006 
Year ending December 31, 2030   54,557 
Thereafter   1,457,398 
Total  $1,813,998 

18

Table of Contents

 

Description of Notes Payable

As a result of the acquisition of iDoc and at the closing of the Business Combination on June 24, 2024, the Company assumed the following outstanding notes payable liabilities from iDoc.

(1)On November 29, 2021, iDoc issued a $654,044 promissory note to a bank, collateralized by all the assets of iDoc. Interest was payable monthly at the annual fixed rate of 4.284%. On November 1, 2023, iDoc entered into a forbearance agreement with a maturity date of January 10, 2024, and increased the effective interest rate to 3% above the Wall Street Journal prime rate (6.75% as at December 31, 2025) (See Note 11 - Commitments, Contingencies, and Concentration Risk). iDoc was required to pay the loan in 36 payments of $19,409. Pursuant to a settlement agreement, the Company paid $1,197,891 to the bank on January 15, 2026, in consideration of the release of certain judgment liens which included the remaining balance due on this note payable. Included in the amount due on January 15, 2026, $336,983 was pertaining to this note. This amount was settled through a payment of $257,820 and a gain on extinguishment amounting to $79,163. The gain on extinguishment was recorded within ‘Gain on extinguishment of financial liabilities’ in the condensed consolidated statements of operations. As of September 30, 2026, and December 31, 2025, the outstanding balance on the promissory note was $0 and $336,983. For the three and nine months ended September 30, 2026, the Company recorded $0 in interest related to the promissory note. For the three and nine months ended September 30, 2025, the Company recorded $11,737 and $31,722 in interest related to the promissory note, respectively. No accrued interest was included within accounts payable and accrued liabilities on the condensed consolidated balance sheets, as of September 30, 2026, and December 31, 2025.
   
(2)On December 1, 2021, iDoc issued a promissory note to a bank in the amount of $500,000. On February 25, 2022, iDoc received an extension of $1,000,600 on the promissory note. The promissory note is collateralized by all the assets of iDoc and the private property of iDoc’s then Chief Executive Officer, Imoigele Aisiku. Interest is accrued monthly at the annual fixed rate of 3.75%. The promissory note matures on December 19, 2051. As of each of September 30, 2026, and December 31, 2025, there was an outstanding balance of $1,500,600 on the promissory note. Commencing on January 1, 2024, iDoc is required to make monthly installment payments, including principal and interest, of $7,682. For the three and nine months ended September 30, 2026, $14,184 and $42,243 were recorded in interest related to the promissory note, respectively. For the three and nine months ended September 30, 2025, $14,184 and $42,088 were recorded in interest related to the promissory note. The accrued interest balance, which was included within accounts payable and accrued liabilities on the condensed consolidated balance sheets, as of September 30, 2026, and December 31, 2025, were $242,636 and $200,393. The note is currently in default for late payment.
   
(3)On August 3, 2023, iDoc issued a 10.00% original issue discount promissory note to an accredited investor with a principal balance of $33,000. Notes payable issued with a face value higher than the proceeds it receives are recognized as a debt discount and is amortized as interest expense over the life of the underlying note payable. The promissory note matured on November 1, 2023, and is collateralized by all the assets of iDoc. Interest is accrued monthly at the annual fixed rate of 8.00%, with principal and interest due upon maturity. Upon an event of default, the interest rate on the note increases to the greater of 26% per annum or the maximum rate allowed by the laws governing this agreement. The Company recognized total interest expense of $2,145 and $6,435 for the three and nine months ended September 30, 2026, and recognized total interest expense of $2,145 and $6,435 for the three and nine months ended September 30, 2025. The accrued interest balance, which is included within accounts payable and accrued liabilities on the condensed consolidated balance sheets, as of September 30, 2026, and December 31, 2025, was $23,790 and $19,370, respectively. As of September 30, 2026, and December 31, 2025, the outstanding balance of the promissory note was $33,000. The note is currently in default for late payment, and as such, the Company has classified the entire note in full in current liabilities.
   
(4)On August 18, 2023, iDoc issued an 8.50% original issue discount promissory note to an accredited investor with a principal balance of $64,000. Notes payable issued with a face value higher than the proceeds it receives are recognized as a debt discount and are amortized as interest expense over the life of the underlying note payable. The promissory note matured on November 16, 2023, and is collateralized by all the assets of iDoc. Interest is accrued monthly at the annual fixed rate of 8.00%, with principal and interest due upon maturity. Upon an event of default, the interest rate on the note increases to the greater of 26% per annum or the maximum rate allowed by the laws governing this agreement. As of September 30, 2026, and December 31, 2025, the balance of promissory note net of unamortized debt discount was $64,000. The Company recognized $4,160 and $12,480 as interest at the default interest rate for the three and nine months ended September 30, 2026, and recognized $4,160 and $12,480 as interest at the default interest rate for the three and nine months ended September 30, 2025. The Company had $47,040 and $34,560 in accrued interest which is included within accounts payable and accrued liabilities in the condensed consolidated balance sheets, as of September 30, 2026, and December 31, 2025, respectively. The note is currently in default for late payment, and as such, the Company has classified the note in full in current liabilities.

 

March 2025 Promissory Note

On March 20, 2025, the Company issued a senior secured convertible promissory note in the principal amount of $555,556 for initial proceeds of $500,000 (the "March 2025 Promissory Note"), together with 1,250 shares of common stock issued to the investor as additional consideration. The proceeds were allocated on a relative fair value basis, $409,366 to the note and $90,634 to the common shares. Because the value of the embedded features that would otherwise require bifurcation was de minimis, the note was accounted for at amortized cost using the effective interest method.

On November 11, 2025, the outstanding principal and accrued interest, totaling $611,878, were converted into 11,767 shares of the Company's common stock at a conversion price of $60.08 per share. The Company accounted for the conversion as a debt extinguishment and recognized a loss on extinguishment of $95,077. Following the conversion, the March 2025 Promissory Note was fully settled, and no amounts were outstanding as of September 30, 2026 or December 31, 2025. Interest expense on the March 2025 Promissory Note was $94,096 and $181,141 for the three and nine months ended September 30, 2025, respectively.

September 2025 Promissory Note

On September 5, 2025, the Company entered into a Master Business Loan Agreement (the “MBLA”) whereby the investor agreed to, for a period of up to three years, make advances to the Company (each, an “Advance”) in the aggregate amount of $2,500,001, upon the Company’s request and satisfaction of certain conditions.

19

Table of Contents

 

On September 5, 2025, the investor made an initial Advance of $525,000 (the “Initial Advance”). Each additional Advance may not individually exceed $250,000 and may only be made at most every 90 days. The MBLA contains customary representations, warranties, and covenants for a transaction of this nature. During the term of the MBLA, the Company is prohibited from: (i) incurring any indebtedness (other than ordinary course trade debt), and (ii) paying any dividends or making distributions on the Company’s equity interests. The MBLA provides for certain events of default that are typical for a transaction of this type, including, among other things, failure to make payment, default with respect to any other indebtedness of the Company, and any change in ownership of 50% or more of the equity interests of the Company. In connection with the Initial Advance, the Company issued a commercial promissory note to the investor (the “September 2025 Promissory Note”), which the Company is required to repay in 12 weekly payments of $7,500 each followed by 40 weekly payments of $15,863 each (for an aggregate total of $724,500).

The September 2025 Promissory Note may be prepaid at any time by payment of an amount equal to the Initial Advance plus 3.167% of the Initial Advance for each month from the date of the advance to the date of payment (subject to a minimum of 20%). Upon an event of default under the MBLA, payment under the September 2025 Promissory Note may be accelerated and a default fee equal to 10% of the outstanding balance will become due. The September 2025 Promissory Note, and any future notes issued pursuant to the MBLA, is secured by a junior lien on all assets of the Company and the validity and performance of which are guaranteed personally by Imoigele Aisiku (the Company’s CEO). Milton Chen, the Company's former Co-Chief Executive Officer, was released from his personal guaranty in connection with his resignation on May 31, 2026. Mr. Aisiku also entered into a pledge agreement in favor of the investor whereby he pledged, as security for the payment and performance of all obligation to the Company under the MBLA, all shares of common stock and other equity interests held by Mr. Aisiku in the Company.

The note was repaid during the quarter ended September 30, 2026. As of September 30, 2026, and December 31, 2025, the outstanding balance on the September 2025 Promissory Note is $0 and $446,192, respectively. The interest expense recognized for the three and nine months ended September 30, 2026, is $7,673 and $119,923, respectively. The interest expense recognized for the three and nine months ended September 30, 2025, is $11,510 and $11,510.

October Promissory Note - 1

On October 9, 2025, the Company entered into a note purchase agreement (the “October Promissory Note - 1 Purchase Agreement”) with an accredited institutional investor (the “October Promissory Note - 1 Investor”) pursuant to which the Company issued to the October Promissory Note - 1 Investor a secured note in the aggregate principal amount of $133,333 (the “October Promissory Note - 1”) for a purchase price of $120,000. The October Promissory Note - 1 bears interest at the rate of 5% per annum, matured on May 8, 2026, and is secured by all assets of the Company. The October Promissory Note - 1 is not convertible and provides for certain events of default that are typical for a transaction of this type, including, among other things, any breach of the representations or warranties made by the Company or its subsidiaries. In connection with any event of default that results in the acceleration of payment of the October Promissory Note - 1, the interest rate will accrue at a rate equal to the lesser of 24% per annum or the maximum rate permitted under applicable law. For as long as the October Promissory Note – 1 remains outstanding, the October Promissory Note - 1 Purchase Agreement: (1) prohibits the Company from entering into a variable rate transaction, (2) requires that the Company provide the October Promissory Note - 1 Investor with any more favorable terms granted to any future purchaser or holder of the Company’s debt or securities and (3) prohibits any exchange transaction involving the Company’s debt or securities.

On December 10, 2025, the October Promissory Note - 1 was entirely paid off by the Company. The interest expense recognized on the October Promissory Note - 1 for the three and nine months ended September 30, 2025, was $0.

October Promissory Note - 2

On October 20, 2025, the Company entered into a note purchase agreement (the “October Promissory Note - 2 Purchase Agreement”) with an accredited institutional investor (the “October Promissory Note - 2 Investor”) pursuant to which the Company issued to the October Promissory Note - 2 Investor a secured note in the aggregate principal amount of $133,333 (the “October Promissory Note - 2”) for a purchase price of $120,000. The October Promissory Note - 2 bears interest at the rate of 5% per annum and matured on May 20, 2026. The October Promissory Note - 2 is not convertible and provides for certain events of default that are typical for a transaction of this type, including, among other things, any breach of the representations or warranties made by the Company or its subsidiaries. In connection with any event of default that results in the acceleration of payment of the October Promissory Note - 2, the interest rate on the October Promissory Note - 2 Note shall accrue at a rate equal to the lesser of 24% per annum or the maximum rate permitted under applicable law. For as long as the October Promissory Note - 2 remains outstanding, the October Promissory Note - 2 Purchase Agreement: (1) prohibits the Company from entering into a variable rate transaction, (2) requires that the Company provide the October Promissory Note - 2 Investor with any more favorable terms granted to any future purchaser or holder of the Company’s debt or securities and (3) prohibits any exchange transaction involving the Company’s debt or securities.

On December 10, 2025, the October Promissory Note - 2 was entirely paid off by the Company. The interest expense recognized on the October Promissory Note - 2 for the three and nine months ended September 30, 2025, was $0.

First Insurance Funding Agreement

The Company entered into a Premium Finance Agreement, effective January 1, 2026, with First Insurance Funding (“First Insurance”), to finance insurance premiums related to a management liability insurance policy.

Under the agreement, First Insurance financed insurance premiums and related taxes and fees totaling approximately $176,750 for a 12-month policy period commencing December 1, 2025. The financed amount accrues a finance charge calculated on a 365-day basis beginning on the effective date of the underlying policy.

The Company made a down payment of $19,250, on January 1, 2026, resulting in an unpaid premium balance of $157,500. The amount financed under the agreement totaled $158,051, which includes financed charges, and accrues finance charges at an annual percentage rate of 9.95%, resulting in total finance charges of approximately $7,297 over the term of the agreement. The agreement requires 10 monthly installments of approximately $16,535 each, with the first installment due on January 1, 2026. The amount payable is secured by the Company’s rights under such policy.

If any payment due under the Premium Finance Agreement is not paid when due, a late charge will be assessed on any installment at least 5 days in default, and the late charge will equal 5% of such payment or the maximum late charge permitted by law, whichever is less.

20

Table of Contents

 

As of September 30, 2026, and December 31, 2025, the Company had an outstanding balance of $16,398 and $0, respectively, on the Premium Finance Agreement. The interest expense recognized for the three and nine months ended September 30, 2026, was $(702) and $7,161, respectively, reflecting an immaterial true-up of interest expense which was recognized in prior periods.

Line of credit

On November 29, 2021, iDoc received a revolving line of credit from a bank as described in the above “Description of Notes Payable” section. The line of credit is collateralized by iDoc’s assets.

On January 15, 2026, the Company entered into a settlement agreement with bank related to its outstanding loan obligations. Pursuant to a settlement agreement, the Company paid $1,197,891 to the bank on January 15, 2026, in consideration for the release of certain judgment liens. Included in the amount due on January 15, 2026, was $456,097 pertaining to line of credit. This amount was settled through a payment of $348,952 and a gain on extinguishment amounting to $107,145. The gain on extinguishment was recorded within ‘Gain on extinguishment of financial liabilities’ in the condensed consolidated statements of operations. Upon payment, the settlement fully resolved all outstanding amounts owed to the bank, including this line of credit, the note payable issued on November 29, 2021, and finance leases of the Company.

The Company recorded $0 in interest related to the line of credit for the three and nine months ended September 30, 2026. The Company recorded $15,886 and $42,935 in interest related to the line of credit for the three and nine months ended September 30, 2025, respectively. The outstanding balance on the condensed consolidated balance sheets, as of September 30, 2026, and December 31, 2025, were $0 and $456,097, respectively.

Encompass SBA Loan

As part of the settlement agreement entered on February 16, 2026, to fully settle the Encompass Purchase liability (see Note 11 – Commitments, Contingencies, and Concentration Risk), the Company was assigned an SBA Economic Injury Disaster Loan with a principal balance of $200,000 (the “Encompass SBA Loan”). The loan was originally issued by the U.S. Small Business Administration on September 25, 2021, bears interest at a rate of 3.75% per annum, and is repayable in monthly installments of $1,030 in accordance with the original loan terms. All remaining principal and accrued interest is due and payable 30 years from the date of the Encompass SBA Loan.

As on September 30, 2026, the outstanding balance of the Encompass SBA Loan is $200,000. The interest expense recognized for the three and nine months ended September 30, 2026, was $1,844 and $4,611, respectively. The accrued interest balance, which were included within accounts payable and accrued liabilities on the condensed consolidated balance sheets, as of September 30, 2026, and December 31, 2025, were $4,611 and $0, respectively.

Note 8 Convertible notes

March 2025 Convertible Note

On March 20, 2025, the Company entered into a Convertible Note Purchase Agreement (the “March 2025 SPA”), pursuant to which the Company issued and sold a senior secured convertible promissory note in the principal amount of $108,696 (the “March 2025 Convertible Note”). The Company received $100,000 in initial proceeds, reflecting an 8% original issue discount. The March 2025 Convertible Note matures on December 20, 2025, and provides for a minimum interest amount guaranteed for the first six months, with interest accruing at 18% per annum and payable monthly in cash or common stock at the holder’s discretion. Interest in excess of the minimum amount (if applicable) will accrue at a rate of 18% per annum, increasing to 28% per annum upon the occurrence of an event of default. The minimum interest amount is payable in 9 equal installments of $1,630 per month beginning on April 20, 2025.

The March 2025 Convertible Note is convertible into shares of the Company’s common stock at any time after three months from issuance (or earlier upon prepayment) by the holder, at a conversion price equal to the greater of (i) $2.00 per share or (ii) the lower of (a) the lowest average historical Nasdaq Official Closing Price (NOCP) for the five trading days immediately preceding the closing, or (b) the NOCP on the day prior to closing, subject to reverse stock split adjustment and most-favored nation protections. In addition, prior to a Qualified Financing, (as defined in the March 2025 Convertible Note), the holder may elect to convert at a price equal to the lower of the then-current conversion price or 75% of the effective price per share at which the Company issues common stock, options, or convertible securities to new investors in the Qualified Financing. The conversion price is subject to standard antidilution adjustments, including adjustments for stock splits, dividends, mergers, asset sales, volume resets, defaults, and down-round events. Conversion is subject to beneficial ownership and exchange cap limitations.

The March 2025 Convertible Note is prepayable at any time (unless an event of default has occurred) at 110% of the outstanding balance and is mandatorily prepayable upon the occurrence of a Qualified Financing (gross proceeds ≥ $2,000,000), with the redemption amount paid from the financing proceeds. The note is also mandatorily prepayable upon a change of control at 120% of the outstanding balance. The note can be accelerated upon an event of default either automatically or at the option of the note holder, depending on the nature of the event. Upon an uncured event of default, the holder may accelerate the note and require payment of 115% of the outstanding principal and accrued interest (“Mandatory Default Amount”), plus $5,000 in liquidated damages, and may convert the Mandatory Default Amount at a more favorable “Alternative Conversion Price,” defined as the lower of the conversion price then in effect or the lowest VWAP during the ten trading days prior to the default.

The March 2025 Convertible Note is secured by substantially all the Company’s assets and includes certain covenants which restrict the Company’s ability to incur additional indebtedness, grant liens, pay dividends, or dispose of assets without the lender’s consent.

In connection with the March 2025 SPA and March 2025 Convertible Note, the Company also issued 313 shares of common stock to the investor as additional consideration for entering into the agreement, which were classified in stockholders’ equity upon issuance.

21

Table of Contents

 

After analyzing the terms of the March 2025 Convertible Note and its embedded features, the Company elected to account for the March 2025 Convertible Note at fair value under the allowable fair value option election. As such, the Company initially recognized the March 2025 Convertible Note at its fair value of $238,020 and will subsequently measure the note at fair value with changes in fair value recorded in current period earnings. The original discount of $8,696 was recognized in the consolidated statements of operations as the March 2025 Convertible Note is recognized at fair value on a recurring basis. The Company recognized a loss of $138,020 on initial recognition of the March 2025 Convertible Note as the fair value of the March 2025 Convertible Note exceeded the proceeds of $100,000, received on issuance.

On October 21, 2025, the March 2025 Convertible Note consisting of principal amount of $108,696 and accrued interest of $44,017, with an aggregate amount of $152,713, was converted to an aggregate of 4,009 shares of the Company’s common stock at a conversion rate of $75.60 per share. The Company accounted for the conversion under the debt extinguishment model and recognized a loss on extinguishment of $150,340, reflecting the difference between the carrying value of the note being converted and the fair value of the shares of common stock issued upon conversion (which was $303,053).

Following this transaction, the March 2025 Convertible Note was fully settled, and no principal remained outstanding as of September 30, 2026, and December 31, 2025.

The interest expense recognized on the March 2025 Convertible Note for the three and nine months ended September 30, 2025, was $7,737 and $12,895, respectively. The Company recognized a change in fair value of $113,044 and $31,148 for the three and nine months ended September 30, 2025, respectively (See Note 16 – Fair Value Measurements).

April 2025 Promissory Note

On April 15, 2025, the Company issued an unsecured promissory note to an institutional investor (the “April 2025 Promissory Note”), with a principal balance of $70,000. The April 2025 Promissory Note bears interest at a fixed rate of 12.00% per annum for the six-month term, equivalent to 2% of the principal balance per month ($1,400 per month), with interest payments due on the 15th day of each month, beginning May 15, 2025. Principal and all outstanding interest was due and payable on October 15, 2025 (the “Maturity Date”).

Upon an event of default, the interest rate increases to the greater of 24% per annum or the maximum rate allowed by law. If any payment is not made within six calendar days of its due date, a late charge equal to 5% of the overdue amount is assessed. The April 2025 Promissory Note may be prepaid in whole or in part at any time upon five business days’ notice to the lender, without penalty or premium. The April 2025 Promissory Note is unsecured.

On May 30, 2025, the Company issued a convertible promissory note (“May 2025 Convertible Note”) with a principal amount of $216,871. The issuance of the May 2025 Convertible Promissory Note resulted in the modification of the previously outstanding April 2025 Promissory Note.

The May 2025 Convertible Note states that the amount due and owing under the original April 2025 Promissory Note is consolidated with the new May 2025 Convertible Note under the terms and conditions set forth therein; and hence, this consolidation leads to a modification of the original debt arrangement. The modification involved changes to the terms and cash flows of the debt. The present value of the cash flows under the new May 2025 Convertible Note differed by more than 10% from the present value of the remaining cash flows under the original April 2025 Promissory Note, exceeding the 10 percent threshold prescribed by ASC 470-50. As a result, the modification was accounted for as an extinguishment of the original April 2025 Promissory Note.

In accordance with ASC 470-50, the original April 2025 Promissory Note was derecognized, and the new May 2025 Convertible Note was recognized at its fair value. Any gain or loss resulting from the extinguishment was recognized in earnings for the period.

The Company recognized the May 2025 Convertible Note at fair value at $342,996 and recognized a loss of $126,125 on derecognition of the original April 2025 Promissory Note. Refer to the May 2025 Convertible Note section below.

May 2025 Convertible Note

On May 30, 2025, the Company issued the May 2025 Convertible Note, which is one of a series of duly authorized and validly issued promissory notes of the Company, issued and sold by the Company pursuant to the September 2024 Securities Purchase Agreement, dated as of March 31, 2025. The principal amount of the May 2025 Convertible Note is $216,871. The May 2025 Convertible Note combines the outstanding amount due under the April 2025 Promissory Note, totaling $70,431, with an additional $146,440 of new funding to issue a single Convertible Promissory Note in the principal amount of $216,871. The note matured on November 1, 2025, and accrues interest at 5% per annum, payable monthly in cash. The May 2025 Convertible Note provides for a minimum interest amount equal to 5% of the initial principal, fully earned and accrued on the original issue date, and payable monthly and any remaining amount upon repayment. Upon an event of default, the interest rate increases to 24% per annum or the maximum rate permitted by law.

The May 2025 Convertible Note is convertible into shares of the Company’s common stock at any time while outstanding, at a conversion price equal to the lowest trading price of the Company’s common stock at any time after the original issue date.

The May 2025 Convertible Note is prepayable at any time (unless an event of default has occurred) with advance notice and is mandatorily prepayable upon the occurrence of a subsequent offering, with the redemption amount paid from the financing proceeds. Before any prepayment can be made, the holder has the option to convert the May 2025 Convertible Note into common stock at a conversion price equal to the lowest Trading Price (as defined in the May 2025 Convertible Note) of a share of the Company’s common stock at any time after the Original Issue Date, with respect to the prepayment amount. The May 2025 Convertible Note can be accelerated upon an event of default either automatically or at the option of the Holder, depending on the nature of the event. Upon an uncured event of default, the Holder may accelerate the note and require immediate payment of all outstanding principal and accrued interest.

If any payment due under the May 2025 Convertible Note is not paid when due, the Company shall pay a late fee equal to ten percent (10%) of such payment, due and payable immediately upon such failure. The May 2025 Convertible Note states that the amount due and owing under the previously outstanding April 2025 Promissory Note is consolidated with the new May 2025 Convertible Note under the terms and conditions set forth therein; this consolidation led to a modification and extinguishment of the original April 2025 Promissory Note, as disclosed separately. Refer to the note above, related to the April 2025 Promissory Note for details.

22

Table of Contents

 

The Company elected to account for the May 2025 Convertible Note at fair value under the allowable fair value option election. As such, the Company initially recognized the May 2025 Convertible Note at its fair value of $342,996 and subsequently measured the note at fair value with changes in fair value recorded in current period earnings.

On September 3, 2025, the May 2025 Convertible Note was amended, and the principal amount was increased by $62,500 which is payable on November 1, 2025.

On February 23, 2026, the May 2025 Convertible Note having a fair value of $311,586, was converted to an aggregate of 10,815 shares of the Company’s common stock at a conversion rate of $27.68 per share. The Company accounted for the conversion under the extinguishment accounting model and recognized a change in fair value of $(12,239) reflecting the difference between the carrying value of the note being converted and the fair value of the shares of common stock issued upon conversion.

Following this transaction, the May 2025 Convertible Note was fully settled, and no principal remained outstanding as of September 30, 2026.

The interest expense recognized on the May 2025 Convertible Note for the three and nine months ended September 30, 2026, and 2025 was $0, and $0, respectively. The Company recognized a change in fair value of $0 and $(62,473) for the three and nine months ended September 30, 2026, and a change in fair value of $17,109 and $79,609 for the three and nine months ended September 30, 2025, respectively. (See Note 16 – Fair Value Measurements).

October 2025 Convertible Note

On October 29, 2025, the Company entered into a convertible note purchase agreement (the “October 2025 Convertible Note Agreement”) with an accredited institutional investor (the “October 2025 Convertible Note Investor”), whereby the October 2025 Convertible Note Investor purchased a convertible promissory note in the initial principal amount of $217,391 (the “October 2025 Convertible Note”) and 625 shares  of the Company’s common stock for an aggregate purchase price of $201,000. Pursuant to the October 2025 Convertible Note Agreement, until the later of (i) 12 months after execution of the October 2025 Convertible Note Agreement and (ii) the Company’s obligations under the October 2025 Convertible Note are no longer outstanding, the October 2025 Convertible Note Investor has the right, but not the obligation, to purchase another convertible promissory note from the Company on the same terms and conditions as the October 2025 Convertible Note. The October 2025 Convertible Note accrues interest at a rate of 18% per annum; provided that interest for the first eight months accrues immediately and is guaranteed. Interest may be paid in cash or in common stock, as determined by the October 2025 Convertible Note Investor, commencing on December 1, 2025, and the October 2025 Convertible Note matures on October 29, 2026. The Company may prepay 100% of the outstanding balance of the October 2025 Convertible Note at any time the Company is not in default, provided that the Company pays a prepayment fee equal to 10% of the outstanding balance. At any time after January 29, 2026, the October 2025 Convertible Note Investor may convert any portion of the outstanding balance of the October 2025 Convertible Note into common stock at a price equal to $0.48 per share, subject to adjustments for dilutive issuances, stock splits, defaults, and low volume of the common stock, as described further therein. The October 2025 Convertible Note may not be converted by the October 2025 Convertible Note Investor into shares of common stock if such conversion would result in the October 2025 Convertible Note Investor and its affiliates owning in excess of 9.99% of the number of shares of the common stock outstanding immediately after giving effect to the issuance of all shares issuable upon conversion of the October 2025 Convertible Note. The October 2025 Convertible Note contains standard and customary events of default and covenants, including that, for as long as the October 2025 Convertible Note remains outstanding: (1) the Company is prohibited from entering into a variable rate transaction, (2) the Company is required to provide the October 2025 Convertible Note Investor with any more favorable terms granted to any future purchaser or holder of the Company’s debt or securities and (3) if the Company conduct a Qualified Financing (as defined in the October 2025 Convertible Note), the Company must prepay the October 2025 Convertible Note out of proceeds from the Qualified Financing and/or the October 2025 Convertible Note Investor may convert October 2025 Convertible Note at the lower of the conversion price then in effect and 75% of the effective price at which the Company issues securities in the Qualified Financing.

On December 18, 2025, the Company made a payment of $295,290, which included repayment of the $217,391 principal amount, accrued interest of $26,086, and default interest of $51,813. Following this payment, the October 2025 Convertible Note was fully satisfied.

Exchange Note

In connection with a securities purchase agreement by and among DHAC, VSee Lab, iDoc and an investor (the “Bridge Investor”) dated October 5, 2022 (the “Original Bridge SPA”), DHAC, VSee Lab, and iDoc each issued to the Bridge Investor a 10% original issue discount senior secured convertible notes (collectively the “Original Bridge Notes” and individually, the “DHAC Bridge Notes,” “VSee Bridge Notes” and “iDoc Bridge Notes” when referring to Original Bridge Notes issued to DHAC, VSee Lab, and iDoc, respectively) in an aggregate principal amount of approximately $2,222,222. On November 21, 2023, DHAC, VSee Lab, iDoc and the Bridge Investor entered into an Exchange Agreement. Pursuant to the Exchange Agreement, the Bridge Investor agreed to exchange all amounts currently due and owing under (i) the DHAC Bridge Note, (ii) the VSee Bridge Note other than the principal amount of $600,000 thereof, and (iii) the iDoc Bridge Note other than the principal amount of $600,000 thereof for a senior secured convertible promissory note with an aggregate principal value of $2,523,744 (the “Exchange Note”). As such, the Company issued and sold the Exchange Note to the Bridge Investor in connection with the closing of the Business Combination on June 24, 2024. The transactions contemplated by the Exchange Agreement and the Exchange Note is hereby referred as the “Exchange Financing.”

The Exchange Note bears interest at a rate of 8% per annum and is convertible into shares of common stock of VSee Health at a fixed conversion price of $10 per share. The conversion price of the Exchange Note is subject to reset if the Company’s common stock trades below $10.00 on the 10th business day after the conversion shares are registered or may otherwise be freely resold, and every 90th day thereafter, to a price equal to the greater of (x) 95% of the average lowest VWAP of the Company’s common stock in the during the 10 trading days prior to the measurement date and (y) $2.0. Amounts repaid may not be reborrowed. The Bridge Investor may set off and deduct the amounts due under the Exchange Note pursuant to and in accordance with the terms of the Exchange Agreement. The Exchange Note is also guaranteed by each of the Company, VSee Lab and iDoc and is fully secured by collateral of the Company and its subsidiaries including, without limitation, the intellectual property, trademark, and patent rights. The conversion price is subject to standard antidilution adjustments, including adjustments for stock splits, dividends, mergers, asset sales, volume resets, defaults, and down-round events.

23

Table of Contents

 

The monetary amount of the obligation is a fixed monetary amount known at inception as represented by the Amortization of Principal Schedule in the Exchange Note (each, an “Amortization Payment”). As a result, the Exchange Note represents a debt instrument that the Company must or may settle by issuing a variable number of its equity shares as each Amortization Payment shall, at the option of the Company, be made in whole or in part, in immediately available Dollars equal to the sum of the Amortization Payments provided for in the Exchange Note or, subject to the Company complying with the equity conditions provided for in the Exchange Note on the date of such Amortization Payment, in common stock issued at 95% of the lowest VWAP in the prior ten (10) trading days prior to such Amortization Payment (the “Amortization Conversion Price”) but in no event will common stock be used to make such Amortization Payment if the Amortization Conversion Price is less than $2.00, subject to standard antidilution adjustments, including adjustments for stock splits, dividends, mergers, asset sales, volume resets, defaults, and down-round events.

The Exchange Note represents share-settled debt that requires or may require the Company to settle the debt instrument by delivering a variable number of shares with a then-current fair value equal to the principal amount of the note plus accrued and unpaid interest. As a result, the Exchange Note is required to be accounted for as a liability under ASC 480. As required under ASC 480, the liability will be re-measured at fair value at each reporting period with the changes in the fair value of the liability recognized in earnings.

On August 8, 2024, $566,740 outstanding principal on the Exchange Note was converted into 2,673 shares of Common Stock, at a conversion price based on a 5% discount to the prior trading day VWAP. The Company accounted for the conversion under the debt extinguishment model and recognized a loss on extinguishment of $98,050, reflecting the difference between the carrying value of the Exchange Note being converted (recorded at fair value) and the fair value of the shares of common stock issued upon conversion (which was $664,790).

On November 26, 2024, $500,000 of outstanding principal with accrued interest expense of $11,693 on the Exchange Note was converted into 3,199 shares of common stock. The portion of the Exchange Note converted on this date had a fair value of $512,693.

On September 3, 2025, $304,288 of outstanding principal with accrued interest expense of $137,057 and default interest expense of $13,712 on the Exchange Note was converted into 7,500 shares of common stock. The portion of the Exchange Note converted on this date had a fair value of $450,000.

In October 2025, $1,219,516 of outstanding principal with accrued interest expense of $34,959 on the Exchange Note was converted into 20,922 shares of common stock. The Company accounted for the conversion as a change in fair value of $34,541 reflecting the difference between the carrying value of the note being converted and the fair value of the shares of common stock issued upon conversion (which was $1,289,840).

Following this transaction, the Exchange Note was fully settled, and no principal remained outstanding as of September 30, 2026, and December 31, 2025.

The Company recognized an interest expense of $125,454 and $186,403 for the three and nine months ended September 30, 2025, respectively and a change in fair value of $1,007,478 and $20,842 for the three and nine months ended September 30, 2025, respectively. (See Note 16 – Fair Value Measurements).

Quantum Financing Purchase Agreement

On November 21, 2023, DHAC entered into a convertible note purchase agreement (the “Quantum Purchase Agreement”), pursuant to which an institutional and accredited investor (the “Quantum Investor”) subscribed for and purchased, and DHAC would issue and sell to the Quantum Investor, at the closing of the Business Combination, a 7% original issue discount convertible promissory note (the “Quantum Convertible Note”) in the aggregate principal amount of $3,000,000.

The Quantum Convertible Note was issued and sold to the Quantum Investor subsequent to the closing of the Business Combination on June 25, 2024. The Quantum Convertible Note was further amended on July 3, 2024, whereby the maturity date of the Quantum Convertible Note was changed from June 25, 2025, to June 30, 2026, and that eighteen months of interest will be guaranteed regardless of early pay or redemption. Furthermore, the Quantum Convertible Note bears an interest at rate of 12% per annum and are convertible into shares of the Company’s Common Stock at (1) a fixed conversion price of $10.00 per share; or (2) 85% of the lowest daily VWAP (as defined in the Quantum Convertible Note) during the seven (7) consecutive trading days immediately preceding the date of conversion or other date of determination. The conversion price of the Quantum Convertible Note is subject to reset if the average of the daily VWAPs for the three (3) trading days prior to the 30-day anniversary of the Quantum Convertible Note issuance date (the “Average Price”) is less than $10.00, to a price equal to the Average Price but in no event less than $2.00. In addition, the Company at its option can redeem early a portion or all amounts outstanding under the Quantum Convertible Note if the Company provides the Quantum Convertible Note holder a notice at least ten (10) trading days prior to such redemption and on the notice day the VWAP of the Company’s Common Stock is less than $10.00. If an event of default occurs, the Quantum Convertible Note would bear interest at a rate of 18% per annum. The conversion price is subject to standard antidilution adjustments, including adjustments for stock splits, dividends, mergers, asset sales, volume resets, defaults, and down-round events.

On June 25, 2024, $2,700,000 net of originally issued discount of $210,000 and legal fees of $90,000 pursuant to the Quantum Convertible Note has been funded to the Company. The Quantum Convertible Note represents share-settled debt that requires or may require the Company to settle the debt instrument by delivering a variable number of shares with a then-current fair value equal to the principal amount of the note plus accrued and unpaid interest. As a result, the Quantum Convertible Note was accounted for as a liability under ASC 480 upon funding of the note. As required under ASC 480, the liability will be re-measured at fair value at each reporting period with the changes in the fair value of the liability recognized in earnings. The original issue discount of $210,000 and direct cost of $90,000 was recognized as interest expense.

On July 3, 2024, the Company and the Quantum Investor agreed to modify certain terms of the Quantum Convertible Note. The modifications included the extension of the maturity date from June 25, 2025, to June 30, 2026, and an interest guarantee whereby the Quantum Investor would receive 18 months of interest regardless of any early repayment or redemption of the Quantum Convertible Note. The Company concluded that these changes represented a modification for accounting purposes as the change in the present value of the cash flows was less than 10% and the change in the estimated fair value of the embedded conversion right was less than 10% of the carrying value. As such, the Company accounted for the change in fair value related to the modification of terms as part of the change in fair value of the Quantum Convertible Note during the ended December 31, 2024 (See Note 16 - Fair Value Measurements).

24

Table of Contents

 

On April 4, 2025, the Company issued 6 shares of its common stock to the Quantum investor at par value of $0.0001 per share.

On August 28, 2025, the Company agreed to issue 6,250 shares of its common stock, to the Quantum investor as consideration for facilitating emergency funding to support the Company. On October 28, 2025, the Company issued the 6,250 shares of its common stock to the Quantum investor in satisfaction of its previously recorded obligation.

On August 28, 2025, the Company and the Quantum Investor agreed to modify certain terms of the Quantum Convertible Note. The modifications included the increase in the aggregate principal amount of the note from $3,000,000 to $3,380,000 and interest on outstanding principal balance increased to an annual rate of 22% upon an Event of Default for so long as it remains uncured.

In October 2025, the Quantum Convertible Note consisting of $3,000,000 of principal and $1,196,203 of accrued interest, with an aggregate amount of $4,196,203 was converted to an aggregate of 55,000 shares of the Company’s common stock. The Company accounted for the conversion as a change in fair value of $739,797 reflecting the difference between the carrying value of the note being converted and the fair value of the shares of common stock issued upon conversion (which was $4,936,550).

In May 2026, the Quantum Convertible Note consisting of $399,364 of principal and $0 of accrued interest, with an aggregate amount of $399,364 was converted to an aggregate of 34,324 shares of the Company’s common stock. The Company accounted for the conversion as a change in fair value of $122,358 reflecting the difference between the carrying value of the note being converted and the fair value of the shares of common stock issued upon conversion (which was $521,721).

As of September 30, 2026, and December 31, 2025, the Quantum Convertible Note’s fair value was $0 and $351,307, respectively. The Company recognized interest expense of $0 and $11,243 for the three and nine months ended September 30, 2026, and $318,157 and $858,157 for the three and nine months ended September 30, 2025, respectively, and a change in fair value of $0 and $159,171 for the three and nine months ended September 30, 2026, and a change in fair value of $131,937 and $200,675 for the three and nine months ended September 30, 2025, respectively (See Note 16 - Fair Value Measurements).

September 2024 Security Purchase Agreement

On September 30, 2024, the Company entered into a securities purchase agreement (the “September 2024 SPA”) with an accredited and institutional investor, pursuant to which the Company issued and sold to the investor promissory notes for an aggregate principal amount of $2,222,222 (the “September 2024 Convertible Note”). The Company received $2,000,000 in initial proceeds from the September 2024 Convertible Note, reflecting a 10% original issue discount. The September 2024 Convertible Note had an original maturity date of March 30, 2026, and provides for a minimum interest amount at 15% of the initial principal amount of the note through maturity, or $333,333. Interest in excess of the minimum interest amount (if applicable) will accrue at a rate of 10% per annum. The interest rate on the September 2024 Convertible Note will increase to 24% per annum upon the occurrence of an event of default. The minimum interest amount is payable in 18 equal installments of $18,519 per month beginning on November 1, 2024. Repayments of principal will be paid in 12 equal installments of $185,185 per month beginning on May 1, 2025. Any repayments of principal that are not funded through draws on the ELOC Agreement are subject to a 5% cash payment fee.

The September 2024 Convertible Note is convertible into shares of the Company’s common stock at any time at an initial fixed conversion price of $2.00 per share, subject to certain beneficial ownership and exchange cap considerations. The conversion price includes standard antidilution adjustments as well as adjustment in the event the Company sells or issues shares of common stock at a price less than the conversion price (a down-round event). The September 2024 Convertible Note is prepayable at any time (unless an event of default has occurred) based on the outstanding principal, accrued interest and any remaining minimum interest amount payable through the remainder of the term of the note. The September 2024 Convertible Note is mandatorily prepayable upon the occurrence of certain events (such as the issuance of stock or incurrence of debt) and can be accelerated upon an event of default either automatically or at the option of the note holder, depending on the nature of the event.

The September 2024 Convertible Note is secured by substantially all of the Company’s assets and includes certain covenants which restrict the Company’s ability to enter into certain agreements or transactions without the lender’s consent.

In connection with the September 2024 SPA and September 2024 Convertible Note, the Company also issued a warrant to the investor to purchase up to 740,741 shares of the Company’s common stock. The warrant exercise price is $180.00 per share (exercisable on a cash or cashless basis) and will expire on September 30, 2029. The exercise price includes standard antidilution adjustments as well as adjustment in the event the Company sells or issues shares of common stock at a price less than the exercise price (a down-round event). The Company assessed the warrant as a freestanding financial instrument and determined it did not include any provisions which would require liability classification under ASC 480, and that it met the requirements to be considered indexed to the Company’s own stock and the additional equity classification requirements under ASC 815-40. As such, the Company classified the warrant in stockholders’ equity upon its issuance. In addition, upon execution of September 2024 SPA, the Company issued 1,250 shares of common stock to the investor as additional consideration for entering into the September 2024 SPA and related agreements, which were also classified in stockholders’ equity upon issuance.

After analyzing the terms of the September 2024 Convertible Note and its embedded features, the Company elected to account for the September 2024 Convertible Note at fair value under the allowable fair value option election. As such, the Company initially recognized the September 2024 Convertible Note at its fair value and will subsequently measure the note at fair value with changes in fair value recorded in current period earnings (or other comprehensive income, if specific to Company credit risk). The Company initially recorded the September 2024 Convertible Note at its estimated issuance date fair value of $2,000,000, based on the initial proceeds received. As the proceeds were allocated in full to the September 2024 Convertible Note recorded at fair value, there were no proceeds remaining to allocate to the equity-classified warrants or shares issued under the terms of the September 2024 SPA, on a residual basis. In addition, the Company allocated the issuance costs incurred to the September 2024 Convertible Note, and as such expensed the $95,000 in issuance costs incurred.

In October 2025, outstanding principal of $2,222,222 and accrued interest of $555,815 on the September 2024 Convertible Note was converted into 46,234 shares of common stock at conversion rates between $56.00 and $110.40 per share.

25

Table of Contents

 

Following this transaction, the September 2024 Convertible Note was fully settled, and no principal remained outstanding as of December 31, 2025. The Company accounted for the conversion as a change in fair value of $958,791 reflecting the difference between the carrying value of the note being converted and the fair value of the shares of common stock issued upon conversion (which was $3,732,827).

The Company recognized interest expense of $123,704 and $240,370 for the three and nine months ended September 30, 2025, respectively, and a total change in fair value of $875,115 and $50,240 for the three and nine months ended September 30, 2025, respectively (See Note 16 - Fair Value Measurements).

ADI Funding Convertible Note 

On June 8, 2026, the Company entered into a Securities Purchase Agreement with ADI Funding, LLC (“ADI Funding”), pursuant to which the Company issued a secured promissory note with an aggregate principal amount of $271,739 (the “ADI Funding Convertible Note”). The Company received gross proceeds of $250,000, reflecting an original issue discount of $21,739, or 8% of the principal amount. The ADI Funding Convertible Note matures on November 30, 2026, and bears interest at a rate of 18% per annum. Pursuant to the terms of the ADI Funding Convertible Note, interest for the first six months on the principal amount accrues immediately and is guaranteed. Interest is payable monthly beginning June 30, 2026, and may be paid in cash or shares of the Company's common stock at ADI Funding’s sole discretion.

The outstanding balance under the ADI Funding Convertible Note is due on November 30, 2026, unless earlier prepaid, accelerated upon an event of default, or converted in accordance with its terms. The Company may voluntarily prepay all or any portion of the outstanding balance at any time, provided that no event of default exists, at a redemption price equal to 110% of the amount being prepaid, together with any other amounts then due under the ADI Funding Convertible Note. In addition, upon receipt of proceeds from the Company's equity line of credit facility, the Company is required to repay the entire outstanding balance within two business days.

Upon the occurrence and continuation of an event of default, the interest rate automatically increases to the lesser of 28% per annum or the maximum rate permitted by applicable law. Following an uncured event of default, ADI Funding may accelerate the ADI Funding Convertible Note and require payment of a mandatory default amount equal to 120% of the outstanding principal and accrued interest. In the event the outstanding balance is not repaid by the maturity date, ADI Funding may convert all or any portion of the outstanding balance into shares of the Company's common stock at a conversion price equal to 80% of the lowest closing market price of the Company's common stock during the ten trading days immediately preceding the applicable conversion notice, subject to a beneficial ownership limitation of 4.99%, which may be increased to 9.99% upon prior notice by ADI Funding.

After evaluating the terms of the ADI Funding Convertible Note, including its conversion, redemption and default provisions, the Company elected the fair value option pursuant to ASC 825, Financial Instruments. Accordingly, the ADI Funding Convertible Note was initially recorded at fair value and will be subsequently remeasured at fair value at each reporting date, with changes in fair value recognized in the condensed consolidated statements of operations. The Company initially recorded the ADI Funding Convertible Note at its estimated issuance date fair value of $250,000, based on the proceeds received. Because the proceeds were fully allocated to the ADI Funding Convertible Note, no proceeds were allocated to any other equity-linked features or instruments associated with the financing.

On June 12, 2026, the Company received a notice from ADI Funding alleging that an event of default had occurred under the ADI Funding Convertible Note and related transaction documents. On July 21, 2026, thereafter, the Company entered into a Settlement Agreement and Mutual Release (the "Settlement Agreement") with ADI Funding and M2B Funding Corp. ("M2B"). The Settlement Agreement was entered into to resolve all disputes among the parties arising from the alleged default and to establish revised settlement and repayment terms related to the outstanding indebtedness owed to ADI Funding.

Pursuant to the Settlement Agreement, the Company agreed to repay the ADI Funding Convertible Note, including accrued interest and other amounts due thereunder, on the earlier of (i) ninety (90) days following execution of the Settlement Agreement or (ii) immediately upon receiving proceeds from certain financing transactions. In addition, until the ADI Funding Convertible Note is repaid in full, the Company is required to apply fifty percent (50%) of gross proceeds received from financing transactions toward repayment of the note, except proceeds received under the M2B equity line of credit arrangement, for which one hundred percent (100%) of proceeds are required to be applied toward repayment. The Settlement Agreement established a payoff amount of $296,196, consisting of outstanding principal of $271,739, accrued and unpaid interest, and amounts associated with acceleration provisions under the original note.

As additional consideration under the Settlement Agreement, the Company agreed to (i) pay ADI Funding $50,000 in cash, (ii) issue the ADI Promissory Note with a principal amount of $50,000, and (iii) issue 6,250 shares of the Company's common stock with piggyback registration rights. The Company made the $50,000 cash payment and issued 6,250 shares of common stock required under the agreement.

The Company evaluated the revised rights and obligations arising from the Settlement Agreement and concluded that the transaction should be accounted for as an extinguishment of the ADI Funding Convertible Note. As part of the extinguishment, the existing note was replaced with a revised debt arrangement consisting of the modified ADI Funding Convertible Note, the ADI Promissory Note of $50,000, the $50,000 cash payment and the common shares issued pursuant to the Settlement Agreement. Based on the fair value of the consideration transferred and obligations assumed, the Company recognized a loss on extinguishment of debt of $126,189 during the three and nine months ended September 30, 2026. The modified ADI Funding Convertible Note remained outstanding following the settlement and continues to represent a payable obligation of the Company. Accordingly, the modified ADI Funding Convertible Note was initially recorded at fair value upon extinguishment and is subsequently remeasured at fair value at each reporting date, with changes in fair value recognized in the condensed consolidated statements of operations. The ADI Promissory Note is accounted for separately and is likewise measured at fair value at each reporting date, with changes in fair value recognized in the condensed consolidated statements of operations.

Upon settlement of the original ADI Funding Convertible Note on July 21, 2026, the Company determined the fair value of the modified ADI Funding Convertible Note based on its original contractual terms and recorded the note at an initial fair value of approximately $235,522. Because the carrying value of the original ADI Funding Convertible Note immediately prior to extinguishment was approximately $254,833, the Company recognized a gain on extinguishment of financial liabilities of $19,311. 

26

Table of Contents

 

As of September 30, 2026, and December 31, 2025, the ADI Funding Convertible Note’s fair value was $283,748 and $0, respectively. The Company recognized a change in fair value of $45,817 and $53,059 for the three and nine months ended September 30, 2026, respectively (See Note 16 – Fair Value Measurements).

ClearThink Convertible Note

On June 22, 2026, the Company entered into a Securities Purchase Agreement with ClearThink Capital Partners, LLC (“ClearThink”), pursuant to which the Company issued an unsecured promissory note with a principal amount of $280,000 (“ClearThink Convertible Note”). The Company received gross proceeds of $250,000, reflecting an original issue discount of $30,000. The ClearThink Convertible Note matures on June 22, 2027. Pursuant to the terms of the ClearThink Convertible Note, a one-time interest charge of 12% of the principal amount, or $33,600, was applied on the issuance date. The accrued interest and outstanding principal are payable in seven monthly installments beginning on December 22, 2026, with six subsequent monthly payments thereafter and any remaining balance due on the maturity date. The Company may accelerate payments or prepay the note in full at any time without penalty.

The ClearThink Convertible Note is convertible, at the Holder's option, into shares of the Company's common stock beginning 180 days after issuance. The conversion price is equal to 85% of the lowest closing price of the Company's common stock during the ten trading days preceding the applicable conversion notice date, subject to a floor price of $0.01 per share. ClearThink’s conversion rights are subject to a beneficial ownership limitation of 4.99% of the Company's outstanding common stock. The floor price is subject to standard antidilution adjustments, including adjustments for stock splits, dividends, mergers, asset sales, volume resets, defaults, and down-round events.

Upon the occurrence and continuation of an event of default, including non-payment, breaches of covenants, bankruptcy-related events, delisting of the Company's common stock, or failure to comply with Exchange Act reporting obligations, the outstanding amount becomes immediately due and payable. Upon an event of default, ClearThink is entitled to receive a default amount equal to 120% of the outstanding principal balance, accrued and unpaid interest, default interest and other amounts due under the ClearThink Convertible Note. If such default amount remains unpaid, the Holder may convert all or a portion of the outstanding balance into shares of the Company's common stock in accordance with the conversion provisions of the ClearThink Convertible Note. The ClearThink Convertible Note also includes customary affirmative and negative covenants and default provisions.

After evaluating the terms of the ClearThink Convertible Note, the Company elected the fair value option pursuant to ASC 825, Financial Instruments. Accordingly, the ClearThink Convertible Note was initially recorded at fair value and will subsequently be remeasured at fair value at each reporting date, with changes in fair value recognized in the condensed consolidated statements of operations. The Company initially recorded the ClearThink Convertible Note at its issuance date fair value of $250,000. Because the proceeds were fully allocated to the ClearThink Convertible Note, no proceeds were allocated to any other embedded or freestanding equity-linked features associated with the financing.

As of September 30, 2026, and December 31, 2025, the ClearThink Convertible Note’s fair value was $273,302 and $0, respectively. The Company recognized a change in fair value of $23,302 for the three and nine months ended September 30, 2026 (See Note 16 – Fair Value Measurements).

Vanquish Funding Convertible Note

On June 18, 2026, the Company entered into a bridge note financing arrangement with Vanquish Funding Group Inc. (“Vanquish Funding”), pursuant to which the Company issued a bridge promissory note with an aggregate principal amount of $295,550 (the “Vanquish Funding Convertible Note”). The Company received net proceeds of approximately $250,000, reflecting an original issue discount of $38,550 and transaction-related fees of $7,000 payable at closing. The Vanquish Funding Convertible Note matures ten months from the issuance date and bears interest at a rate of 12% per annum. Pursuant to the terms of the Vanquish Funding Convertible Note, a minimum interest amount of $35,466 is due and payable to Vanquish Funding regardless of actual interest accrual.

Outstanding principal and interest under the Vanquish Funding Convertible Note are payable in five installments consisting of an initial payment of $165,508 due on December 15, 2026, followed by four monthly payments of $41,377 due on January 15, 2027, February 15, 2027, March 15, 2027, and April 15, 2027. The Company is entitled to a five-day grace period with respect to each payment, after which a missed payment constitutes an event of default.

The Vanquish Funding Convertible Note may be prepaid by the Company at any time, subject to payment of a specified percentage of the then-outstanding balance. The applicable prepayment percentage ranges from 95% during the first 60 days following issuance to 98% during days 121 through 180, as set forth in the Vanquish Funding Convertible Note.

Upon the occurrence of an event of default, the outstanding principal and interest balance of the Vanquish Funding Convertible Note is increased to 150% of the then-outstanding amount. Following an event of default, Vanquish Funding may, at its sole discretion, convert amounts outstanding under the Vanquish Funding Convertible Note into shares of the Company’s common stock at a conversion price equal to 75% of the lowest closing bid price of the Company’s common stock during the ten trading days immediately preceding conversion. Vanquish Funding’s conversion rights are subject to a beneficial ownership limitation of 4.99% of the Company’s outstanding common stock. In addition, unless an exception applies, conversions are subject to an exchange limitation that restricts issuances in excess of 19.99% of the Company’s outstanding common stock.

As of September 30, 2026, and December 31, 2025, the Vanquish Funding Convertible Note’s carrying value was $286,049 and $0, respectively. The Company recognized an interest expense of $36,049 for the three and nine months ended September 30, 2026.

Vanquish Funding Convertible Note - 2

On September 24, 2026, the Company entered into a securities purchase agreement with Vanquish Funding, pursuant to which the Company issued an unsecured convertible promissory note with an aggregate principal amount of $180,550, including an original issue discount of $23,550 (the "Vanquish Funding Convertible Note - 2"). The Vanquish Funding Convertible Note - 2 is subject to a one-time interest charge of 12% applied upon issuance and matures on July 30, 2027. The Company did not receive the proceeds until October 1, 2026, and its obligation to repay arose only upon funding. Accordingly, no liability was recognized in the condensed consolidated balance sheet as of September 30, 2026. The Company received net proceeds of $150,000 on October 1, 2026 (see Note 17 – Subsequent Events), and the note will be recognized in the subsequent quarter ended December 31, 2026.

27

Table of Contents

 

Labrys Convertible Promissory Note

On July 8, 2026, the Company entered into a Securities Purchase Agreement (the "Labrys SPA") with Labrys Fund II, L.P. ("Labrys"). Pursuant to the Labrys SPA, the Company issued an unsecured convertible promissory note with an aggregate principal amount of $336,000 (the "Labrys Convertible Promissory Note"), which included an original issue discount of $36,000, resulting in gross proceeds of $300,000 received by the Company. The Labrys Convertible Promissory Note is subject to a one-time interest charge equal to 12% of the principal amount, which was earned in full upon issuance, and matures on June 30, 2027. The Company may prepay the Labrys Convertible Promissory Note at any time prior to the date that is 181 days following issuance, subject to specified prepayment premiums. In addition, if the Company receives proceeds from certain financing transactions, asset sales, or other specified sources, Labrys may require the Company to apply up to 50% of such proceeds toward repayment of amounts outstanding under the Labrys Convertible Promissory Note. The Labrys Convertible Promissory Note is also subject to scheduled amortization payments beginning on December 30, 2026.

The Labrys Convertible Promissory Note is convertible into shares of the Company's common stock at the option of the holder upon the occurrence of certain events specified in the agreement, including the passage of time following issuance, the occurrence of certain payment defaults, or the effectiveness of a resale registration statement covering the underlying conversion shares. Upon the occurrence and continuation of an event of default, amounts outstanding under the Labrys Convertible Promissory Note become immediately due and payable and are subject to a default amount equal to 150% of the outstanding principal balance together with accrued and unpaid interest and applicable default interest.

After evaluating the terms of the Labrys Convertible Promissory Note, including its conversion, repayment, prepayment, and default provisions, the Company elected the fair value option pursuant to ASC 825, Financial Instruments, which allows the Labrys Convertible Promissory Note and its contractual features to be measured as a single instrument at fair value, eliminating the need to separately assess and account for such features.

Accordingly, the Labrys Convertible Promissory Note was initially recorded at its fair value of $250,000 and is subsequently remeasured at fair value at each reporting date, with changes in fair value recognized in the condensed consolidated statements of operations. The Company received net proceeds of $291,000 upon issuance. As a result, the Company recognized a gain on issuance of financial instruments of $41,000.

As of September 30, 2026, and December 31, 2025, the fair value of the Labrys Convertible Promissory Note was $372,017 and $0, respectively. The Company subsequently recognized a change in fair value of $122,017 for the three and nine months ended September 30, 2026 (See Note 16 - Fair Value Measurements).

ADI Promissory Note

As part of the Settlement Agreement and Mutual Release entered into on July 21, 2026, the Company issued a promissory note to ADI Funding LLC (the "ADI Promissory Note") with a principal amount of $50,000. The ADI Promissory Note was issued as settlement consideration in connection with the resolution of certain disputes and outstanding matters between the parties. The note matures on January 21, 2027, bears no interest prior to maturity, contains no original issue discount, and may be prepaid by the Company at any time without premium or penalty.

Upon non-payment of the outstanding balance at the maturity date, ADI may convert all or any portion of the outstanding balance into shares of the Company's common stock at a conversion price equal to 75% of the lowest volume weighted average price ("VWAP") of the Company's common stock during the twenty trading days immediately preceding the applicable conversion notice, subject to certain beneficial ownership limitations. In addition, the ADI Promissory Note becomes subject to an interest rate of 18% per annum, applied retroactively to the original issuance date. Prior to maturity, the ADI Promissory Note does not bear interest.

After evaluating the terms of the ADI Promissory Note, including its conversion and default provisions, the Company elected the fair value option pursuant to ASC 825, Financial Instruments. Accordingly, the ADI Promissory Note was initially recorded at fair value and is subsequently remeasured at fair value at each reporting date, with changes in fair value recognized in the condensed consolidated statements of operations.

As of September 30, 2026, and December 31, 2025, the fair value of the ADI Promissory Note was $61,628 and $0, respectively. The Company recognized a change in fair value of $11,628 and $11,628 for the three and nine months ended September 30, 2026, respectively (See Note 16 - Fair Value Measurements).

M2B Promissory Note

On April 22, 2026, the Company entered into an Equity Purchase Agreement with M2B Funding Corp. ("M2B") establishing an equity line of credit (the "M2B ELOC"). Under the M2B ELOC, the Company was required to issue commitment shares to M2B. In addition, the Securities Purchase Agreement with ADI Funding, LLC ("ADI") dated June 8, 2026, required the Company, no later than June 11, 2026, to file a registration statement on Form S-1 registering the shares issuable under the M2B ELOC, file a related Current Report on Form 8-K, and deliver irrevocable transfer agent instructions for the issuance of the commitment shares to M2B. The Company did not complete these actions by that date. ADI subsequently delivered a notice of default, and disputes arose with M2B concerning the Company's obligations under the M2B ELOC, including the issuance of the commitment shares and the related registration and SEC disclosure obligations.

On July 21, 2026, the Company, ADI and M2B entered into a Settlement Agreement and Mutual Release (the "Settlement Agreement") to resolve these disputes. In exchange for M2B's release of its claims, the Company issued M2B 6,250 common shares and a promissory note with a principal amount of $125,000 (“the M2B Promissory Note”). The M2B Promissory Note matures on January 21, 2027, contains no original issue discount, and may be prepaid by the Company at any time without premium or penalty.

28

Table of Contents

 

Upon non-payment of the outstanding balance at the maturity date, M2B may convert all or any portion of the outstanding balance into shares of the Company's common stock at a conversion price equal to 75% of the lowest volume weighted average price ("VWAP") of the Company's common stock during the twenty trading days immediately preceding the applicable conversion notice, subject to certain beneficial ownership limitations. In addition, the M2B Promissory Note becomes subject to an interest rate of 18% per annum, applied retroactively to the original issuance date. Prior to maturity, the M2B Promissory Note does not bear interest.

After evaluating the terms of the M2B Promissory Note, including its conversion and default provisions, the Company elected the fair value option pursuant to ASC 825, Financial Instruments. Accordingly, the M2B Promissory Note was initially recorded at fair value and is subsequently remeasured at fair value at each reporting date, with changes in fair value recognized in the condensed consolidated statements of operations.

The Company evaluated the settlement arrangement and recognized a loss on settlement of approximately $170,500 during the three and nine months ended September 30, 2026 (representing the fair value of the settlement shares of $45,500 and the initial fair value of the M2B Promissory Note of $125,000), which is recorded in the condensed consolidated statements of operations under “(Loss)/Gain on extinguishment of financial liabilities”. As of September 30, 2026, and December 31, 2025, the fair value of the M2B Promissory Note was $152,916 and $0, respectively. The Company recognized a change in fair value of $27,916 for each of the three and nine months ended September 30, 2026 (See Note 16 - Fair Value Measurements).

Other instruments

ELOC / Equity Financing

On November 21, 2023, DHAC entered into the equity line of credit purchase agreement ("ELOC Agreement") with the Bridge Investor pursuant to which DHAC may sell and issue to the Bridge Investor, and the Bridge Investor is obligated to purchase from DHAC, up to $50,000,000 of its newly issued shares of the Company's common stock, from time to time over a 36 month period beginning from the sixth (6th) trading day following the closing of the Business Combination transaction, provided that certain conditions are met. The choice to exercise the ELOC Agreement is solely at the discretion of the Company, and the ELOC Agreement does not impose a fee or fine if the Company chooses not to exercise the contract. When the Company's per share stock price drops below $2, the Bridge Investor has the discretion to decide whether to purchase the Company's common stock under the ELOC Agreement at a floor price of $2 per share. The Company has analyzed the ELOC Agreement and determined that the contract should be recorded as a liability under ASC 815 and measured at fair value, with re-measurement at each reporting period until the liability is settled. The Company has determined that the fair value of the ELOC Agreement is based upon management's expected usage of the facility. On March 20, 2025, the Company entered Amendment No. 1 to the ELOC Agreement, which modified the floor price to $1.25 and related terms of the ELOC Agreement. In accordance with ASC 815, the amendment requires remeasurement of the ELOC Agreement derivative liability at fair value as of the amendment date. The ELOC Agreement continued to be treated as a liability measured at fair value, with ongoing remeasurement at each reporting date until settlement.

On October 18, 2025, the Company terminated the ELOC Agreement. Upon termination, no further shares may be sold under the ELOC Agreement, and the Company has no remaining obligations under the Equity Purchase Agreement. In accordance with ASC 815, the termination represents a settlement event, and as such the Company has written off the ELOC Agreement liability through earnings as of the termination date. The Company recorded a gain on extinguishment of the ELOC Agreement liability amounting to $42, during the year ended December 31, 2025. There were no amounts outstanding as of September 30, 2026, and December 31, 2025, respectively.

Note 9 Standby Equity Purchase Agreement

June 2026 SEPA

On June 2, 2026, the Company entered into a Standby Equity Purchase Agreement ("June 2026 SEPA") with YA II PN, Ltd. (the "Investor"), pursuant to which the Company has the right, but not the obligation, to sell to the Investor up to $10.0 million of shares of the Company's common stock over a 36-month period, subject to the terms and conditions set forth in the SEPA. The June 2026 SEPA provides the Company with discretion to deliver advance notices requiring the Investor to purchase shares of common stock, subject to the effectiveness of a registration statement and other conditions precedent. The Investor's purchase obligation is subject to specified ownership limitations, including a 4.99% beneficial ownership cap. The purchase price for shares sold pursuant to an advance is equal to 97% of the lowest daily volume weighted average price ("VWAP") during the applicable three-trading-day pricing period.

The June 2026 SEPA became effective upon execution of the agreement on June 2, 2026.The SEPA liability was initially recognized at fair value upon issuance. On June 2, 2026, the Company recorded a SEPA liability with a fair value of $145,174 and recognized a corresponding loss on issuance of financial instruments of $145,174 in the condensed consolidated statement of operations.

The June 2026 SEPA liability is remeasured at fair value at each reporting date, with changes in fair value recognized in earnings. As of September 30, 2026, the fair value of the June 2026 SEPA liability was $116,319, and accordingly, change in fair value of $(28,855) was recognized for the three and nine months ended September 30, 2026 (See Note 16 - Fair Value Measurements).

As of September 30, 2026, no advances had been requested or completed under the SEPA and the June 2026 SEPA remained outstanding and available for future use by the Company, subject to the terms and conditions of the agreement.

Strata SEPA

On September 2, 2026, the Company entered into a Standby Equity Purchase Agreement (the "Strata SEPA") with ClearThink Capital Partners, LLC, pursuant to which the Company has the right, but not the obligation, to sell up to $5.0 million of shares of its common stock over a 36-month period. The Company may, from time to time, deliver purchase notices requiring the investor to purchase shares of common stock, subject to specified conditions, including the effectiveness of a registration statement covering the resale of such shares and a 9.99% beneficial ownership limitation. The purchase price for shares sold under the facility is generally equal to 85% of the lowest daily closing price of the Company's common stock during the applicable ten-trading-day valuation period. In connection with entering into the agreement, the Company issued 40,000 common shares to the investor as commitment shares.

29

Table of Contents

 

The Strata SEPA became effective upon execution of the agreement. As of September 30, 2026, the Company had not submitted any purchase notices and no shares had been sold under the facility. Upon issuance, the Company recorded a loss on issuance of financial instruments of $205,288 in the condensed consolidated statements of operations. The loss on issuance consisted of the initial fair value of the Strata SEPA liability of $137,288 and $68,000 of commitment fees, which were paid through the issuance of 40,000 shares of common stock to the investor.

The Strata SEPA liability is remeasured at fair value at each reporting date, with changes in fair value recognized in earnings. During the three and nine months ended September 30, 2026, the Company recognized a change in fair value of $(46,944). As of September 30, 2026, the fair value of the Strata SEPA liability was $90,344.

As of September 30, 2026, the Strata SEPA remained outstanding and available for future use by the Company, subject to the terms and conditions of the agreement.

Note 10 Related Party

Related Party Transactions by iDoc

(1)A related party balance due from the then CEO of iDoc, Imoigele Aisiku, for cash transferred through a company controlled by him. The balance due from the related party on September 30, 2026, and December 31, 2025, were $ 319,690 and $304,614 respectively. The transactions and amounts are unsecured and non-interest-bearing and are not necessarily what third parties would agree to.
   
(2)iDoc issued a promissory note on May 15, 2023, with a principal balance of $200,000 from a board member (“Holder”). The note bears no interest and was matured on May 15, 2026, and is past due. iDoc shall use the funds solely for the purchase of telepresence robots. The Holder has security rights to eight (8) telepresence robots, from the twelfth through twentieth, that iDoc deployed. iDoc is required to make payments to the Holder based on eighty percent (80%) of the monthly revenue generated on the eight telepresence robots from the twelfth through the twentieth deployment of the telepresence robots. As of September 30, 2026, and December 31, 2025, the related party promissory note amounted to $141,651, including a fair value adjustment of $58,349. The loan is included in the Related Party Loan Payable disclosure on the condensed consolidated balance sheets. No interest is recognized for the three and nine months ending September 30, 2026, and 2025. The note is currently in default and repayable on demand.

 

Related Party Transactions by VSee Health (DHAC)

(1)On November 21, 2023, DHAC entered into a convertible note purchase agreement, pursuant to which an institutional and accredited investor, the Quantum Investor, subscribed for and purchased, and the Company issued and sold to the Quantum Investor, after the Closing of the Business Combination on June 25, 2024, and as further amended on July 3, 2024, a 7% original issue discount convertible promissory note, the Quantum Convertible Note, in the aggregate principal amount of $3,000,000. SCS Capital Partners LLC, a Sponsor affiliate, owns approximately 40.74% of the Quantum Investor. As of September 30, 2026, and December 31, 2025, $0 and $351,307, respectively (inclusive of principal plus accrued interest) of the Quantum Convertible Note was due and payable.

 

 (2)On June 21, 2024, the Company entered into a Consulting Services Agreement with SCS, LLC (“SCS”), who is an affiliate of our Sponsor, pursuant to which we shall pay SCS $12,500 per month for business consulting services and $2,500 per month for access to remote office space in Boca Raton, Florida. In addition, the Consulting Services Agreement calls for the issuance of $25,000 worth of shares of common stock at issuance and an additional $25,000 worth of common stock on or about each of the Company’s filings on Form 10-K or Form 10-Q. The agreement shall continue for twelve (12) months and shall automatically continue on a six-month term basis thereafter unless terminated by either party. During the nine months ended September 30, 2026, the Company accrued expense amounting to $75,000, pertaining to the above-said agreements.
   
 (3)On June 24, 2024, DHAC owed the Sponsor and certain Sponsor affiliates $504,659 in advance to cover working capital needs, which were non-interest bearing due on demand. On June 25, 2024, $47,800 of such advances were repaid in cash. On November 8, 2024, the Sponsor affiliate, SCS and the Company executed a securities purchase agreement whereby certain working capital funds advanced by SCS in the aggregate amount of $405,000 as of December 31, 2024, were converted into 2,531 shares of Common Stock. The Company determined that the partial settlement of the working capital advances represented a troubled debt restructuring, as the Company determined it was experiencing financial difficulties and the lender granted a concession through the exchange for shares of Common Stock. Under the troubled debt restructuring accounting, the Company reduced the carrying amount of the working capital funds advances by the fair value of the shares of Common Stock issued ($261,225) and then compared the future undiscounted cash flows associated with the working capital advances to the carrying value. The Company determined an additional $143,775 reduction in the carrying value was necessary to equate it to the future undiscounted cash flows, representing a gain on restructuring. As SCS is a related party to the Company, the restructuring gain was treated as a capital transaction and recorded to additional paid in capital along with the fair value of the shares of common stock issued in the settlement. As of September 30, 2026, and December 31, 2025, $51,900 of advances due to the Sponsor and certain Sponsor affiliates remain due and payable. The Sponsor has no further obligation to fund working capital needs.

 

(4)On May 31, 2026, the Company entered into and consummated a Stock Purchase Agreement with Milton Chen, the Company's then co-Chief Executive Officer, Chairman of the Board, and Chief Executive Officer of VSee Lab, pursuant to which the Company sold all of its equity interests in VSee Lab, to Milton Chen and Milton Chen transferred to the Company 35,876 shares of the Company's common stock owned by him. See Note 3 – Discontinued Operations for further details.

 

30

Table of Contents

 

Related Party Transactions by VSee Labs

As VSee Labs was divested on May 31, 2026, the following related party transactions are presented solely for historical comparative purposes and relate to VSee Lab prior to its divestiture. (See Note 3 – Discontinued Operations)

(1)During the year ended December 31, 2022, employees subscribed $127,710 of cash for shares in VSee Lab representing 597,000 common stock shares in VSee Lab. As a result of the closing of the Business Combination, the shares were issued to the subscribing employees for total 239,424 shares of common stock in VSee Health, Inc. and as such the payable was reclassified to equity in additional paid in capital as share were issued. In addition, $210,796 of the related party payable was eliminated at consolidation between iDoc and VSee Lab.
   
(2)During the year ended December 31, 2022, VSee Lab received a loan of $110,000 from the then CEO, Milton Chen, for advanced cash and paid operating expenses incurred by VSee Lab. On March 29, 2023, VSee Lab revised the terms of the loan to a 10.00% original issue discount promissory note with a principal balance of $121,000 from Mr. Milton Chen for advanced cash and paid operating expenses on behalf of VSee Lab. Notes payable issued with a face value higher than the proceeds received are recognized as a debt discount and is amortized as interest expense via effective interest method over the life of the underlying note payable. The promissory note matured on June 27, 2023. Interest is accrued monthly at the annual fixed rate of 12.00%, with principal and interest due upon maturity. The note has a default interest rate of 26% from the default date. As of December 31, 2025, the related party promissory note, net of unamortized debt discount, was $121,000. The Company (as the successor of VSee Lab for accounting purposes) recognized interest expense of $0 and $7,757 for the three and nine months ended September 30, 2026. Accrued interest related to the promissory note was $80,850 as of December 31, 2025 and was included within accounts payable and accrued liabilities on the condensed consolidated balance sheets. On May 31, 2026, the Company completed the divestiture of VSee Lab. As a result of the divestiture and deconsolidation of VSee Lab, the related party promissory note and related accrued interest were eliminated from the Company's consolidated financial statements as of May 31, 2026.
   
(3)On March 29, 2023, VSee Lab received a 10.00% original issue discount promissory note with a principal balance of $132,000 from the then CEO, Milton Chen, for advanced cash and paid operating expenses on behalf of VSee Lab. Notes payable issued with a face value higher than the proceeds received are recognized as a debt discount and amortized via effective interest method as interest expense over the life of the underlying note payable. The promissory note matured on June 27, 2023. Interest is accrued monthly at the annual fixed rate of 12.00%, with principal and interest due upon maturity. The note has a default interest rate of 26% from the default date. As of December 31, 2025, the related party promissory note net of unamortized debt discount was $132,000. The Company (as the successor of VSee Lab for accounting purposes) recognized interest expense of $0 and $8,642 for the three and nine months ended September 30, 2026. The Company (as the successor of VSee Lab for accounting purposes) had accrued interest of $89,760 as of December 31, 2025, which was included within accounts payable and accrued liabilities on the condensed consolidated balance sheets. On May 31, 2026, the Company completed the divestiture of VSee Lab. As a result of the divestiture and deconsolidation of VSee Lab, the related party promissory note and related accrued interest were eliminated from the Company's consolidated financial statements as of May 31, 2026.
   
(4)On December 26, 2023, VSee Lab received a 10.00% original issue discount promissory note with a principal balance of $77,000 from the then CEO, Milton Chen, for advanced cash and paid operating expenses on behalf of the Company. Notes payable issued with a face value higher than the proceeds received are recognized as a debt discount and amortized via effective interest method as interest expense over the life of the underlying note payable. The promissory note matured on March 28, 2024. Interest is accrued monthly at the annual fixed rate of 12.00%, with principal and interest due upon maturity. The note has a default interest rate of 26% from the default date. As of December 31, 2025, the related party promissory note was $70,000. The Company (as the successor of VSee Lab for accounting purposes) recognized interest expense of $0 and $4,936 for the three and nine months ended September 30, 2026. The Company (as the successor of VSee Lab for accounting purposes) had accrued interest of $37,345 as of December 31, 2025, which was included within accounts payable and accrued liabilities on the condensed consolidated balance sheets. On May 31, 2026, the Company completed the divestiture of VSee Lab. As a result of the divestiture and deconsolidation of VSee Lab, the related party promissory note and related accrued interest were eliminated from the Company's consolidated financial statements as of May 31, 2026.

 

Note 11 Commitments, Contingencies, and Concentration Risk

Litigation

We are currently involved in, and may in the future be involved in, legal proceedings, claims, and government investigations in the ordinary course of business. These include proceedings, claims, and investigations relating to, among other things, regulatory matters, commercial matters, intellectual property, competition, tax, employment, pricing, discrimination, consumer rights, personal injury, and property rights.

Depending on the nature of the proceeding, claim, or investigation, we may be subject to settlement awards, monetary damage awards, fines, penalties, or injunctive orders. Furthermore, the outcome of these matters could materially adversely affect the Company’s business, results of operations, and financial condition. The outcomes of legal proceedings, claims, and government investigations are inherently unpredictable and subject to significant judgment to determine the likelihood and amount of loss related to such matters. While it is not possible to determine the outcomes, the Company believes based on its current knowledge that the resolution of its pending legal matter described below will not, either individually or in the aggregate, have a material adverse effect on the business, results of operations, cash flows or financial condition.

On April 21, 2026, Toppan Merrill LLC filed a lawsuit in the Superior Court in the County of Middlesex, Massachusetts. The plaintiff alleges that the Company owes $845,891 for services rendered by the plaintiff. The plaintiff is also seeking a preliminary injunction enjoining the Company from disposing assets outside of the ordinary course of business. The Company intends to vigorously defend itself against these allegations. The Company has accrued an amount it believes to be reasonable related to this matter based on the services reflected in its accounts payable balance, which differs from the amount claimed by the plaintiff.

31

Table of Contents

 

Encompass Purchase Liability

On January 1, 2022, iDoc acquired 100% of Encompass Healthcare Billing, LLC. (“Encompass”) with a stock purchase agreement to acquire the equity interests of Encompass, according to the acquisition agreement (“Encompass Acquisition Agreement”). Per the Encompass Acquisition Agreement, iDoc acquired all the outstanding shares of Encompass for a cash payment of $300,000, due upon the closing of the Business Combination. On January 9, 2023, iDoc agreed to an additional obligation of $45,000, which was accounted for as interest expense and reflected in accounts payable and accrued liabilities as of September 30, 2026.

On February 16, 2026, the Company entered into a settlement agreement to fully settle the Encompass Purchase liability for an aggregate amount of $650,000. The settlement consists of (i) a cash payment of $50,000, (ii) issuance of Company shares with an aggregate fair value of $400,000, and (iii) assignment of a loan liability of $200,000. The Company paid $50,000 per the settlement agreement and recognized a loan liability of $200,000 during the nine months ended September 30, 2026. The issuance of Company shares with an aggregate fair value of $400,000 remains pending as of September 30, 2026.

As of September 30, 2026, and December 31, 2025, the value of purchase liability related to the Encompass Acquisition agreement was $400,000 and $650,000, respectively.

Contingencies

During the normal course of business, the Company may be exposed to litigation. When the Company becomes aware of potential litigation, it evaluates the merits of the case in accordance with ASC 450, Contingencies. Litigation and contingency accruals are based on the Company’s assessment, including advice of legal counsel, regarding the expected outcome of litigation or other dispute resolution proceedings. If the Company determines that an unfavorable outcome is probable and the amount of loss can be reasonably estimated, it establishes the necessary accruals.

As of September 30, 2026, the Company has the following contractual commitments:

(1)iDoc entered into a purchase agreement with a vendor to purchase twenty (20) Telepresence Robots, receive maintenance services, and access user-related Ava Telepresence applications and the Ava Cloud Service for a total purchase commitment of $711,900. As of September 30, 2026, and December 31, 2025, the Company had an unpaid commitment of $179,900 and $179,900, respectively on this agreement. The commitment is not reflected in the condensed consolidated financial statements as it is due and payable upon invoicing from the vendor for delivery and servicing installation of the Telepresence Robots and software applications.
   
(2)iDoc has a promissory note with a principal balance of $200,000 with a related party (See – Note 10 Related Party Transactions by iDoc sub-point (2)). The related party has security rights to eight (8) telepresence robots, from the 13th to 20th, that iDoc deployed. iDoc is required to make payments to the holder based on eighty percent (80%) of the monthly revenue generated on the eight telepresence robots from the thirteenth through the twentieth deployment of the telepresence robots. The monthly revenue generated on the eight telepresence robots deployed by iDoc would be used to pay off principal balance of the note. Once the principal balance is paid off, iDoc will continue making payments through the deployment of 125 telepresence robots by iDoc.
   
(3)On May 12, 2023, iDoc entered in a partnership agreement with an accredited investor to agree and collaborate in the development of telepresence robots for telehealth solutions. The investor pledged to pay $352,000 directly to the vendor. In consideration thereof, the investor is entitled to 80% of the monthly revenue generated from the first eleven telepresence robots deployed by iDoc under the partnership agreement. Payments will continue until the last remaining robot is being paid for by customers and will remain as full payments for the length of time that a minimum of eleven robots is deployed. After the number reduces below eleven deployed robots, the amount will pro rate down but will remain in the same ratio as 80% of the monthly revenue generated.
   
(4)On January 16, 2026, the Company entered into a Stock Purchase Agreement with GoMyRx, Inc. ("GoMyRx") and Go Biz Holdings, LLC to acquire an approximately 10% ownership interest in GoMyRx for a total purchase consideration of $2,000,000 (See Note 2 Summary of Significant Accounting Policies – Long-term Investments). As of September 30, 2026, the Company had funded $749,800 of the total committed investment, of which $100,000 was funded in cash and $649,800 was satisfied through the issuance of 22,500 shares of the Company's common stock, resulting in an unfunded commitment of $1,250,200. The unfunded commitment is not reflected in the condensed consolidated financial statements as it will be recognized when the remaining consideration is funded.

 

VSee Health, Inc. Incentive Plan

DHAC approved and adopted the VSee Health, Inc. 2024 Equity Incentive Plan (the “2024 Plan”) to be effective as of one day prior to the closing Business Combination. The 2024 Plan provides for an initial share reserve equal to 15% of the number of shares of Company common stock outstanding (including shares of Company common stock issuable upon conversion of the outstanding Series A Preferred Stock) following the closing after giving effect to the Business Combination. As of September 30, 2026, the Company reserved 31,800 shares of its common stock for issuance under the 2024 Plan. On December 30, 2025, the Company’s stockholders approved the VSee Health, Inc. 2025 Equity Incentive Plan (the “2025 Plan”). The 2025 Plan provides for an initial share reserve equal to 31,918 shares of Company common stock. The number of shares of common stock available for issuance under the 2025 Plan automatically increases on January 1st of each year until the completion of the term of the 2025 Plan, so that the amount of shares of common stock of the Company issuable under the 2025 Plan will be equal to fifteen percent (15%) of the total number of outstanding shares of the Company’s common Stock as of December 31st of the preceding calendar year. There were 62,237 shares reserved for issuance under the 2025 Plan, of which 32 shares were available for future issuance.

Indemnities

The Company generally indemnifies its customers for the services it provides under its contracts and other specified liabilities, which may subject the Company to indemnity claims, liabilities, and related litigation. As of September 30, 2026, and December 31, 2025, the Company was unaware of any material asserted or unasserted claims concerning these indemnity obligations.

32

Table of Contents

 

Other Matters

The Company continues to analyze potential sales tax exposure using a state-by-state assessment. In accordance with ASC 450, Contingencies, the Company estimated and recorded a liability of $0 and $1.2 million as of September 30, 2026, and December 31, 2025, respectively, which is included within Accounts payable and accrued liabilities, a component of current liabilities from discontinued operations on the condensed consolidated balance sheets. The entire sales tax accrual recorded in the prior period related to VSee Lab and was derecognized upon the disposal.

Credit Risk and Major Customers/Supplier Concentration 

Financial instruments potentially subject the Company to credit risk concentrations consisting of cash and trade accounts receivables. The Company maintains all its cash in commercial depository accounts, insured by the Federal Deposit Insurance Corporation. At times, cash deposits may exceed federally insured limits. Any loss incurred or lack of access to such funds could have an adverse impact on the Company’s financial condition, results of operations, and cash flows.

In aggregate, the Company had two customers whose accounts receivable represented 23% of the Company’s total accounts receivable as of September 30, 2026. In the aggregate, the Company had three customers whose accounts receivable represented 49% of the Company’s total accounts receivable as of December 31, 2025.

The Company has one customer whose revenue accounted for approximately 40% and 42% of the Company’s total revenue for the three months ended September 30, 2026, and nine months ended September 30, 2026, respectively. The Company has three customers whose revenue accounted for approximately 54% and 50% of the Company’s total revenue for the three months ended September 30, 2025, and nine months ended September 30, 2025, respectively. Although the Company seeks to reduce dependence on those customers, the partial or complete loss of certain of these customers could have at least a temporary adverse effect on the Company’s results of operations.

The Company had three vendors whose accounts payable and accrued liabilities represented 78% of the Company’s total accounts payable and accrued liabilities as of September 30, 2026. The Company had one vendor whose accounts payable and accrued liabilities represented 30% of the Company’s total accounts payable and accrued liabilities as of December 31, 2025.

Note 12 Income Taxes

The components of our income (loss) before income taxes were as follows:

   For the nine months ended 
   September 30,
2026
   September 30,
2025
 
United States  $(4,593,095)  $(6,844,479)
Total  $(4,593,095)  $(6,844,479)

 

   For the three months ended 
   September 30,
2026
   September 30,
2025
 
United States  $(2,848,701)  $(289,745)
Total  $(2,848,701)  $(289,745)

The components of income tax expense (benefit) were as follows: 

   For the nine months ended 
   September 30,
2026
   September 30,
2025
 
Continuing operations  $5,260   $15,233 
Discontinued operations   3,335    2,756 
Total  $8,595   $17,989 

   For the three months ended 
   September 30,
2026
   September 30,
2025
 
Continuing operations  $         -   $        - 
Discontinued operations   -    - 
Total  $-   $- 

The Company evaluates and updates the estimated annual effective income tax rate on a quarterly basis based on current and forecasted operating results and tax laws. Consequently, based upon the mix and timing of the Company’s actual earnings compared to annual projections, the effective tax rate may vary quarterly and may make quarterly comparisons not meaningful. The quarterly income tax provision is generally comprised of tax expense on income or benefit on loss at the most recent estimated annual effective tax rate. The tax effect of discrete items is recognized in the period in which they occur at the applicable statutory rate.

For the nine-month periods ended September 30, 2026, and September 30, 2025, the Company recorded income tax expense of $5,260 and $15,233 for continuing operations, respectively, and income tax expense of $3,335 and $2,756 from discontinued operations, respectively. The effective tax rate of (0.19%) and (0.26%) applied to income for nine months ended September 30, 2026, and September 30, 2025, respectively varied from the statutory United States federal income tax rate of 21.0% primarily due to the effect of state income taxes, net of the federal benefit, and adjustments for meals, entertainment and penalties, changes in fair value of financial instruments, stock compensation expenses and changes to valuation allowance.

33

Table of Contents

 

For the three-month periods ended September 30, 2026, and September 30, 2025, the Company recorded income tax expense of $0 and $0 for continuing operations, respectively, and income tax expense of $0 and $0 from discontinued operations, respectively. The effective tax rate of 0.0% and 0.0% applied to income for three months ended September 30, 2026 and September 30, 2025, respectively varied from the statutory United States federal income tax rate of 21.0% primarily due to the effect of state income taxes, net of the federal benefit, and adjustments for meals, entertainment and penalties, changes in fair value of financial instruments, stock compensation expenses and changes to valuation allowance.

The Company does not have any uncertain income tax positions as of September 30, 2026, and December 31, 2025.

Note 13 Equity

Preferred Stock

The Company has 10,000,000 shares of preferred stock authorized with a par value of $0.0001. The Company has designated 6,500 and 2,000 of such shares for the Series A and Series B Preferred Stock, respectively. As of September 30, 2026, and December 31, 2025, the Company had 122 and 1,788 shares of Series A Preferred Stock issued and outstanding, respectively. As of September 30, 2026, and December 31, 2025, the Company had no shares of Series B Preferred Stock issued and outstanding, respectively.

Series A Preferred Stock

The Series A Preferred has the following rights and privileges:

Voting – Series A preferred stockholders are permitted to vote with the same voting rights as common stockholders in any actions to be taken by the stockholders of the Company, including any action with respect to the election of directors to the Board of Directors of the Company. With respect to any vote with the class of Common Stock, each Preferred Share shall entitle the holder thereof to cast that number of votes per share as is equal to the number of shares of Common Stock into which it is then convertible (subject to the ownership limitations specified 4.99%) using the record date for determining the stockholders of the Company eligible to vote on such matters as the date as of which the Conversion Price is calculated.

Dividends – Series A preferred stockholders shall be entitled to receive cumulative participating dividends when and if declared. Dividends are prior and in preference to any declaration or payment of any dividend to the common stockholders of the Company.

Liquidation – In the event of a Liquidation Event, the Holders shall be entitled to receive in cash out of the assets of the Company, whether from capital or from earnings available for distribution to its stockholders (the “Liquidation Funds”), before any amount shall be paid to the holders of any of shares of Junior Stock, but junior with respect to any Senior Preferred Stock then outstanding, an amount per Preferred Share equal to the amount per share such Holder would receive if such Holder converted such Preferred Share into Common Stock immediately prior to the date of such payment.

Conversion – Series A preferred stock is convertible into common stock at the option of the holder, at any time after the earlier of (i) twelve months from the Initial Issuance Date (June 24, 2024) or (ii) the date on which no shares of Series A preferred stock remain outstanding, at the initial rate of $10.00 per share, with an alternate optional conversion, with respect to any Alternate Conversion that price which shall be the lowest of (i) the applicable Conversion Price as in effect on the applicable Conversion Date of the applicable Alternate Conversion, and (ii) the greater of (x) the Floor Price and (y) 90% of the price computed as the quotient of (I) the sum of the VWAP of the Common Stock for each of the three (3) Trading Days with the lowest VWAP of the Common Stock during the ten (10) consecutive Trading Day period ending and including the Trading Day immediately preceding the delivery or deemed delivery of the applicable Conversion Notice, divided by (II) three (3) (such period, the “Alternate Conversion Measuring Period”). All such determinations to be appropriately adjusted for any stock dividend, stock split, stock combination, reclassification or similar transaction that proportionately decreases or increases the Common Stock during such Alternate Conversion Measuring Period. The conversion price is subject to standard antidilution adjustments, including adjustments for stock splits, dividends, mergers, asset sales, volume resets, defaults, and down-round events.

Redemption – The Company shall have the right to redeem all, or any portion, of the Series A preferred stock then outstanding at a price equal to 100% of the stated value ($1,000 per share) of the shares being redeemed. The Company’s right to redeem the Series A preferred stock is one-time in nature and such exercise shall be irrevocable. The preferred stock is not mandatorily redeemable.

The Company reviewed the Series A Preferred Stock under ASC 480 and ASC 815 and concluded that Series A Preferred Stock did not include any elements that would preclude them from equity treatment and therefore are not subject to the liability treatment under ASC 480 or derivative guidance under ASC 815.

Series B Preferred Stock

The Series B Preferred Stock has the following rights and privileges:

Ranking – The Series B Preferred Stock rank (i) senior to the common stock, and any other class or series of capital stock of the Company creates hereafter, the terms of which specifically provide that such class or series shall rank junior to the Series B Preferred Stock (“Junior Securities”), (ii) on parity with the Company’s outstanding Series A Preferred Stock as well as any class or series of capital stock of the Company created specifically ranking by its terms on parity with the Series B Preferred Stock (“Parity Securities”), and (iii) junior to any class or series of capital stock of the Company hereafter created specifically ranking by its terms senior to the Series B Preferred Stock.

Dividends – Holders of the Series B Preferred Stock participate on dividends and any other distributions of the Company’s assets as if such holder had held the number of shares of common stock acquirable upon complete conversion of the Series B Preferred Stock immediately prior to the date on which a record is taken for such dividend or distribution, subject to certain limitations on beneficial ownership.

34

Table of Contents

 

Conversion Rights – The number of shares of common stock into which the Series B Preferred Stock are convertible (the “Conversion Rate”) is equal to the Stated Value ($1,000 per share) of the shares of Series B Preferred Stock held divided by the $0.65 (the “Series B Conversion Price”), subject to adjustment. The Series B Preferred Stock are convertible at any time after the gross proceeds received by the holder in connection with the sale of 3,000,000 shares of common stock received in a private placement from the sale of such shares is less than $2.3 million. Any conversion will be settled only in shares of common stock; provided that the Company shall not affect any conversion to the extent that after giving effect to such conversion, the converting holder would beneficially own in excess of 9.99% of the common stock outstanding immediately after giving effect to the conversion. The conversion price is subject to standard antidilution adjustments, including adjustments for stock splits, dividends, mergers, asset sales, volume resets, defaults, and down-round events.

Purchase Rights – If at any time the Company grants, issues or sells any options, convertible securities, or rights to purchase stock, warrants, securities or other property pro rata to all or substantially all of the record holders of any class of Common Stock (the “Purchase Rights”), then each holder of Series B Preferred Stock will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which such holder could have acquired if such holder had held the number of shares of common stock acquirable upon complete conversion of all the Series B Preferred Shares held by such holder immediately prior to the date as of which the record holders of shares of common stock are to be determined for the grant, issue or sale of such Purchase Rights; subject to certain limitations on beneficial ownership.

Automatic Cancellation – When the gross proceeds received by the holder in connection with the sale of 3,000,000 shares of common stock received in a private placement from the sale of such shares equals or exceeds $2.3 million, any outstanding shares of Series B Preferred Stock will be automatically cancelled and returned to the Company.

Rights Upon Issuance of Other Securities; Adjustment of Conversion Price upon Subdivision or Combination of Common Stock – If the Company at any time subdivides (or combines) one or more classes of its outstanding shares of common stock into a greater (or lesser) number of shares, the Conversion Price will be proportionately reduced (or increased).

Adjustment of Conversion Price – The Company may, with the prior written consent of the holders of Series B Preferred Stock, reduce the Conversion Price to any amount and for any period of time deemed appropriate by the Board of Directors.

Voting Rights – The holders of Series B Preferred Stock are entitled to notice of all stockholder meetings at which holders of common stock shall be entitled to vote. Except as otherwise provided in the Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock, or as otherwise required by Delaware Law, the holders of Series B Preferred Stock shall have no voting rights.

Reservation Requirements – So long as any Series B Preferred Stock remains outstanding, the Company shall at all times reserve not less than such aggregate number of shares of the common stock as shall be issuable (taking into account the adjustments and restrictions of Section 7 of the Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock) upon the conversion of the then outstanding shares of Series B Preferred Stock (assuming any such conversions are made without regard to any limitations on conversion set forth in the Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock).

Liquidation – Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, the holders of the Series B Preferred Stock shall be entitled to receive out of the assets legally available for distribution to stockholders, prior and in preference to any distribution of any of the assets or surplus funds of the Company to the holders of the common stock and Junior Securities and pari passu with any distribution to holders of Parity Securities, an amount equal to the Stated Value of for each share of Series B Preferred Stock and an amount equal to any accrued and unpaid dividends thereon, and thereafter holders of Series B Preferred Stock shall be entitled to receive out of the assets, whether capital or surplus, of the Company the same amount that a holder of common stock would receive if the Series B Preferred Stock were fully converted (disregarding for such purposes any conversion limitations set forth in the Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock).

The Company reviewed the Series B Preferred Stock under ASC 480 and ASC 815 and concluded that Series B Preferred Stock did not include any elements that would preclude them from equity treatment and therefore are not subject to the liability treatment under ASC 480 or derivative guidance under ASC 815.

Common Stock

The Company is authorized to issue 100,000,000 shares of common stock with a par value of $0.0001 per share. As of September 30, 2026, and December 31, 2025, there were 806,078 and 414,995 shares of common stock outstanding.

The Company issued 110,000 and 7,500 shares of common stock during the three months ended September 30, 2026, and 2025, respectively.

Stock Options

In June 2024, the DHAC board of directors and stockholders approved the 2024 Plan. There are currently 31,800 shares of common stock reserved for issuance under the 2024 Plan as of September 30, 2026.

The 2024 Plan provides for the grant of stock options, including options that are intended to qualify as “incentive stock options” under Section 422 of the Code, as well as non-qualified stock options. Each award is set forth in a separate agreement with the person who received the award which indicates the type, terms and conditions of the award. 

On December 30, 2025, the Company's stockholders approved the VSee Health, Inc. 2025 Equity Incentive Plan (the "2025 Plan"). The 2025 Plan provides for an initial share reserve of 31,918 shares of common stock. Beginning January 1, 2026, the number of shares available for issuance under the 2025 Plan automatically increases annually by an amount equal to fifteen percent (15%) of the total number of outstanding shares of the Company's common stock as of December 31 of the preceding calendar year. As a result of the January 1, 2026 evergreen increase of 30,319 shares, the total share reserve under the 2025 Plan increased to 62,237 shares. There were 62,237 shares reserved for issuance under the 2025 Plan, of which 32 shares remained available for future issuance.

As of September 30, 2026, and December 31, 2025, there was no unrecognized compensation cost. Stock-based compensation expense of $0 and $0 was recognized for the three months ended September 30, 2026, and 2025, respectively, and expense of $643,861 and $764,036 for the nine months ended September 30, 2026, and 2025, respectively, within compensation and related benefits on the condensed consolidated statements of operations.

 

35

Table of Contents

 

Common Stock Issuance Obligation

In connection with the Business Combination on June 24, 2024, the Company agreed to assume an obligation by iDoc to issue 640 shares of common stock (contingent on the Business Combination) to certain employees. In accordance with ASC 718, the Company determined that it was not obligated to replace the awards, and as such, recognized the fair value of the award at the Business Combination date as additional stock-based compensation (included in cost of revenues). The grant date fair value was estimated to be $619,935 (see Note 16 - Fair Value Measurements). The Company also determined that it should classify this award as a liability under ASC 718 and remeasure the award at its then current fair value each reporting date. As of September 30, 2026, and December 31, 2025, the common stock issuance obligation amounted to $1,440 and $18,941, respectively. The net stock-based compensation expense reversed was $17,501 and $38,394 for the nine months ended September 30, 2026, and September 30, 2025, respectively. The net stock-based compensation expense reversed was $4,478 and $28,156 for the three months ended September 30, 2026, and September 30, 2025, respectively.

As of September 30, 2026, and December 31, 2025, no shares of common stock have been issued under the common stock issuance obligation arrangements.

Note 14 Warrants

DHAC Assumed Warrants

The Company has analyzed the public warrants, private warrants, Bridge Warrants (as defined below), September 2024 Warrants and the Extension Warrants and determined they are considered to be freestanding instruments and do not exhibit any of the characteristics in ASC 480 and therefore are not classified as liabilities under ASC 480. The warrants meet all of the requirements for equity classification under ASC 815 and therefore are classified in equity. Below is a summary of the warrants issued and outstanding:

   Public   Private   Bridge   Extension   September
2024
Warrants
   Pre-funded
Warrants
   Common
Stock
Warrants
   Total 
Outstanding, December 31, 2025   123,795    6,963    2,174    326    9,259    122,951    245,902    511,370 
Issued   -    -    -    -    -    -    -    - 
Exercised   -    -    -    -    -    (122,951)   -    (122,951)
                                         
Outstanding, September 30, 2026   123,795    6,963    2,174    326    9,259    -    245,902    388,419 
                                         
Exercisable, September 30, 2026   123,795    6,963    2,174    326    9,259    -    245,902    388,419 
                                         
Weighted Average Exercise Price *  $920.00   $920.00   $920.00   $920.00   $180.00   $-   $48.80   $350.82 
Weighted Average Remaining Life in Years   2.73    2.73    1.01    1.60    3.00    
-
    4.17    3.64 

 

*Exercise Price has been restated for the 1-for-80 reverse stock split effective September 22, 2026 See Note 2 – “Summary of Significant Accounting Policies”.

Public and Private Warrants

As of September 30, 2026, and December 31, 2025, there are 130,758 public and private warrants issued and outstanding, which were assumed as a result of the Business Combination. The warrants were issued by DHAC in connection with DHAC’s Initial Public Offering. Each warrant entitles the registered holder to purchase 1 share of common stock. However, out of the 130,758 warrants outstanding, 9,800 warrants entitle the holder to purchase 0.967 share of common stock. Each warrant is exercisable at a price of $920.00 per share\, subject to adjustment, at any time commencing on the later of 30 days after the completion of an initial business combination or 12 months from the closing of the Initial Public Offering.

However, no warrants will be exercisable for cash unless the Company has an effective and current registration statement covering the shares of common stock issuable upon exercise of the warrants and a current prospectus relating to such shares of common stock. Notwithstanding the foregoing, if a registration statement covering the shares of common stock issuable upon exercise of the public warrants is not effective within a specified period following the consummation of the initial business combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company shall have failed to maintain an effective registration statement, exercise warrants on a cashless basis pursuant to the exemption provided by Section 3(a)(9) of the Securities Act, provided that such exemption is available. If that exemption, or another exemption, is not available, holders will not be able to exercise their warrants on a cashless basis. In the event of such cashless exercise, each holder would pay the exercise price by surrendering the warrants for that number of shares of common stock equal to the quotient obtained by dividing (x) the product of the number of shares of common stock underlying the warrants, multiplied by the difference between the exercise price of the warrants and the “fair market value” (defined below) by (y) the fair market value. The “fair market value” for this purpose will mean the average reported last sale price of the shares of common stock for the 5 trading days ending on the trading day prior to the date of exercise. The warrants will expire on the fifth anniversary of the completion of an initial business combination, at 5:00 p.m., New York City time, or earlier upon redemption or liquidation.

36

Table of Contents

 

The private warrants are identical to the warrants underlying the units in the Initial Public Offering. The Company may call the warrants for redemption, in whole and not in part, at a price of $0.01 per warrant,

●at any time after the warrants become exercisable;
   
●upon not less than 30 days’ prior written notice of redemption to each warrant holder;
   
●if, and only if, the reported last sale price of the shares of common stock equals or exceeds $1,440 per share (to be adjusted for stock splits, stock dividends, reorganizations and recapitalizations), for any 20 trading days within a 30-trading day period commencing at any time after the warrants become exercisable and ending on the third business day prior to the notice of redemption to warrant holders; and
   
●if, and only if, there is a current registration statement in effect with respect to the shares of common stock underlying such warrants.

 

The exercise price and number of shares of common stock issuable on exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. However, except as described below, the warrants will not be adjusted for issuances of shares of common stock at a price below their respective exercise prices. If (x) the Company issues additional shares of common stock or equity-linked securities for capital raising purposes in connection with the closing of the initial business combination at an issue price or effective issue price of less than $9.20 per share of common stock (with such issue price or effective issue price to be determined in good faith by the board of directors, and in the case of any such issuance to the Company’s Sponsor, initial stockholders or their affiliates, without taking into account any founders’ shares held by them prior to such issuance), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial business combination on the date of the consummation of the initial business combination (net of redemptions), and (z) the Market Value is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the greater of (i) the Market Value or (ii) the price at which the Company issue the additional shares of common stock or equity-linked securities and the $18.00 per share redemption trigger price described above will be adjusted (to the nearest cent) to be equal to 180% of the Market Value. The warrants may be exercised upon surrender of the warrant certificate on or prior to the expiration date at the offices of the warrant agent, with the exercise form on the reverse side of the warrant certificate completed and executed as indicated, accompanied by full payment of the exercise price, by certified or official bank check payable to the Company, for the number of warrants being exercised. The warrant holders do not have the rights or privileges of holders of shares of common stock and any voting rights until they exercise their warrants and receive shares of common stock. After the issuance of shares of common stock upon exercise of the warrants, each holder will be entitled to one vote for each share held of record on all matters to be voted on by stockholders. The market price is subject to standard antidilution adjustments, including adjustments for stock splits, dividends, mergers, asset sales, volume resets, defaults, and down-round events.

Warrant holders may elect to be subject to a restriction on the exercise of their warrants such that an electing warrant holder would not be able to exercise their warrants to the extent that, after giving effect to such exercise, such holder would beneficially own in excess of 9.8% of the shares of common stock outstanding.

No fractional shares will be issued upon exercise of the warrants. If, upon exercise of the warrants, a holder would be entitled to receive a fractional interest in a share, the Company will, upon exercise, round up to the nearest whole number the number of shares of common stock to be issued to the warrant holder.

Bridge Warrants

In connection with the Business Combination, the Company assumed 2,174 warrants to the Bridge Investor (the “Bridge Warrants”) issued on October 6, 2022. Each Bridge Warrant entitles the holder to purchase one share of common stock at $920.00 per share and expires five years from issuance. If no effective registration statement is available, Bridge Warrants may be exercised on a cashless basis. The exercise price and share count are subject to adjustment for corporate actions and certain issuances. Holders do not have shareholder rights until exercise.

Extension Warrants

In connection with the Business Combination, the Company assumed 326 Extension Warrants issued on May 5, 2023. Each Extension Warrant allows the holder to purchase one share of common stock at $920.00 per share and expires five years from issuance. If no effective registration statement is available, warrants may be exercised on a cashless basis. The exercise price and share count are subject to adjustment for corporate actions and certain issuances. Holders do not have shareholder rights until exercise.

September 2024 Warrants

On September 30, 2024, the Company issued 9,259 warrants to an institutional investor under a securities purchase agreement (the “September 2024 Warrants”). Each September 2024 Warrant is exercisable for one share of common stock at $180.00 per share for five years, subject to standard and down round antidilution adjustments. The September 2024 Warrants were classified in stockholders’ equity under ASC 480 and ASC 815-40. The Company will reserve sufficient shares for potential exercises and adjust terms for corporate actions or diluted issuances. Holders do not have shareholder rights until exercise.

Warrant Exchange Agreement

On October 29, 2025, the Company also entered into a warrant exchange arrangement with Alta Partners (“Alta”) relating to holdings of its Public Warrants, which were issued in connection with the Company’s initial public offering. Pursuant to the arrangement, Alta exchanged a total of 19,500 Public Warrants for 18,851 shares of the Company’s Common Stock, representing an exchange ratio of approximately 0.9667 share per warrant. Alta continues to hold 9,800 warrants exercisable for 9,473 shares of common stock at an exercise price of $920.00 per shares. In connection with the exchange, the Company recognized proceeds of $1,500,003 in the condensed consolidated statements of stockholders’ equity (deficit).

37

Table of Contents

 

Private Placement with Armistice  

On November 25, 2025, the Company entered into a securities purchase agreement with Armistice Capital (“Armistice”) pursuant to which Armistice agreed to purchase an aggregate of 122,951 shares of the Company’s common stock or, at Armistice’s election, pre-funded warrants exercisable at $0.008 per share in lieu thereof, together with common warrants to purchase up to 245,902 shares of common stock. The securities were sold at a combined purchase price of $48.80 per pre-funded warrant and per share and accompanying common warrants, for gross proceeds of $5,999,016. The private placement closed on December 1, 2025. In connection with the offering, the Company recognized proceeds of $5,519,085, net of issuance costs, in additional paid-in capital. The Company incurred $479,931 in legal and other offering-related costs, which were treated as share issuance costs and recorded as a reduction to the proceeds.

During the nine months ended September 30, 2026, a total of 122,951 pre-funded warrants were exercised for 122,951 shares of common stock at an exercise price of $0.008 per share, resulting in aggregate consideration of approximately $984. As of September 30, 2026, no pre-funded warrants remained outstanding.

Note 15 Reportable segment

Historically, the Company had two reportable segments, Telehealth and Healthcare Technology. These reportable segments reflect the manner in which the Company's Chief Executive Officer, who serves as the chief operating decision maker ("CODM"), regularly reviews financial information, allocates resources, and assesses performance. As of September 30, 2026, the Company’s Chief Executive Officer was the sole CODM. As of December 31, 2025, the Company’s CODM role was shared between the two Co-Chief Executive Officers of the Company.

Following the disposition of VSee Lab, the Company no longer conducts Healthcare Technology operations, and the results of continuing operations is reported through the Telehealth segment. Therefore, as of September 30, 2026, the Company has one reportable segment: Telehealth Services.

The CODM reviews gross margin and net loss from our reportable segment to evaluate budgets and forecasts, assess actual performance and allocate resources. The CODM’s review focuses on month to month and quarter to quarter changes in these profit measures in order to identify potential future liquidity issues, evaluate performance and need for potential cost reductions and identify potential vendor sourcing changes. The measure of segment assets is reported on the balance sheet as total consolidated assets.

Our reportable segment is described below.

Telehealth Services – The Company provides high-acuity patient care solutions through physician services delivered using a proprietary technology platform. The Company delivers neuro-critical care, tele-critical care, teleradiology and specialty telehealth services to hospital systems, long-term acute care facilities, correctional facilities and other customers, staffed by board-certified intensivists, neurointensivists, neurologists and advanced practice providers on a 24/7 basis.  

The accounting policies of our reportable segment is the same as those described in the “Summary of Significant Accounting Policies” for the Company. In addition, the Company currently operates in one primary geographic area (the United States) and as such, the disclosures below are attributable to that geographic area.

The following table summarizes total revenue and significant expense categories and amounts for the Company's reportable segment that aligns with the segment level information that is regularly provided to the CODM:

   For the Three Months Ended   For the Nine Months Ended 
   September 30,   September 30, 
   2026   2025   2026   2025 
Revenues:  $   $   $   $ 
Patient fees   604,464    882,529    2,086,896    2,069,565 
Telehealth fees   892,315    1,436,393    2,851,060    2,499,662 
Institutional fees   -    -    -    2,500 
Total revenues  $1,496,779   $2,318,922   $4,937,956   $4,571,727 
                     
Cost of revenues   1,186,100    1,187,296    3,693,712    2,014,819 
Segment gross margin  $310,679   $1,131,626   $1,244,244   $2,556,908 
                     
Less:                    
Compensation and related benefits   447,350    416,528    1,345,866    1,357,571 
General and administrative   2,033,147    2,535,231    6,425,055    6,122,603 
Interest expense   67,503    745,965    240,146    1,662,939 
Other segment items, net (1)   611,380    (2,523,642)   420,846    (1,015,915)
Income tax expense   -    -    5,260    15,233 
Segment operating loss  $(2,848,701)  $(42,456)  $(7,192,929)  $(5,585,523)
                     
Reconciliation to net loss:                    
Income (loss) from discontinued operations, net of tax   -    (247,289)   2,591,239    (1,276,945)
Net loss  $(2,848,701)  $(289,745)  $(4,601,690)  $(6,862,468)

 

(1)Other segment items, net includes Other income, net, Change in fair value of financial instruments, Gain/(Loss) on extinguishment of financial liabilities, Loss on settlement of ELOC dispute and Loss on issuance of financial instruments.

38

Table of Contents

 

Note 16 Fair Value Measurements

The following tables present fair value information as of September 30, 2026, and December 31, 2025. The Company’s financial liabilities that were accounted for at fair value on a recurring basis indicate the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value:

September 30, 2026,  Fair Value   (Level 1)   (Level 2)   (Level 3) 
Liabilities:                
ADI Funding LLC Convertible Note  $283,748   $-   $        -   $283,748 
ClearThink Capital Partners Convertible Note  $273,302   $-   $-   $273,302 
Common stock issuance obligation  $1,440   $1,440   $-   $- 
June 2026 SEPA liability  $116,319   $-   $-   $116,319 
Strata SEPA liability  $90,344   $-   $-   $90,344 
Labrys Convertible Promissory Note  $372,017   $-   $-   $372,017 
M2B Promissory Note  $152,916   $-   $-   $152,916 
ADI Promissory Note  $61,628   $-   $-   $61,628 

December 31, 2025  Fair Value   (Level 1)   (Level 2)   (Level 3) 
Liabilities:                
Quantum Convertible Note, related party  $351,307   $-   $         -   $351,307 
Common stock issuance obligation  $18,941   $18,941   $-   $- 
May 2025 Convertible Note  $361,821   $-   $-   $361,821 

Measurement

Quantum Convertible Note

The Company established the initial fair value for the Quantum Convertible Note as of June 25, 2024, which was the date the Quantum Convertible Note was funded. As of December 31, 2025, the fair value was remeasured. Accordingly, the Company measured the debt at fair value using Monte Carlo Model (MCM) . The Quantum Convertible Note was converted and fully settled in May 2026. The MCM was used to value the Quantum Convertible Note for the initial periods and subsequent measurement periods. The initial value in excess of proceeds on June 25, 2024, was recognized in the statement of operations under loss on issuance of financial instruments. The change in fair value between December 31, 2025, and September 30, 2026, was recognized in the statement of operations under change in fair value of financial instruments.

The Quantum Convertible Note was classified within Level 3 of the fair value hierarchy December 31, 2025, due to the use of unobservable inputs. The key inputs into the MCM model for the Quantum Convertible Note were as follows on December 31, 2025:

   December 31,
2025
 
Risk-free interest rate   3.53%
Expected term (years)   0.50 
Volatility   95.22%
Stock price  $29.6 

Common Stock Issuance Obligation

The Company established the initial fair value for the common stock issuance obligation to certain employees of the historical iDoc entity as of June 24, 2024, the date the Business Combination closed. As of September 30, 2026, and December 31, 2025, the fair value was remeasured. As the obligation is to issue shares of the Company’s common stock, the Company estimated the fair value of the obligation based on the shares of common stock expected to be issued and the closing price of the Company’s common stock on the date of the fair value measurement. As the key inputs into this fair value estimate are observable, the Company classified the common stock issuance obligation within Level 1 of the fair value hierarchy as of September 30, 2026, and December 31, 2025. The change in fair value between December 31, 2025, and September 30, 2026, was recognized as compensation expense within cost of revenues in the condensed consolidated statements of operations.

May 2025 Convertible Note

The Company established the initial fair value for the May 2025 Convertible Note as of May 30, 2025, which was the date the May 2025 Convertible was funded. As of December 31, 2025, the fair value was remeasured. Accordingly, the Company measured the debt at fair value using MCM. This note was converted into shares of the Company's common stock and fully settled in February 2026. The MCM was used to value the May 2025 Convertible Note for the initial periods and subsequent measurement periods. The change in fair value between December 31, 2025, and September 30, 2026, was recognized in the statement of operations under change in fair value of financial instruments.

39

Table of Contents

 

The May 2025 Convertible Note was classified within Level 3 of the fair value hierarchy as of December 31, 2025, due to the use of unobservable inputs. The key inputs into the MCM model for the May 2025 Convertible Note were as follows on December 31, 2025:

   December 31,
2025
 
Risk-free interest rate   3.67%
Expected term (years)   0.08 
Volatility   46.18%
Stock price  $29.6 

ADI Funding Convertible Note 

The Company established the initial fair value for the ADI Funding Convertible Note as of June 8, 2026, which was the date the ADI Funding Convertible Note was funded. As of September 30, 2026, the fair value was remeasured. Accordingly, the Company measured the debt at fair value using MCM. The MCM was used to value the ADI Funding Convertible Note for the initial periods and subsequent measurement periods. The change in fair value between June 8, 2026, and September 30, 2026, was recognized in the statement of operations under change in fair value of financial instruments.

The ADI Funding Convertible Note was classified within Level 3 of the fair value hierarchy as of September 30, 2026, due to the use of unobservable inputs. The key inputs into the MCM model for the ADI Funding Convertible Note were as follows on September 30, 2026, and on December 31, 2025:

   September 30,
2026
 
Risk-free interest rate   3.94%
Expected term (years)   0.05 
Volatility   97%
Stock price  $2.25 

ClearThink Convertible Note

The Company established the initial fair value for the ClearThink Convertible Note as of June 22, 2026, which was the date the ClearThink Convertible Note was funded. As of September 30, 2026, the fair value was remeasured. Accordingly, the Company measured the debt at fair value using MCM. The MCM was used to value the ClearThink Convertible Note for the initial periods and subsequent measurement periods.

The ClearThink Convertible Note was classified within Level 3 of the fair value hierarchy as of September 30, 2026, due to the use of unobservable inputs. The key inputs into the MCM model for the ClearThink Convertible Note were as follows on September 30, 2026, and on December 31, 2025:

   September 30,
2026
 
Risk-free interest rate   4.33%
Expected term (years)   0.73 
Volatility   121%
Stock price  $2.25 

June 2026 SEPA liability

The Company established the initial fair value for the June 2026 SEPA liability as of June 2, 2026, which was the date the agreement was entered. As of September 30, 2026, the fair value was remeasured. Accordingly, the Company measured the SEPA liability at fair value using MCM. The MCM was used to value the June 2026 SEPA liability for the initial periods and subsequent measurement periods.

The June 2026 SEPA liability was classified within Level 3 of the fair value hierarchy as of September 30, 2026, due to the use of unobservable inputs. The key inputs into the MCM model for the June 2026 SEPA liability were as follows on September 30, 2026, and on December 31, 2025:

   September 30,
2026
 
Risk-free interest rate   4.84%
Expected term (years)   2.67 
Volatility   120%
Stock price  $2.25 

Strata SEPA liability

The Company established the initial fair value for the Strata SEPA liability as of September 2, 2026, which was the date the agreement was entered. As of September 30, 2026, the fair value was remeasured. Accordingly, the Company measured the SEPA liability at fair value using MCM. The MCM was used to value the Strata SEPA liability for the initial periods and subsequent measurement periods.

40

Table of Contents

 

The Strata SEPA liability was classified within Level 3 of the fair value hierarchy as of September 30, 2026, due to the use of unobservable inputs. The key inputs into the MCM model for the Strata SEPA liability were as follows on September 30, 2026, and on December 31, 2025:

   September 30,
2026
 
Risk-free interest rate   4.88%
Expected term (years)   3.01 
Volatility   105%
Stock price  $2.25 

Labrys Convertible Promissory Note

The Company established the initial fair value of the Labrys Convertible Promissory Note as of July 8, 2026, which was the issuance date of the note. As of September 30, 2026, the fair value was remeasured. Accordingly, the Company measured the debt at fair value using MCM. The MCM was used to value the Labrys Convertible Promissory Note for the initial periods and subsequent measurement periods.

The Labrys Convertible Promissory Note was classified within Level 3 of the fair value hierarchy as of September 30, 2026, due to the use of unobservable inputs. The key inputs into the MCM model for the Labrys Convertible Promissory Note were as follows on September 30, 2026, and on December 31, 2025:

   September 30,
2026
 
Risk-free interest rate   4.11%
Expected term (years)   0.24 
Volatility   159.38%
Stock price  $2.25 

M2B Promissory Note

The Company established the initial fair value of the M2B Promissory Note as of July 21, 2026, which was the issuance date of the note. As of September 30, 2026, the fair value was remeasured. Accordingly, the Company measured the debt at fair value using MCM. The MCM was used to value the M2B Promissory Note for the initial periods and subsequent measurement periods.

The M2B Promissory Note was classified within Level 3 of the fair value hierarchy as of September 30, 2026, due to the use of unobservable inputs. The key inputs into the MCM model for the M2B Promissory Note were as follows on September 30, 2026, and on December 31, 2025:

   September 30,
2026
 
Risk-free interest rate   4.18%
Expected term (years)   0.31 
Volatility   152%
Stock price  $2.25 

ADI Promissory note

The Company established the initial fair value of the ADI Promissory note as of July 21, 2026, which was the issuance date of the note. As of September 30, 2026, the fair value was remeasured. Accordingly, the Company measured the debt at fair value using MCM. The MCM was used to value the ADI Promissory note for the initial periods and subsequent measurement periods.

The ADI Promissory note was classified within Level 3 of the fair value hierarchy as of September 30, 2026 due to the use of unobservable inputs. The key inputs into the MCM model for the ADI Promissory note were as follows on September 30, 2026, and on December 31, 2025:

   September 30,
2026
 
Risk-free interest rate   4.18%
Expected term (years)   0.31 
Volatility   152%
Stock price  $2.25 

 

41

Table of Contents

 

Level 3 Changes in Fair Value

The change in the fair value of the Level 3 financial liabilities for the period from December 31, 2025, through September 30, 2026, is summarized as follows:

   Quantum Convertible Note   May 2025
Convertible Note
   ADI Funding LLC Convertible Note   ClearThink Capital Partners Convertible Note   June 2026 SEPA liability   Strata SEPA liability   Labrys Convertible Promissory Note   M2B Promissory Note   ADI Promissory Note   Total 
Fair value as of December 31, 2025  $351,307   $361,821   $-   $-   $-   $-   $-   $-   $-   $713,128 
Initial fair value at issuance   -    -    250,000    250,000    145,174    137,288    250,000    125,000    50,000    1,207,462 
Conversion   (521,721)   (299,348)   -    -    -    -    -    -    -    (821,069)
Interest accrued   11,243    -    -    -    -    -    -    -    -    11,243 
Change in fair value of financial instruments   159,171    (62,473)   53,059    23,302    (28,855)   (46,944)   122,017    27,916    11,628    258,821 
Gain/(Loss) on extinguishment of financial liabilities   -    -    (19,311)   -    -    -    -    -    -    (19,311)
Fair value as of September 30, 2026  $-   $-   $283,748   $273,302   $116,319   $90,344   $372,017   $152,916   $61,628   $1,350,274 

The change in the fair value of the Level 3 financial liabilities for the period from December 31, 2024, through September 30, 2025, is summarized as follows:

   Quantum Convertible Note   Exchange Note   ELOC   September Convertible Note   March 2025
Convertible Note
   May 2025
Convertible Note
   Total 
Fair value as of December 31, 2024  $3,248,000   $1,499,000   $80,000   $2,094,000   $-   $-   $6,921,000 
Initial fair value at issuance   -    -    -    -    238,020    342,996    581,016 
Conversion   (550)   (450,000)   -    -    -    -    (450,550)
Additions to principal   380,000    -    -    -    -    62,500    442,500 
Change in fair value of financial instruments   200,675    (20,842)   (37,606)   (50,240)   (156,273)   (79,609)   (143,895)
Fair value as of September 30, 2025  $3,828,125   $1,028,158   $42,394   $2,043,760   $81,747   $325,887   $7,350,071 

 

Transfers to/from Levels 1, 2 and 3 are recognized at the end of the reporting period in which a change in valuation technique or methodology occurs. There were no transfers to or from the various levels for the nine months ended September 30, 2026, and September 30, 2025.

Note 17 Subsequent Events

The Company evaluated subsequent events from the date of the condensed consolidated balance sheets as of September 30, 2026, through the date of the release of the condensed consolidated financial statements.

On October 1, 2026, the Company received net proceeds of $150,000 under the Vanquish Funding Convertible Note - 2, which the Company entered into with Vanquish Funding on September 24, 2026 (see Note 8 – Convertible Notes). The note has an aggregate principal amount of $180,550, including an original issue discount of $23,550, is unsecured, bears a one-time interest charge of 12% applied upon issuance, and matures on July 30, 2027. Upon funding, the Company will recognize the note as a liability in the subsequent quarter ended December 31, 2026. No amounts related to the note were recognized in the condensed consolidated financial statements as of September 30, 2026.

On October 14, 2026, the Company entered into a Settlement Agreement and Stipulation with Silverback Capital Corporation to settle certain outstanding obligations through the issuance of shares of the Company’s common stock pursuant to Section 3(a)(10) of the Securities Act of 1933. The settlement was approved by the Circuit Court on August 5, 2026. Refer to Note 5 - Accounts Payable and Accrued Liabilities, for additional information regarding the settlement agreement and related share issuances.

The Company is not aware of any other events or transactions that would require recognition or disclosure in the condensed consolidated financial statements.

42

Table of Contents

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF VSEE HEALTH

The following discussion and analysis provide information that VSee Health’s management believes is relevant to an assessment and understanding of the results of operations and financial of VSee Health, Inc. (“VSee Health” and for purposes of this section only, referred to as the “Company”, “we,” “us” and “our”). The discussion and analysis should be read together with VSee Health’s consolidated financial statements as of and for the three and nine months ended September 30, 2026 and 2025, and the related respective notes thereto. This discussion may contain forward-looking statements based upon VSee Health’s current expectations, estimates and projections that involve risks and uncertainties. Actual results could differ materially from those anticipated in these forward-looking statements due to, among other considerations, the matters discussed under “Risk Factors” in the Annual Report for the year ended December 31, 2025, and the section herein entitled “Cautionary Note Regarding Forward-Looking Statements.

Overview

Prior to June 24, 2024, we were a blank check company incorporated in the State of Delaware organized for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. On June 24, 2024, we completed the Business Combination pursuant to the Business Combination Agreement dated as of November 21, 2023, as amended by the first amendment dated February 13, 2024, and the second amendment dated April 17, 2024 (as amended, the “Business Combination Agreement”) that we entered into with VSee Lab and iDoc. Upon the completion of the Business Combination, we changed our name to “VSee Health, Inc.” and the business of VSee Lab and iDoc became our business. On May 31, 2026, the Company divested VSee Lab by selling 100% of its ownership interest to Milton Chen, the Company’s former co-Chief Executive Officer. Following the divestiture, VSee Lab became an independent standalone business and is no longer a subsidiary of VSee Health. Accordingly, VSee Lab has been classified as a discontinued operation for periods subsequent to the divestiture date, where applicable. (See Note 3 – Discontinued Operations). Mr. Chen also resigned as the Company’s co-Chief Executive Officer and Chairman of the Board of Directors in connection therewith.

We put telehealth software tools in the hands of clinicians to enable them to make changes without programming so that they can achieve the best patient outcomes. We provide our clients with capabilities specifically built to enable them to collaborate with their clinical and non-clinical colleagues, securely coordinate patient care, conduct virtual patient visits including remote physical exam and remote patient monitoring, and an analytical dashboard to manage their entire telehealth operations from patient satisfaction score to patient wait time to staffing allocations. We empower clinicians to create the workflow they want without waiting for IT; where today, most clinicians feel helpless given that IT departments often cannot give clinicians what they want.

 Our wholly owned subsidiary iDoc is a high acuity patient care solution providing elite physician services in intensive care units of our major hospital systems and other customers. iDoc delivers neuro-critical care through a proprietary technology platform. iDoc serves a diverse range of customers from large hospital systems to small/micro hospitals, long-term acute care (LTAC) facilities, correctional facilities and others. In addition to the specialization of neuro critical care, iDoc provides general tele-critical care services, and specialty e-consults to large organizations such as correctional facilities. iDoc has an experienced team of board-certified intensivists, neurointensivists, neurologists, and advanced practice providers that treat and coordinate care for acutely ill patients 24/7 in the Neurointensive Care Unit (“NICU”) and Intensive Care Unit (“ICU”) for stroke, brain trauma, spinal cord, and all other neurological conditions. Our Neurocritical care experts will also help develop multidisciplinary plans of care to optimally treat neurological conditions in relation to their overall medical needs. Our Neuro Critical care service delivery will focus on physicians and provider services in tele neurocritical care, epileptology, and tele neurology. In addition to standard interventions, our Neurocritical care experts will offer specific care including monitoring intracranial pressure, cerebral hemodynamic, advanced multimodal neuro monitoring (brain oximetry, cerebral micro dialysis and continuous electroencephalography). 

We strive to be the solutions provider of access to the shortage of intensivists across the care continuum utilizing sophisticated telehealth solutions to bridge the care gap. In a post Covid, physician burnout health care system, we aim to provide a solution to physician burnout and to a lack of patient access to quality intensive care. By using the sophisticated leading telehealth software and hardware devices, we provide access to highly skilled physicians in the highest acuity in patient setting, the ICU. We provide elite physician services in the Intensive care units of major hospital systems and other customers. Our core service delivers general critical care, neurology, EEG reading, and neuro critical care through a custom internal virtual health care technology platform. We also serve a diverse range of customers from large hospital systems to small/micro hospitals, to long-term acute care (LTAC) facilities to the federal prison system and others. We connect critically ill patients to high-quality Neurointensivists, general and cardiac intensivists and specialty specific e-consultations and helps to improve outcomes for patients as well as improved productivity and physician burnout while reduced costs for health systems. We have developed a unique quality control program in collaboration with each hospital by development of a hospital specific reporting dashboard to monitor and achieve high-quality critical care quality. In addition, current workflows and protocols are evaluated to adjust to incorporate critical care. Continuous process improvement and readjustment of target metrics with the ICU team to maximize patient safety and improve outcomes.

Implications of Being an Emerging Growth Company

The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended (the “Securities Act”), as modified by the Jumpstart Our Business Startups Act of 2012(the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

43

Table of Contents

 

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The Jobs Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

The Company is also a “smaller reporting company,” meaning that either (i) the market value of our shares held by non-affiliates is less than $250 million or (ii) the market value of our shares held by non-affiliates is less than $700 million and our annual revenue was less than $100 million during the most recently completed fiscal year. The Company may continue to be a smaller reporting company if either (i) the market value of our shares held by non-affiliates is less than $250 million or (ii) our annual revenue was less than $100 million during the most recently completed fiscal year and the market value of our shares held by non-affiliates is less than $700 million. The Company may take advantage of certain of the scaled disclosures available to smaller reporting companies.

Performance Factors

We believe that our future performance will depend on many factors, including the following:

The Rapid Transformation of the Telehealth Market

The Telehealth market today is one characterized by rapid transformation, with major customers and hospital systems looking to build or add capabilities and major legacy competitors looking to shore up historical limitations. We believe that the rapid transformation of the telehealth market indicates strong future growth of the market, and our current offerings provide an attractive value proposition to health systems, medical groups, and individual medical practitioners, driving higher market share. We plan to continue to harness our scale to further grow the value proposition of our platform for all stakeholders.

Ability to Expand Within the Market and Attract New Customers

Telehealth is still in its total infancy stages in terms of utilization, scope, and services. Most of the growth is expected within hospital systems, definition, and segmentation structure, and we believe our software platform and services have significant potential. We plan to leverage our industry relationships with government, hospital systems and insurance providers to increase our customer base.

Innovation and New Product Offerings

Despite the rapid advancements in technology, growth in virtual healthcare delivery, and improvement in decision support algorithms and machine learning tools, Telehealth Technology Solutions have not fully penetrated medicine and hospital systems to become the standard methodology of care and represent less than 1% of total healthcare spending according to Grandview Research. Major reasons for Telehealth solutions not capturing its full potential include:

●Many of the existing video and hardware and software used in telehealth are repurposed businesses that are not healthcare specific.
   
●Remote monitoring/diagnostic devices do not readily integrate into telehealth systems limiting doctors real time metrics to enable diagnostics and assessment.
   
●Backend software coordination is not optimized for telehealth use and connectivity, resulting in significant greater complexity and costs for implementation.
   
●The software and code foundations of the early telemedicine companies have major functionality limitations and arduous implementation and incremental coding/connectivity requirements adding significant cost and reducing functionality.

 

We believe our technology solutions meet the performance and compliance standards in healthcare, increase the sharing of patient history, files and scheduling are integrated into the video view for doctors, create sophisticated video engagement between patients, staff and doctors and seamlessly integrate patients’ records to provide more comprehensive telehealth care. We believe our ability to invest in new technology and develop new features, modules, and solutions will be critical to our long-term success.

Significant Accounting Policies and Critical Accounting Estimates

We prepare our consolidated financial statements in accordance with U.S. GAAP. The preparation of consolidated financial statements also requires we make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, costs and expenses and related disclosures. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results could differ significantly from the estimates made by our management. To the extent that there are differences between our estimates and actual results, our future financial statement presentation, balance sheet, results of operations and cash flows will be affected. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving our management’s judgments and estimates. Critical accounting policies and estimates are those that we consider the most important to the portrayal of our balance sheet and results of operations because they require our most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effects of matters that are inherently uncertain.

The preparation of our consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and judgments that affect the amounts reported in those consolidated financial statements and accompanying notes. Although we believe that the estimates we use are reasonable, due to the inherent uncertainty involved in making those estimates, actual results reported in future periods could differ from those estimates. Our significant accounting policies are described in Note 2 to our Unaudited Condensed Consolidated Financial Statements for the three-month and nine-month period ended September 30, 2026 included elsewhere in this report. Our critical accounting policies are described below.

44

Table of Contents

 

Revenue Recognition

The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers (“ASC 606”). ASC 606 establishes a principle for recognizing revenue upon the transfer of promised goods or services to customers in an amount that reflects the expected consideration received in exchange for those goods or services. The core principle of ASC 606 is to recognize revenue to depict the transfer of promised goods or services to clients in an amount that reflects the consideration the entity expects to be entitled in exchange for those goods or services. 

The Company derives revenue from business services associated with direct tele-physician provider patient fee services, telehealth services and institutional services provided to our clients.

The Company determines revenue recognition in accordance with ASC 606 through the following five steps:

1) Identify the contract with a customer

The Company considers the terms and conditions of its contracts and the Company’s customary business practices in identifying its contracts under ASC 606. The Company determines it has a contract with a customer when the contract has been approved by both parties, it can identify each party’s rights regarding the services to be transferred and the payment terms for the services, it has determined the customer to have the ability and intent to pay, and the contract has commercial substance. The Company applies judgment in determining the customer’s ability and intent to pay, which is based on a variety of factors, including the customer’s payment history or, in the case of a new customer, credit and financial information pertaining to the customer.

The Company also has service contracts with hospitals or hospital systems, physician practice groups, and other users. These customer contracts typically range from two to three years, with an automatic renewal process. The Company either invoices these customers for the monthly fixed fee in advance or at the end of the month, depending on the contract terms.

The contracts typically contain cancellation clauses with advance notice; therefore, the Company does not believe that it has any material outstanding commitment for future revenues beyond one year from the end of a reporting period.

2) Identify the performance obligations in the contract

Performance obligations promised in a contract are identified based on the services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the service either on its own or together with other resources that are readily available, and are distinct in the context of the contract, whereby the transfer of the services is separately identifiable from other promises in the contract. The Company’s contracts typically contain cancellation clauses with advance notice; therefore, the Company does not believe that they have any material outstanding commitments for future revenues beyond one year from the end of a reporting period.

3) Determine the transaction price

The total transaction price is based on the amount to which the Company is entitled to based on the contracts with its customers. The Company believes the quoted transaction prices in the customer contracts represent the stand-alone selling prices for each of the separate performance obligations which are distinct and priced separately within the contract. The transaction price for each service provided is independent and established in the contract and based on the duration of service provided or for a rate for service provided. Fees are established based on the service transferred to the client.

4) Allocate the transaction price to performance obligations in the contract

If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation based on a relative stand-alone selling price (“SSP”). The determination of a SSP for each distinct performance obligation requires judgment. The Company believes the quoted transaction prices in the customer contracts represent the standalone selling prices for each of the separate performance obligations that are distinct and priced separately within the contract.

5) Recognize revenue when or as the Company satisfies a performance obligation

Revenue is recognized when or as control of the promised goods or service is transferred to the customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services.

Patient Fees Services and Performance Obligation

Patient Fee Services

Patient fees represent a series of distinct services because performance obligations are met when the Company’s physicians provide professional medical services to patients at the client site. The patient benefits from professional services when care is rendered by the Company’s medical professionals. Revenue recognition commences when the Company satisfies its performance obligation to provide professional medical services to patients.

The Company acts as the principal in these arrangements because it controls the medical services before they are transferred to the patient. This control is evidenced by the Company’s primary responsibility for fulfilling the service and its direct authority over the affiliated physicians, including the right to direct their clinical activities and administrative protocols.

Patient Fee Contracts Involving Third-Party Payors

The Company receives payments from patients, third-party payors, and others for patient fee services. Third-party payors reimburse based on contracted rates or billed charges, which are generally lower than billed amounts. The Company determines the transaction price on patient fees based on standard charges for services provided, reduced by adjustments provided to third-party payors, and implicit price concessions provided to uninsured patients. The Company monitors its revenue and receivables from third-party payors and records an estimated contractual allowance to properly account for the differences between billed and collected amounts.

45

Table of Contents

 

Revenue from third-party payors is presented net of an estimated provision for contractual adjustments. Patient revenues are net of service credits and service adjustments and expected credit losses. These adjustments and implicit price concessions represent the difference between the amount billed and the estimated consideration the Company expects to receive, based on historical collection experience, market conditions and other factors. Although the Company believes that its approach to estimates and judgments as described herein is reasonable, actual results could differ, from estimated amounts and such difference could be material.

All of the Company’s telemedicine contracts for patient reimbursement fees are directly billed to the payors by the Company. The Company earns patient fees by providing high acuity patient care solutions. For patient fees, performance obligations are met when the Company’s physicians provide professional medical services to patients at the client site as this is deemed as transfer of goods and services to respective patients. The patient benefits from the professional services when care is rendered by the Company’s medical professionals. The revenue is determined based on the telemedicine billing code(s) associated with the respective professional service rendered to patients.

The Company earns primarily from reimbursement from the following third-party payors:

Medicare

The Company’s affiliated provider network is reimbursed by the Medicare Part B and Part C programs for certain of the telemedicine services it provides to Medicare beneficiaries. Medicare coverage for telemedicine services is treated distinctly from other types of professional medical services and is limited by federal statute and subject to specific conditions of participation and payment pursuant to Medicare regulations, policies and guidelines, including the location of the patient, the type of service, and the modality for delivering the telemedicine service, among others.

Medicaid

Medicaid programs are funded jointly by the federal government and the states and are administered by states (or the state’s designated managed care or other similar organizations) under approved plans. Our affiliated provider network is reimbursed by certain State Medicaid programs for certain of the telemedicine services it provides to Medicaid beneficiaries. Medicaid coverage for telemedicine services varies by state and is subject to specific conditions of participation and payment.

Commercial Insurance Providers

The Company is reimbursed by commercial insurance carriers. The basis for payment to the commercial insurance providers is consistent with Medicare reimbursement fee structure guidelines and the Company is in-network or out-of-network with the commercial insurance carriers based on state and insurer requirements.

Telehealth Fees Service Contracts and Performance Obligation

Contract For Telemedicine Care Services

Performance obligations in the contract for telemedicine care are based on services provided via the use of hardware and software integration that includes multi-participant video conferencing, and electronic communication for 24 hours per day, seven days per week for the duration of the contract. The Company provides administrative support for the tele-physician services and coordinates the services of its clinicians’ network through administrative support, hardware support, and software support and provider coverage availability. The Company provides coverage availability of its physician services ranging from 12 to 24 hours per day. Performance obligations in the contract for these services transferred to the customer are distinct in the context of the contract, whereby the transfer of the services is separately identifiable from patient services and institutional services obligations. Performance obligations are met when the Company provides administrative, business, and medical records and reports related to their professional services rendered pursuant to the agreement in such format and upon such interval as hospitals may require. Revenue from telemedicine care services is included in telehealth fees in the condensed consolidated financial statements.

The Company recognizes revenue for variable consideration when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. The Company estimates the amount of revenue to be recognized on variable consideration, using the expected value or the most likely amount method, whichever is expected to better predict the amount. The Company’s estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on assessments of legal enforceability, performance, and all information that is reasonably available to the Company. The determination of the amount of revenue the Company can recognize each accounting period requires management to make estimates and judgments on the estimated expected customer life or expected performance period.

The Company commences revenue recognition when the Company satisfies its performance obligation to provide the contractual tele-physician hours services. Prior to the commencement of services, customers generally make initial start-up nonrefundable payments to the Company when contracting for Company training, hardware and software installation and integration, which includes a onetime setup of software security, API interfaces, and compatibility between existing hospital equipment and hardware and software. The Company recognizes revenue upon completion of the implementation when the performance obligation of equipment setup and initial training is completed. The start-up fees do not significantly modify or customize the other goods in the contract. As the start-up service primarily covers initial administrative services for which the Company’s clients can cancel future services upon completion, management considers it to be separable from the ongoing business services, and the Company records start-up fees as revenue when the start-up service is completed over time, using the input method to measure progress each financial period. 

Institutional Fees Service Contracts and Performance Obligation

Contract For Electroencephalogram (“EEG”) Professional Interpretation Services

Performance obligations in the contract for EEG professional interpretation services are based on the number of professional services EEG interpretation the Company provides. The performance obligation in the contract for these services transferred to the customer is distinct in the context of the contract, whereby the transfer of the services is separately identifiable from other promises in the contract. To facilitate the delivery of the EEG professional interpretation services, the Company’s physicians use EEG telemedicine equipment provided by the Company. The performance obligation is satisfied based on the number of EEG professional interpretations performed by the Company’s physicians. The number of professional interpretations is traced monthly by both parties and used to determine the revenue earned based on established contractual rates and is included in institutional fees in the condensed consolidated financial statements.

46

Table of Contents

 

Under most of the Company’s contracts, including contracts with its two top customers, the customer pays fixed monthly fees for telemedicine consultation services, EEG professional interpretation services, platform software services, and hardware fees. The fixed monthly fee provides for a predetermined number of daily, monthly, or annual physician hours of coverage and agreed-upon rates for interpretation and software services. To facilitate the delivery of the consultation services, the facilities use telemedicine equipment and the Company’s virtual healthcare platform, which is provided and installed by the Company. The Company also provides the hospitals with user training, maintenance and support services for the telemedicine equipment used to perform the consultation services.

The Company commences revenue recognition on EEG professional interpretation services when the Company satisfies its performance obligation to provide professional interpretation monthly.

Fair Value of Financial Instruments

“Fair value” is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. ASC 820 establishes a fair value hierarchy that prioritizes and ranks the level of observability of inputs used to measure investments at fair value. The observability of inputs is impacted by a number of factors, including the type of investment, characteristics specific to the investment, market conditions and other factors. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). Investments with readily available quoted prices or for which fair value can be measured from quoted prices in active markets will typically have a higher degree of input observability and a lesser degree of judgment applied in determining fair value.

See Note 16 - Fair Value Measurements of the financial statements for additional information on assets and liabilities measured at fair value.

Goodwill

Goodwill represents the excess of purchase price in a business combination over the fair value of the net identifiable assets acquired. We evaluate goodwill for impairment at the reporting unit level by assessing whether it is more likely than not that the fair value of a reporting unit exceeds it carrying value. If this assessment concludes that it is more likely than not that the fair value of a reporting unit exceeds its carrying value, then goodwill is not considered impaired and no further impairment testing is required. Conversely, if the assessment concludes that it is more likely than not that the fair value of a reporting unit is less than it carrying value, a goodwill impairment test is performed to compare the fair value of the reporting unit to its carrying value. The Company determines fair value of the reporting unit using both income and market-based models. Our models contain significant assumptions and accounting estimates about discount rates, future cash flows, and terminal values that could materially affect our operating results or financial position if they were to change significantly in the future and could result in an impairment. We perform our goodwill impairment assessment whenever events or changes in facts or circumstances indicate that impairment may exist and during the fourth quarter each year. The cash flow estimates and discount rates incorporate management’s best estimates, using appropriate and customary assumptions and projections at the date of evaluation. For the three and nine months ended September 30, 2026, the Company performed qualitative analysis by assessing that no adverse economic, industry, operational, or regulatory indicators were identified that would suggest impairment. Based on the qualitative assessment of relevant factors, the Company concludes that no impairment indicators exist determined that there were no triggering events that required the Company to perform a quantitative analysis.

Impairment of Long-lived and Intangible Assets Other than Goodwill

In accordance with ASC 360-10, the Company, on a regular basis, reviews the carrying amount of long-lived assets, including fixed assets, right-of-use assets and intangible assets, for the existence of facts or circumstances, both internally and externally, that suggest impairment. The Company determines if the carrying amount of a long-lived asset is impaired based on anticipated undiscounted cash flows, before interest, from the use of the asset. In the event of impairment, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the asset. Fair value is determined based on the appraised value of the assets or the anticipated cash flows from the use of the asset, discounted at a rate commensurate with the risk involved.

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax basis and operating loss, capital loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest and penalties related to unrecognized tax benefits as a component of general and administrative expenses. The Company’s federal tax return and any state tax returns are not currently under examination.

The Company applies ASC 740-10, Accounting for Income Taxes, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually from differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.

47

Table of Contents

 

Financial Statement Components

Three Months Ended September 30, 2026, and 2025 Results of Operations

The following table presents VSee Health’s results of operations for the three months ended September 30, 2026, and 2025:

   2026   2025   Change   % 
Total revenues  $1,496,779   $2,318,922    (822,143)   -35%
Cost of revenues   1,186,100    1,187,296    (1,196)   0%
Gross margin   310,679    1,131,626    (820,947)   -73%
Total operating expenses   2,480,497    2,951,759    (471,262)   -16%
Total other income (expense), net   (678,883)   1,777,677    (2,456,560)   -138%
Loss from continued operations before provision for income taxes   (2,848,701)   (42,456)   (2,806,245)   6610%
Provision for income taxes for continuing operations   -    -    -    0%
Income(loss) from continuing operations  $(2,848,701)  $(42,456)   (2,806,245)   6610%

Nine Months Ended September 30, 2026, and 2025 Results of Operations

The following table presents VSee Health’s results of operations for the nine months ended September 30, 2026, and 2025:

   2026   2025   Change   % 
Total revenues  $4,937,956   $4,571,727    366,229    8%
Cost of revenues   3,693,712    2,014,819    1,678,893    83%
Gross margin   1,244,244    2,556,908    (1,312,664)   -51%
Total operating expenses   7,770,921    7,480,174    290,747    4%
Total other income (expense), net   (660,992)   (647,024)   (13,968)   2%
Loss from continued operations before provision for income taxes   (7,187,669)   (5,570,290)   (1,617,379)   29%
Provision for income taxes for continuing operations   (5,260)   (15,233)   9,973    -65%
Income(loss) from continuing operations  $(7,192,929)  $(5,585,523)   (1,607,406)   29%

Revenue

We generate revenue through management and administrative services contracts with hospitals and hospital systems to provide telehealth physician services, teleradiology services, and acute care patient services. We also generate revenue by directly billing insurance companies for care provided at hospitals and hospital systems. Revenue streams include telehealth fees, patient fees, teleradiology fees, and institutional fees. These contracts typically range from two to three years and are subject to automatic renewal.

Revenue was $1,496,779 and $4,937,956 for the three and nine months ended September 30, 2026, respectively, compared to $2,318,922 and $4,571,727 for the corresponding periods in 2025, representing (decreases)/increases of $(822,143), or (35)%, and $366,229, or 8%, respectively. The increases were primarily driven by growth in telehealth fees and patient fees.

Patient fee revenue decreased by $278,065, or 32%, to $604,464 for the three months ended September 30, 2026, compared to $882,529 for the three months ended September 30, 2025. The decrease was primarily attributable to the cessation of Virtual Neuro insurance billings after March 2026, which contributed approximately $217,000 in revenue during the prior-year quarter but did not recur in the current-year period. Patient fee revenue from core insurance services also declined modestly compared to the prior-year period.

For the nine months ended September 30, 2026, patient fees increased by $17,331, or 1%, to $2,086,896 from $2,069,565 for the comparable prior-year period. The increase was driven primarily by higher monthly patient fee revenue during 2026, including revenue associated with Virtual Neuro billing, partially offset by a $503,000 decrease in Virtual Neuro revenue following the reclassification of billings from patient fees to insurance fees after March 2026. Additionally, miscellaneous revenue decreased by $9,177 due to a one-time MedCenter Patients item recognized in February 2025 that did not recur in 2026.

Telehealth fees decreased by $544,078, or 37%, to $892,315 for the three months ended September 30, 2026, from $1,436,393 for the comparable prior-year period. The decrease was primarily attributable to the absence of Tele-ICU revenue in the current-year period following the expiration of the Piedmont Atlanta Neuro ICU and VIBRA Houston coverage contracts, which contributed approximately $443,000 of revenue during the prior-year quarter. The decrease was further impacted by a decline of approximately $87,000 in teleradiology revenue and a decrease of approximately $32,000 in platform hardware and software fees related to the same customer attrition. These decreases were partially offset by an increase of approximately $18,000 in prison telehealth revenue resulting from higher service volumes.

48

Table of Contents

 

For the nine months ended September 30, 2026, telehealth fees increased by $351,398, or 14%, to $2,851,060 from $2,499,662 for the comparable prior-year period. The increase was driven primarily by higher teleradiology revenue, reflecting a full nine months of operations during 2026 compared to only four months during the prior-year period, including increased activity from University Hospital and the addition of new Select Specialty Hospital locations. Telehealth revenue also benefited from higher prison telehealth service volume. These increases were partially offset by the loss of Tele-ICU revenue following the expiration of the Piedmont Atlanta Neuro ICU and VIBRA Houston coverage contracts, as well as lower platform hardware and software revenues associated with those contracts.

As a result of these factors, revenue decreased by 35% and increased by 8% for the three and nine months ended September 30, 2026, respectively, compared to the corresponding periods in 2025.

Cost of Goods Sold

Cost of revenues consists primarily of physician contractor fees, personnel-related costs for clinical and operational support teams, costs associated with teleradiology services, and other costs directly associated with the delivery of telehealth and patient care services.

Cost of revenues was $1,186,100 and $3,693,712 for the three and nine months ended September 30, 2026, respectively, compared to $1,187,296 and $2,014,819 for the corresponding periods in 2025, respectively, representing a (decrease)/increase of $(1,196), or (0)%, and $1,678,893, or 83%, respectively.

Cost of revenues remained relatively consistent at approximately $1.2 million for the three months ended September 30, 2026, compared to the prior-year period. The composition of cost of revenues changed significantly, however, driven by an increase of approximately $164,000 in medical independent contractor fees associated with the Company's Infinity Teleradiology services, which utilize contracted radiologists to provide diagnostic interpretations. This increase was substantially offset by a decrease of approximately $166,000 in clinical salaries and wages, reflecting the transition of clinical service delivery from internally employed personnel to independent contractors.

For the nine months ended September 30, 2026, cost of revenues increased by approximately $1.68 million, or 83%, compared to the prior-year period. The increase was primarily attributable to approximately $2.26 million of higher medical independent contractor fees associated with the expansion of the Company's Infinity Teleradiology services. Infinity Teleradiology operated for a full nine-month period during 2026, compared to only the period from July through September in the prior year. The increase was partially offset by a decrease of approximately $518,000 in clinical salaries and wages as service delivery shifted toward contracted providers, as well as a decrease of approximately $66,000 in peripheral device costs.

Gross profit decreased by $820,947, from $1,131,626 to $310,679, for the three months ended September 30, 2026, and decreased by $1,312,664, from $2,556,908 to $1,244,244, for the nine months ended September 30, 2026. As a result, gross margin declined to 21% and 25% for the three- and nine-month periods, respectively, from 48% and 55% in the comparable prior-year periods. The decrease was primarily attributable to a change in revenue mix, as higher-margin Tele-ICU and Virtual Neuro revenues were replaced by Infinity Teleradiology services. While teleradiology contributed significantly to revenue growth during 2026, the service line utilizes third-party providers and carries a higher direct cost structure than the Company's legacy Tele-ICU offerings. In addition, the loss of certain Tele-ICU contracts during 2025 reduced the contribution of higher-margin revenue streams, further impacting overall profitability.

Operating Expenses

Operating expenses include all operating costs not included in cost of revenues. These costs consist of compensation and related benefits and general and administrative expenses composed primarily of payroll and payroll-related expenses, professional fees, insurance, software costs, occupancy expenses, depreciation and amortization, and other costs related to the administration of our business.

Operating expenses were $2,480,497 and $7,770,921 for the three and nine months ended September 30, 2026, respectively, compared to $2,951,759 and $7,480,174 for the corresponding periods in 2025, representing a (decrease)/increase of $(471,262), or (16)%, and $290,747, or 4%, respectively.

General and administrative expenses increased by $302,452, or 4%, to $6,425,055 for the nine months ended September 30, 2026, from $6,122,603 for the comparable prior-year period. The increase was primarily driven by higher bad debt expense of approximately $748,000, increased business consulting expenses of approximately $434,000, higher legal fees of approximately $284,000, increased advisory fees of approximately $142,000, and higher investor relations costs of approximately $132,000. These increases were partially offset by decreases in audit fees of approximately $772,000, accounting fees of approximately $240,000, franchise tax expense of approximately $134,000, tax-related fees of approximately $113,000, lease and rental expense of approximately $106,000, and factoring fees of approximately $80,000.

Compensation and related benefits decreased by $11,705, or 0%, to $1,345,866 for the nine months ended September 30, 2026, from $1,357,571 for the comparable prior-year period. The decrease was primarily attributable to lower executive compensation expense, including the settlement of previously accrued salary liabilities, and lower employee benefit costs. These decreases were partially offset by higher salaries, bonus expense, contractor costs, and payroll service fees incurred during the current-year period.

Other Income (Expense)

Other income (expense), net, was $(678,883) and $(660,992) for the three and nine months ended September 30, 2026, respectively, compared to $1,777,677 and $(647,024) for the corresponding periods in 2025. This represents an increase in expense of $(2,456,560), or (138)%, for the three-month period and an increase in expense of $(13,968), or (2)%, for the nine-month period.

For the three months ended September 30, 2026, other expense was $678,883, consisting primarily of a $296,689 loss recognized on the extinguishment of financial liabilities in connection with debt settlement and modification activities, a $164,288 loss related to the issuance of financial instruments, and a $150,403 loss from changes in the fair value of financial instruments. The Company also incurred interest expense of $67,503 during the period.

49

Table of Contents

 

For the nine months ended September 30, 2026, other expense remained relatively consistent with the comparable prior-year period. The current-year period benefited from a $1,420,000 reduction in interest expense, primarily due to the retirement, conversion, and settlement of various debt instruments. This favorable impact was largely offset by the absence of the $1,410,000 million gain recognized in the prior-year period from changes in the fair value of financial instruments. In addition, the current-year period included a $309,462 loss on the issuance of financial instruments and a $182,504 loss from changes in the fair value of financial instruments, partially offset by a $71,120 gain on the extinguishment of financial liabilities compared to a $126,125 loss recognized in the prior-year period.

Net Loss

Net loss from continuing operations was $2,848,701 and $7,192,929 for the three and nine months ended September 30, 2026, respectively, compared to $42,456 and $5,585,523 for the corresponding periods in 2025. Net loss increased by $2,806,245 for the three-month period, primarily due to lower gross profit resulting from the shift in revenue mix from higher-margin Tele-ICU and Virtual Neuro services to lower-margin teleradiology services, as well as the recognition of losses related to the settlement of the ELOC and the extinguishment of financial liabilities during the current-year period. For the nine-month period, net loss increased by $1,607,406, primarily due to lower gross profit driven by the increased proportion of lower-margin teleradiology services within the Company's revenue mix and higher operating expenses, including increased bad debt, consulting, legal, and investor relations costs. These unfavorable impacts were partially offset by lower interest expense resulting from reduced outstanding debt balances and a gain on extinguishment of financial liabilities recognized during the current-year period.

Cash Flows

The following table presents selected captions from VSee Health’s consolidated statements of cash flows for the nine months ended September 30, 2026, and 2025:

   For the nine months ended 
   September 30, 
   2026   2025 
Net cash used in operating activities - continuing operations  $(2,996,674)  $(1,124,839)
Net cash used in investing activities - continuing operations   (102,288)   - 
Net cash (used in) provided by financing activities - continuing operations   (760,450)   1,689,052 
Change in cash due to continuing operations  $(3,859,412)  $564,213 
Change in cash due to discontinued operations   (1,150,367)   (417,569)
NET CHANGE IN CASH  $(5,009,779)  $146,644 

Our principal sources of liquidity are cash and cash equivalents, totaling $41,666 and $472,759 as of September 30, 2026, and 2025, respectively.

Our future capital requirements will depend on many factors, including our growth rate, contract renewal activity, number of subscription renewals, the continuing market acceptance of telehealth, and debt funding.

Cash Used in Operating Activities

Cash used in operating activities from continuing operations was $2,996,674 for the nine months ended September 30, 2026, compared to $1,124,839 for the nine months ended September 30, 2025. The increase in cash used was primarily attributable to a net loss from continuing operations of $7,192,929 in 2026, partially offset by non-cash adjustments of $4,067,963. Changes in operating assets and liabilities resulted in a net cash inflow of approximately $128,292 during the 2026 period.

Cash Used in Investing Activities

Cash used in investing activities from continuing operations was $102,288 for the nine months ended September 30, 2026, compared to $0 for the nine months ended September 30, 2025. The cash outflow in 2026 was primarily attributable to the purchase of long-term investments.

Cash (Used in) Provided by Financing Activities

Cash used in financing activities from continuing operations was $760,450 for the nine months ended September 30, 2026, compared to cash provided by financing activities of $1,689,052 for the nine months ended September 30, 2025. During the nine months ended September 30, 2026, financing cash outflows consisted primarily of repayments of notes payable of $969,864, payments on financing lease liabilities of $591,118, repayments under the line of credit of $348,952, and payments related to the Encompass acquisition liability of $50,000. These outflows were partially offset by proceeds from convertible notes issued of $1,041,000, proceeds from notes issued during the period of $157,500, and proceeds from pre-funded warrants, net of issuance costs, of $984. For the nine months ended September 30, 2025, financing cash inflows consisted primarily of proceeds from notes issued during the period of $1,907,791, proceeds from the issuance of common stock of $541,184, These inflows were partially offset by $10,000, $56,787, $25,000, $44 and $668,092 of payments to shareholder, for factoring payables, on financing lease liability, due on acquisition purchase and repayment on note payable.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

As a smaller reporting company, we are not required to provide the information required by this item.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Disclosure controls are procedures that are designed with the objective of ensuring that information required to be disclosed in our reports filed under the Exchange Act, such as this Report, is recorded, processed, summarized, and reported within the time period specified in the SEC’s rules and forms. Disclosure controls are also designed with the objective of ensuring that such information is accumulated and communicated to our management, including the chief executive officer and chief financial officer, as appropriate to allow timely decisions regarding required disclosure. Our management evaluated, with the participation of our current chief executive officer and chief financial officer (our “Certifying Officers”), the effectiveness of our disclosure controls and procedures as of September 30, 2026, pursuant to Rule 13a-15(b) under the Exchange Act. Based upon that evaluation, our Certifying Officers concluded that, as of September 30, 2026, our disclosure controls and procedures were not effective.

50

Table of Contents

 

Management concluded that material weaknesses in internal control over financial reporting existed relating to the lack of sufficient number of personnel within the accounting function to adequately segregate duties, we did not have a designed and implemented effective Information Technology General Controls (“ITGC”) related to access controls to financial accounting system, we did not have a formalized control environment and oversite of controls over financial reporting, and we lack proper accounting for significant or non-recurring transactions. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis.

We lack the resources to employ additional personnel to help mitigate these material weaknesses and we foresee that these material weaknesses will not be remediated until we receive additional funding to support our accounting department.

We cannot assure you that these or other measures will fully remediate the material weakness in a timely manner. Notwithstanding the identified material weakness, our management believes that the consolidated financial statements included in this report fairly represent in all material respects our financial condition, results of operations and cash flows at and for the periods presented in accordance with U.S. GAAP.

We do not expect that our disclosure controls and procedures will prevent all errors and all instances of fraud. Disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Further, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and the benefits must be considered relative to their costs. Because of the inherent limitations in all disclosure controls and procedures, no evaluation of disclosure controls and procedures can provide absolute assurance that we have detected all our control deficiencies and instances of fraud, if any. The design of disclosure controls and procedures also is based partly on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Subsequent to the quarter end, in light of the material weakness as described above, we have enhanced our processes to identify and appropriately apply applicable accounting requirements to better evaluate and understand the nuances of the complex accounting standards that apply to our financial statements on a timely basis. Our plans at this time include providing enhanced access to accounting literature, research materials and documents and increased communication among our personnel and third-party professionals with whom we consult regarding application and financial reporting. The elements of our remediation plan can only be accomplished over time, and we can offer no assurance that these initiatives will ultimately have the intended effects.

51

Table of Contents

 

PART II — OTHER INFORMATION

Item 1. Legal Proceedings

We are from time to time subject to claims, lawsuits and other legal and administrative proceedings arising in the ordinary course of business. Defending such proceedings is costly and can impose a significant burden on management and employees. The results of any future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. We are not presently a party to any litigation the outcome of which, we believe, if determined adversely to us, would individually or taken together have a material adverse effect on our business, operating results, cash flows or financial condition.

On April 21, 2026, Toppan Merrill LLC filed a lawsuit in the Superior Court in the County of Middlesex, Massachusetts. The plaintiff alleges that the Company owes $845,891 for services rendered by the plaintiff. The plaintiff is also seeking a preliminary injunction enjoining the Company from disposing assets outside of the ordinary course of business. The Company intends to vigorously defend itself against these allegations. The Company has accrued an amount it believes to be reasonable related to this matter based on the services reflected in its accounts payable balance, which differs from the amount claimed by the plaintiff.

Item 1A. Risk Factors

In addition to the other information set forth in this report, you should carefully consider the risk factors discussed in “Part I, Item 1A. Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and in “Part II, Item 1A. Risk Factors” of our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, which could materially affect our business, financial condition, or future operating results and cash flows. We do not believe that there have been any material changes to the risk factors disclosed in “Part I, Item 1A. Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and in “Part II, Item 1A. Risk Factors” of our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. The risks described in “Part I, Item 1A. Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, in “Part II, Item 1A. Risk Factors” of our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 and other reports we file with the SEC are not the only risks facing our Company. Additional risks and uncertainties not currently known to us or that we currently deem immaterial also may materially adversely affect our business, financial condition, operating results and/or cash flows.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Other than as described in our Current Reports on Form 8-K filed with the SEC on July 7, 2026, July 24, 2026, July 31, 2026, September 9, 2026, and September 30, 2026, for this fiscal quarter ended September 30, 2026, there were no unregistered securities to report which have not been previously included in a Quarterly Report on Form 10-Q, Annual Report on Form 10-K, or a Current Report on Form 8-K.

52

Table of Contents

 

Item 3. Defaults Upon Senior Securities

Not applicable.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

During the three months ended September 30, 2026, none of our directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) informed us of the adoption or termination of a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement” (as defined in Item 408 of Regulation S-K).

Item 6. Exhibits

The following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.

Exhibit No. Description
3.1 Second Amended and Restated Certificate of Incorporation of VSee Health, Inc. (incorporated by reference to Exhibit 3.1 filed with the Form 8-K filed by the Registrant on June 28, 2024).
3.2 Certificate of Designation of Series A Convertible Preferred Stock of VSee Health, Inc. (incorporated by reference to Exhibit 3.2 filed with the Form 8-K filed by the Registrant on June 28, 2024).
3.3 Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock, dated December 5, 2025 (incorporated by reference to Exhibit 3.1 filed with the Form 8-K filed by the Registrant on December 11, 2025).
3.4 Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation of VSee Health, Inc., dated September 22, 2026 (incorporated by reference to Exhibit 3.1 filed with the Form 8-K filed by the Registrant on September 23, 2026).
3.5 Amended and Restated Bylaws of VSee Health, Inc. (incorporated by reference to Exhibit 3.3 filed with the Form 8-K filed by the Registrant on June 28, 2024).
3.6 Amendment No. 1 to the Amended and Restated Bylaws of VSee Health, Inc. (incorporated by reference to Exhibit 3.1 filed with the Form 8-K filed by the Registrant on December 18, 2025).
10.1 Settlement and Mutual Release, dated July 21, 2026, by and among ADI Funding LLC and M2B Funding Corp. (incorporated by reference to Exhibit 10.80 filed with the Form S-1 filed by the Registrant on October 1, 2026).
10.2 Settlement Promissory Note (ADI), dated July 21, 2026 (incorporated by reference to Exhibit 10.81 filed with the Form S-1 filed by the Registrant on October 1, 2026).
10.3 Settlement Promissory Note (M2B), dated July 21, 2026 (incorporated by reference to Exhibit 10.82 filed with the Form S-1 filed by the Registrant on October 1, 2026).
10.4 Strata Purchase Agreement, dated September 2, 2026, between VSee Health, Inc. and ClearThink Capital Partners, LLC (incorporated by Ference to Exhibit 10.1 filed with the Form 8-K filed by the Registrant on September 9, 2026).
10.5 Unsecured Convertible Promissory Note, dated September 24, 2026 (incorporated by reference to Exhibit 10.2 filed with the Form 8-K filed by the Registrant on September 30, 2026).
31.1* Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934.
31.2* Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934.
32.1* Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. § 1350.
101.INS XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH XBRL Taxonomy Extension Schema Document.
101.CAL XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB XBRL Taxonomy Extension Label Linkbase Document.
101.PRE XBRL Taxonomy Extension Presentation Linkbase Document.
104 Cover Page Interactive Data File - the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

 

*Filed herewith (furnished herewith with respect to Exhibit 32.1)

 

53

Table of Contents

 

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 VSEE HEALTH, INC.
   
Date: November 16, 2026By:/s/ Imoigele Aisiku
 Name: Imoigele Aisiku
 Title:Chief Executive Officer and Chairman of the Board
  (Principal Executive Officer)
   
Date: November 16, 2026By:/s/ Jerry Leonard
 Name: Jerry Leonard
 Title:Chief Financial Officer and Secretary
  (Principal Financial and Accounting Officer)

 

54

NASDAQ NASDAQ P2Y P3Y P0Y P8M 20 12 13 20 P3D P0Y 0001864531 false Q3 --12-31 Shorter of lease term or estimated useful life 0001864531 2026-01-01 2026-09-30 0001864531 us-gaap:CommonStockMember 2026-01-01 2026-09-30 0001864531 vsee:Warrant1Member 2026-01-01 2026-09-30 0001864531 2026-11-15 0001864531 2026-09-30 0001864531 2025-12-31 0001864531 vsee:September2024ConvertibleNoteMember 2026-09-30 0001864531 vsee:September2024ConvertibleNoteMember 2025-12-31 0001864531 us-gaap:RelatedPartyMember 2026-09-30 0001864531 us-gaap:RelatedPartyMember 2025-12-31 0001864531 us-gaap:RevolvingCreditFacilityMember 2026-09-30 0001864531 us-gaap:RevolvingCreditFacilityMember 2025-12-31 0001864531 us-gaap:SeriesAPreferredStockMember 2026-09-30 0001864531 us-gaap:SeriesAPreferredStockMember 2025-12-31 0001864531 us-gaap:SeriesBPreferredStockMember 2026-09-30 0001864531 us-gaap:SeriesBPreferredStockMember 2025-12-31 0001864531 us-gaap:HealthCarePatientServiceMember 2026-07-01 2026-09-30 0001864531 us-gaap:HealthCarePatientServiceMember 2025-07-01 2025-09-30 0001864531 us-gaap:HealthCarePatientServiceMember 2026-01-01 2026-09-30 0001864531 us-gaap:HealthCarePatientServiceMember 2025-01-01 2025-09-30 0001864531 vsee:TelehealthFeesMember 2026-07-01 2026-09-30 0001864531 vsee:TelehealthFeesMember 2025-07-01 2025-09-30 0001864531 vsee:TelehealthFeesMember 2026-01-01 2026-09-30 0001864531 vsee:TelehealthFeesMember 2025-01-01 2025-09-30 0001864531 vsee:InstitutionalFeesMember 2026-07-01 2026-09-30 0001864531 vsee:InstitutionalFeesMember 2025-07-01 2025-09-30 0001864531 vsee:InstitutionalFeesMember 2026-01-01 2026-09-30 0001864531 vsee:InstitutionalFeesMember 2025-01-01 2025-09-30 0001864531 2026-07-01 2026-09-30 0001864531 2025-07-01 2025-09-30 0001864531 2025-01-01 2025-09-30 0001864531 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2025-12-31 0001864531 us-gaap:CommonStockMember 2025-12-31 0001864531 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001864531 us-gaap:RetainedEarningsMember 2025-12-31 0001864531 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001864531 2026-01-01 2026-03-31 0001864531 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001864531 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001864531 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2026-01-01 2026-03-31 0001864531 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2026-01-01 2026-03-31 0001864531 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2026-03-31 0001864531 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2026-03-31 0001864531 us-gaap:CommonStockMember 2026-03-31 0001864531 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001864531 us-gaap:RetainedEarningsMember 2026-03-31 0001864531 2026-03-31 0001864531 us-gaap:RetainedEarningsMember 2026-04-01 2026-06-30 0001864531 2026-04-01 2026-06-30 0001864531 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2026-04-01 2026-06-30 0001864531 us-gaap:SeriesAPreferredStockMember us-gaap:CommonStockMember 2026-04-01 2026-06-30 0001864531 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2026-04-01 2026-06-30 0001864531 us-gaap:SeriesBPreferredStockMember us-gaap:CommonStockMember 2026-04-01 2026-06-30 0001864531 us-gaap:SeriesBPreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2026-04-01 2026-06-30 0001864531 us-gaap:CommonStockMember 2026-04-01 2026-06-30 0001864531 us-gaap:AdditionalPaidInCapitalMember 2026-04-01 2026-06-30 0001864531 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2026-06-30 0001864531 us-gaap:CommonStockMember 2026-06-30 0001864531 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001864531 us-gaap:RetainedEarningsMember 2026-06-30 0001864531 2026-06-30 0001864531 us-gaap:RetainedEarningsMember 2026-07-01 2026-09-30 0001864531 us-gaap:CommonStockMember 2026-07-01 2026-09-30 0001864531 us-gaap:AdditionalPaidInCapitalMember 2026-07-01 2026-09-30 0001864531 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2026-09-30 0001864531 us-gaap:CommonStockMember 2026-09-30 0001864531 us-gaap:AdditionalPaidInCapitalMember 2026-09-30 0001864531 us-gaap:RetainedEarningsMember 2026-09-30 0001864531 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2024-12-31 0001864531 us-gaap:CommonStockMember 2024-12-31 0001864531 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001864531 us-gaap:RetainedEarningsMember 2024-12-31 0001864531 2024-12-31 0001864531 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001864531 2025-01-01 2025-03-31 0001864531 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001864531 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001864531 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2025-03-31 0001864531 us-gaap:CommonStockMember 2025-03-31 0001864531 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001864531 us-gaap:RetainedEarningsMember 2025-03-31 0001864531 2025-03-31 0001864531 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001864531 2025-04-01 2025-06-30 0001864531 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001864531 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001864531 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2025-06-30 0001864531 us-gaap:CommonStockMember 2025-06-30 0001864531 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001864531 us-gaap:RetainedEarningsMember 2025-06-30 0001864531 2025-06-30 0001864531 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0001864531 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0001864531 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0001864531 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2025-09-30 0001864531 us-gaap:CommonStockMember 2025-09-30 0001864531 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0001864531 us-gaap:RetainedEarningsMember 2025-09-30 0001864531 2025-09-30 0001864531 vsee:VSeeLabMember 2026-05-31 0001864531 vsee:VseeLabIncMember 2024-06-24 0001864531 vsee:ServiceContractsWithHospitalsOrHospitalSystemsPhysicianPracticeGroupsAndOtherUsersMember srt:MinimumMember 2026-01-01 2026-09-30 0001864531 vsee:ServiceContractsWithHospitalsOrHospitalSystemsPhysicianPracticeGroupsAndOtherUsersMember srt:MaximumMember 2026-01-01 2026-09-30 0001864531 vsee:TelehealthAndInstitutionalServicesMember 2026-01-01 2026-09-30 0001864531 vsee:InitialFixedConversionPriceMember 2026-09-30 0001864531 srt:MaximumMember us-gaap:InterestRateFloorMember 2026-09-30 0001864531 vsee:AssumesFloorConversionPriceMember 2026-09-30 0001864531 vsee:FloorConversionPriceMember 2026-09-30 0001864531 us-gaap:InterestRateFloorMember 2026-09-30 0001864531 2025-01-01 2025-12-31 0001864531 vsee:GoMyRxIncMember 2026-01-16 0001864531 vsee:GoMyRxIncMember 2026-01-16 2026-01-16 0001864531 us-gaap:DevelopedTechnologyRightsMember 2026-09-30 0001864531 us-gaap:CustomerListsMember 2026-09-30 0001864531 us-gaap:TransferredOverTimeMember 2026-07-01 2026-09-30 0001864531 us-gaap:TransferredOverTimeMember 2025-07-01 2025-09-30 0001864531 us-gaap:TransferredOverTimeMember 2026-01-01 2026-09-30 0001864531 us-gaap:TransferredOverTimeMember 2025-01-01 2025-09-30 0001864531 us-gaap:TransferredAtPointInTimeMember 2026-07-01 2026-09-30 0001864531 us-gaap:TransferredAtPointInTimeMember 2025-07-01 2025-09-30 0001864531 us-gaap:TransferredAtPointInTimeMember 2026-01-01 2026-09-30 0001864531 us-gaap:TransferredAtPointInTimeMember 2025-01-01 2025-09-30 0001864531 us-gaap:SegmentContinuingOperationsMember 2026-07-01 2026-09-30 0001864531 us-gaap:SegmentContinuingOperationsMember 2025-07-01 2025-09-30 0001864531 us-gaap:SegmentContinuingOperationsMember 2026-01-01 2026-09-30 0001864531 us-gaap:SegmentContinuingOperationsMember 2025-01-01 2025-09-30 0001864531 vsee:PublicWarrantsMember us-gaap:SegmentContinuingOperationsMember 2026-07-01 2026-09-30 0001864531 vsee:PublicWarrantsMember us-gaap:SegmentContinuingOperationsMember 2025-07-01 2025-09-30 0001864531 vsee:PublicWarrantsMember us-gaap:SegmentContinuingOperationsMember 2026-01-01 2026-09-30 0001864531 vsee:PublicWarrantsMember us-gaap:SegmentContinuingOperationsMember 2025-01-01 2025-09-30 0001864531 vsee:PrivateWarrantsMember us-gaap:SegmentContinuingOperationsMember 2026-07-01 2026-09-30 0001864531 vsee:PrivateWarrantsMember us-gaap:SegmentContinuingOperationsMember 2025-07-01 2025-09-30 0001864531 vsee:PrivateWarrantsMember us-gaap:SegmentContinuingOperationsMember 2026-01-01 2026-09-30 0001864531 vsee:PrivateWarrantsMember us-gaap:SegmentContinuingOperationsMember 2025-01-01 2025-09-30 0001864531 vsee:BridgeWarrantsMember us-gaap:SegmentContinuingOperationsMember 2026-07-01 2026-09-30 0001864531 vsee:BridgeWarrantsMember us-gaap:SegmentContinuingOperationsMember 2025-07-01 2025-09-30 0001864531 vsee:BridgeWarrantsMember us-gaap:SegmentContinuingOperationsMember 2026-01-01 2026-09-30 0001864531 vsee:BridgeWarrantsMember us-gaap:SegmentContinuingOperationsMember 2025-01-01 2025-09-30 0001864531 vsee:ExtensionWarrantsMember us-gaap:SegmentContinuingOperationsMember 2026-07-01 2026-09-30 0001864531 vsee:ExtensionWarrantsMember us-gaap:SegmentContinuingOperationsMember 2025-07-01 2025-09-30 0001864531 vsee:ExtensionWarrantsMember us-gaap:SegmentContinuingOperationsMember 2026-01-01 2026-09-30 0001864531 vsee:ExtensionWarrantsMember us-gaap:SegmentContinuingOperationsMember 2025-01-01 2025-09-30 0001864531 vsee:September2024WarrantsMember us-gaap:SegmentContinuingOperationsMember 2026-07-01 2026-09-30 0001864531 vsee:September2024WarrantsMember us-gaap:SegmentContinuingOperationsMember 2025-07-01 2025-09-30 0001864531 vsee:September2024WarrantsMember us-gaap:SegmentContinuingOperationsMember 2026-01-01 2026-09-30 0001864531 vsee:September2024WarrantsMember us-gaap:SegmentContinuingOperationsMember 2025-01-01 2025-09-30 0001864531 vsee:QuantumConvertibleNoteRelatedPartyMember us-gaap:SegmentContinuingOperationsMember 2026-07-01 2026-09-30 0001864531 vsee:QuantumConvertibleNoteRelatedPartyMember us-gaap:SegmentContinuingOperationsMember 2025-07-01 2025-09-30 0001864531 vsee:QuantumConvertibleNoteRelatedPartyMember us-gaap:SegmentContinuingOperationsMember 2026-01-01 2026-09-30 0001864531 vsee:QuantumConvertibleNoteRelatedPartyMember us-gaap:SegmentContinuingOperationsMember 2025-01-01 2025-09-30 0001864531 vsee:ExchangeNoteMember us-gaap:SegmentContinuingOperationsMember 2026-07-01 2026-09-30 0001864531 vsee:ExchangeNoteMember us-gaap:SegmentContinuingOperationsMember 2025-07-01 2025-09-30 0001864531 vsee:ExchangeNoteMember us-gaap:SegmentContinuingOperationsMember 2026-01-01 2026-09-30 0001864531 vsee:ExchangeNoteMember us-gaap:SegmentContinuingOperationsMember 2025-01-01 2025-09-30 0001864531 vsee:September2024ConvertibleNoteMember us-gaap:SegmentContinuingOperationsMember 2026-07-01 2026-09-30 0001864531 vsee:September2024ConvertibleNoteMember us-gaap:SegmentContinuingOperationsMember 2025-07-01 2025-09-30 0001864531 vsee:September2024ConvertibleNoteMember us-gaap:SegmentContinuingOperationsMember 2026-01-01 2026-09-30 0001864531 vsee:September2024ConvertibleNoteMember us-gaap:SegmentContinuingOperationsMember 2025-01-01 2025-09-30 0001864531 vsee:SeriesAPreferredStockCommonStockEquivalentsMember us-gaap:SegmentContinuingOperationsMember 2026-07-01 2026-09-30 0001864531 vsee:SeriesAPreferredStockCommonStockEquivalentsMember us-gaap:SegmentContinuingOperationsMember 2025-07-01 2025-09-30 0001864531 vsee:SeriesAPreferredStockCommonStockEquivalentsMember us-gaap:SegmentContinuingOperationsMember 2026-01-01 2026-09-30 0001864531 vsee:SeriesAPreferredStockCommonStockEquivalentsMember us-gaap:SegmentContinuingOperationsMember 2025-01-01 2025-09-30 0001864531 us-gaap:EmployeeStockOptionMember us-gaap:SegmentContinuingOperationsMember 2026-07-01 2026-09-30 0001864531 us-gaap:EmployeeStockOptionMember us-gaap:SegmentContinuingOperationsMember 2025-07-01 2025-09-30 0001864531 us-gaap:EmployeeStockOptionMember us-gaap:SegmentContinuingOperationsMember 2026-01-01 2026-09-30 0001864531 us-gaap:EmployeeStockOptionMember us-gaap:SegmentContinuingOperationsMember 2025-01-01 2025-09-30 0001864531 vsee:CommonStockIssuanceObligationMember us-gaap:SegmentContinuingOperationsMember 2026-07-01 2026-09-30 0001864531 vsee:CommonStockIssuanceObligationMember us-gaap:SegmentContinuingOperationsMember 2025-07-01 2025-09-30 0001864531 vsee:CommonStockIssuanceObligationMember us-gaap:SegmentContinuingOperationsMember 2026-01-01 2026-09-30 0001864531 vsee:CommonStockIssuanceObligationMember us-gaap:SegmentContinuingOperationsMember 2025-01-01 2025-09-30 0001864531 vsee:March2025ConvertibleNoteMember us-gaap:SegmentContinuingOperationsMember 2026-07-01 2026-09-30 0001864531 vsee:March2025ConvertibleNoteMember us-gaap:SegmentContinuingOperationsMember 2025-07-01 2025-09-30 0001864531 vsee:March2025ConvertibleNoteMember us-gaap:SegmentContinuingOperationsMember 2026-01-01 2026-09-30 0001864531 vsee:March2025ConvertibleNoteMember us-gaap:SegmentContinuingOperationsMember 2025-01-01 2025-09-30 0001864531 vsee:May2025ConvertibleNoteMember us-gaap:SegmentContinuingOperationsMember 2026-07-01 2026-09-30 0001864531 vsee:May2025ConvertibleNoteMember us-gaap:SegmentContinuingOperationsMember 2025-07-01 2025-09-30 0001864531 vsee:May2025ConvertibleNoteMember us-gaap:SegmentContinuingOperationsMember 2026-01-01 2026-09-30 0001864531 vsee:May2025ConvertibleNoteMember us-gaap:SegmentContinuingOperationsMember 2025-01-01 2025-09-30 0001864531 vsee:CommonStockWarrantsMember us-gaap:SegmentContinuingOperationsMember 2026-07-01 2026-09-30 0001864531 vsee:CommonStockWarrantsMember us-gaap:SegmentContinuingOperationsMember 2025-07-01 2025-09-30 0001864531 vsee:CommonStockWarrantsMember us-gaap:SegmentContinuingOperationsMember 2026-01-01 2026-09-30 0001864531 vsee:CommonStockWarrantsMember us-gaap:SegmentContinuingOperationsMember 2025-01-01 2025-09-30 0001864531 vsee:ClearThinkConvertibleNoteMember us-gaap:SegmentContinuingOperationsMember 2026-07-01 2026-09-30 0001864531 vsee:ClearThinkConvertibleNoteMember us-gaap:SegmentContinuingOperationsMember 2025-07-01 2025-09-30 0001864531 vsee:ClearThinkConvertibleNoteMember us-gaap:SegmentContinuingOperationsMember 2026-01-01 2026-09-30 0001864531 vsee:ClearThinkConvertibleNoteMember us-gaap:SegmentContinuingOperationsMember 2025-01-01 2025-09-30 0001864531 vsee:LabrysConvertiblePromissoryNoteMember us-gaap:SegmentContinuingOperationsMember 2026-07-01 2026-09-30 0001864531 vsee:LabrysConvertiblePromissoryNoteMember us-gaap:SegmentContinuingOperationsMember 2025-07-01 2025-09-30 0001864531 vsee:LabrysConvertiblePromissoryNoteMember us-gaap:SegmentContinuingOperationsMember 2026-01-01 2026-09-30 0001864531 vsee:LabrysConvertiblePromissoryNoteMember us-gaap:SegmentContinuingOperationsMember 2025-01-01 2025-09-30 0001864531 us-gaap:SegmentDiscontinuedOperationsMember 2026-07-01 2026-09-30 0001864531 us-gaap:SegmentDiscontinuedOperationsMember 2025-07-01 2025-09-30 0001864531 us-gaap:SegmentDiscontinuedOperationsMember 2026-01-01 2026-09-30 0001864531 us-gaap:SegmentDiscontinuedOperationsMember 2025-01-01 2025-09-30 0001864531 vsee:PublicWarrantsMember us-gaap:SegmentDiscontinuedOperationsMember 2026-07-01 2026-09-30 0001864531 vsee:PublicWarrantsMember us-gaap:SegmentDiscontinuedOperationsMember 2025-07-01 2025-09-30 0001864531 vsee:PublicWarrantsMember us-gaap:SegmentDiscontinuedOperationsMember 2026-01-01 2026-09-30 0001864531 vsee:PublicWarrantsMember us-gaap:SegmentDiscontinuedOperationsMember 2025-01-01 2025-09-30 0001864531 vsee:PrivateWarrantsMember us-gaap:SegmentDiscontinuedOperationsMember 2026-07-01 2026-09-30 0001864531 vsee:PrivateWarrantsMember us-gaap:SegmentDiscontinuedOperationsMember 2025-07-01 2025-09-30 0001864531 vsee:PrivateWarrantsMember us-gaap:SegmentDiscontinuedOperationsMember 2026-01-01 2026-09-30 0001864531 vsee:PrivateWarrantsMember us-gaap:SegmentDiscontinuedOperationsMember 2025-01-01 2025-09-30 0001864531 vsee:BridgeWarrantsMember us-gaap:SegmentDiscontinuedOperationsMember 2026-07-01 2026-09-30 0001864531 vsee:BridgeWarrantsMember us-gaap:SegmentDiscontinuedOperationsMember 2025-07-01 2025-09-30 0001864531 vsee:BridgeWarrantsMember us-gaap:SegmentDiscontinuedOperationsMember 2026-01-01 2026-09-30 0001864531 vsee:BridgeWarrantsMember us-gaap:SegmentDiscontinuedOperationsMember 2025-01-01 2025-09-30 0001864531 vsee:ExtensionWarrantsMember us-gaap:SegmentDiscontinuedOperationsMember 2026-07-01 2026-09-30 0001864531 vsee:ExtensionWarrantsMember us-gaap:SegmentDiscontinuedOperationsMember 2025-07-01 2025-09-30 0001864531 vsee:ExtensionWarrantsMember us-gaap:SegmentDiscontinuedOperationsMember 2026-01-01 2026-09-30 0001864531 vsee:ExtensionWarrantsMember us-gaap:SegmentDiscontinuedOperationsMember 2025-01-01 2025-09-30 0001864531 vsee:September2024WarrantsMember us-gaap:SegmentDiscontinuedOperationsMember 2026-07-01 2026-09-30 0001864531 vsee:September2024WarrantsMember us-gaap:SegmentDiscontinuedOperationsMember 2025-07-01 2025-09-30 0001864531 vsee:September2024WarrantsMember us-gaap:SegmentDiscontinuedOperationsMember 2026-01-01 2026-09-30 0001864531 vsee:September2024WarrantsMember us-gaap:SegmentDiscontinuedOperationsMember 2025-01-01 2025-09-30 0001864531 vsee:QuantumConvertibleNoteRelatedPartyMember us-gaap:SegmentDiscontinuedOperationsMember 2026-07-01 2026-09-30 0001864531 vsee:QuantumConvertibleNoteRelatedPartyMember us-gaap:SegmentDiscontinuedOperationsMember 2025-07-01 2025-09-30 0001864531 vsee:QuantumConvertibleNoteRelatedPartyMember us-gaap:SegmentDiscontinuedOperationsMember 2026-01-01 2026-09-30 0001864531 vsee:QuantumConvertibleNoteRelatedPartyMember us-gaap:SegmentDiscontinuedOperationsMember 2025-01-01 2025-09-30 0001864531 vsee:ExchangeNoteMember us-gaap:SegmentDiscontinuedOperationsMember 2026-07-01 2026-09-30 0001864531 vsee:ExchangeNoteMember us-gaap:SegmentDiscontinuedOperationsMember 2025-07-01 2025-09-30 0001864531 vsee:ExchangeNoteMember us-gaap:SegmentDiscontinuedOperationsMember 2026-01-01 2026-09-30 0001864531 vsee:ExchangeNoteMember us-gaap:SegmentDiscontinuedOperationsMember 2025-01-01 2025-09-30 0001864531 vsee:September2024ConvertibleNoteMember us-gaap:SegmentDiscontinuedOperationsMember 2026-07-01 2026-09-30 0001864531 vsee:September2024ConvertibleNoteMember us-gaap:SegmentDiscontinuedOperationsMember 2025-07-01 2025-09-30 0001864531 vsee:September2024ConvertibleNoteMember us-gaap:SegmentDiscontinuedOperationsMember 2026-01-01 2026-09-30 0001864531 vsee:September2024ConvertibleNoteMember us-gaap:SegmentDiscontinuedOperationsMember 2025-01-01 2025-09-30 0001864531 vsee:SeriesAPreferredStockCommonStockEquivalentsMember us-gaap:SegmentDiscontinuedOperationsMember 2026-07-01 2026-09-30 0001864531 vsee:SeriesAPreferredStockCommonStockEquivalentsMember us-gaap:SegmentDiscontinuedOperationsMember 2025-07-01 2025-09-30 0001864531 vsee:SeriesAPreferredStockCommonStockEquivalentsMember us-gaap:SegmentDiscontinuedOperationsMember 2026-01-01 2026-09-30 0001864531 vsee:SeriesAPreferredStockCommonStockEquivalentsMember us-gaap:SegmentDiscontinuedOperationsMember 2025-01-01 2025-09-30 0001864531 us-gaap:EmployeeStockOptionMember us-gaap:SegmentDiscontinuedOperationsMember 2026-07-01 2026-09-30 0001864531 us-gaap:EmployeeStockOptionMember us-gaap:SegmentDiscontinuedOperationsMember 2025-07-01 2025-09-30 0001864531 us-gaap:EmployeeStockOptionMember us-gaap:SegmentDiscontinuedOperationsMember 2026-01-01 2026-09-30 0001864531 us-gaap:EmployeeStockOptionMember us-gaap:SegmentDiscontinuedOperationsMember 2025-01-01 2025-09-30 0001864531 vsee:CommonStockIssuanceObligationMember us-gaap:SegmentDiscontinuedOperationsMember 2026-07-01 2026-09-30 0001864531 vsee:CommonStockIssuanceObligationMember us-gaap:SegmentDiscontinuedOperationsMember 2025-07-01 2025-09-30 0001864531 vsee:CommonStockIssuanceObligationMember us-gaap:SegmentDiscontinuedOperationsMember 2026-01-01 2026-09-30 0001864531 vsee:CommonStockIssuanceObligationMember us-gaap:SegmentDiscontinuedOperationsMember 2025-01-01 2025-09-30 0001864531 vsee:March2025ConvertibleNoteMember us-gaap:SegmentDiscontinuedOperationsMember 2026-07-01 2026-09-30 0001864531 vsee:March2025ConvertibleNoteMember us-gaap:SegmentDiscontinuedOperationsMember 2025-07-01 2025-09-30 0001864531 vsee:March2025ConvertibleNoteMember us-gaap:SegmentDiscontinuedOperationsMember 2026-01-01 2026-09-30 0001864531 vsee:March2025ConvertibleNoteMember us-gaap:SegmentDiscontinuedOperationsMember 2025-01-01 2025-09-30 0001864531 vsee:May2025ConvertibleNoteMember us-gaap:SegmentDiscontinuedOperationsMember 2026-07-01 2026-09-30 0001864531 vsee:May2025ConvertibleNoteMember us-gaap:SegmentDiscontinuedOperationsMember 2025-07-01 2025-09-30 0001864531 vsee:May2025ConvertibleNoteMember us-gaap:SegmentDiscontinuedOperationsMember 2026-01-01 2026-09-30 0001864531 vsee:May2025ConvertibleNoteMember us-gaap:SegmentDiscontinuedOperationsMember 2025-01-01 2025-09-30 0001864531 vsee:CommonStockWarrantsMember us-gaap:SegmentDiscontinuedOperationsMember 2026-07-01 2026-09-30 0001864531 vsee:CommonStockWarrantsMember us-gaap:SegmentDiscontinuedOperationsMember 2025-07-01 2025-09-30 0001864531 vsee:CommonStockWarrantsMember us-gaap:SegmentDiscontinuedOperationsMember 2026-01-01 2026-09-30 0001864531 vsee:CommonStockWarrantsMember us-gaap:SegmentDiscontinuedOperationsMember 2025-01-01 2025-09-30 0001864531 srt:MinimumMember us-gaap:OfficeEquipmentMember 2026-09-30 0001864531 srt:MaximumMember us-gaap:OfficeEquipmentMember 2026-09-30 0001864531 srt:MinimumMember vsee:MedicalEquipmentMember 2026-09-30 0001864531 srt:MaximumMember vsee:MedicalEquipmentMember 2026-09-30 0001864531 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2026-09-30 0001864531 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2026-09-30 0001864531 srt:MinimumMember vsee:LeasedEquipmentMember 2026-09-30 0001864531 vsee:LeasedEquipmentMember 2026-09-30 0001864531 srt:MaximumMember vsee:LeasedEquipmentMember 2026-09-30 0001864531 srt:MinimumMember us-gaap:LeaseholdImprovementsMember 2026-09-30 0001864531 srt:MaximumMember us-gaap:LeaseholdImprovementsMember 2026-09-30 0001864531 us-gaap:CustomerRelationshipsMember 2026-09-30 0001864531 us-gaap:CustomerRelationshipsMember 2025-12-31 0001864531 us-gaap:TechnologyBasedIntangibleAssetsMember 2026-09-30 0001864531 us-gaap:TechnologyBasedIntangibleAssetsMember 2025-12-31 0001864531 vsee:MiltonChenMember 2026-05-31 0001864531 2026-05-31 2026-05-31 0001864531 vsee:SubscriptionFeesMember 2026-07-01 2026-09-30 0001864531 vsee:SubscriptionFeesMember 2025-07-01 2025-09-30 0001864531 vsee:SubscriptionFeesMember 2026-01-01 2026-09-30 0001864531 vsee:SubscriptionFeesMember 2025-01-01 2025-09-30 0001864531 vsee:ProfessionalServicesAndOtherFeesMember 2026-07-01 2026-09-30 0001864531 vsee:ProfessionalServicesAndOtherFeesMember 2025-07-01 2025-09-30 0001864531 vsee:ProfessionalServicesAndOtherFeesMember 2026-01-01 2026-09-30 0001864531 vsee:ProfessionalServicesAndOtherFeesMember 2025-01-01 2025-09-30 0001864531 vsee:TechnicalEngineeringFeesMember 2026-07-01 2026-09-30 0001864531 vsee:TechnicalEngineeringFeesMember 2025-07-01 2025-09-30 0001864531 vsee:TechnicalEngineeringFeesMember 2026-01-01 2026-09-30 0001864531 vsee:TechnicalEngineeringFeesMember 2025-01-01 2025-09-30 0001864531 2026-01-15 2026-01-15 0001864531 vsee:SilverbackCapitalSettlementAgreementMember us-gaap:SubsequentEventMember 2026-10-14 0001864531 vsee:SilverbackCapitalSettlementAgreementMember us-gaap:SubsequentEventMember 2026-10-14 2026-10-14 0001864531 vsee:SilverbackCapitalSettlementAgreementMember us-gaap:CommonStockMember 2026-07-01 2026-09-30 0001864531 vsee:SilverbackCapitalSettlementAgreementMember 2026-07-01 2026-09-30 0001864531 vsee:FutureReceiptsSaleAgreement1Member 2023-06-21 0001864531 vsee:FutureReceiptsSaleAgreement1Member 2023-06-28 0001864531 vsee:FutureReceiptsSaleAgreement1Member 2023-10-13 0001864531 vsee:NotePayableIssuedNovember292021Member 2021-11-29 0001864531 vsee:LineOfCreditIssuedNovember292021Member 2023-11-01 2023-11-01 0001864531 vsee:LineOfCreditIssuedNovember292021Member 2025-01-01 2025-12-31 0001864531 vsee:NotePayableIssuedNovember292021Member 2023-11-01 2023-11-01 0001864531 2026-01-15 0001864531 2021-11-29 0001864531 2021-11-29 2021-11-29 0001864531 vsee:NotePayableIssuedNovember292021Member 2026-09-30 0001864531 vsee:NotePayableIssuedNovember292021Member 2025-12-31 0001864531 vsee:NotePayableIssuedNovember292021Member 2025-07-01 2025-09-30 0001864531 vsee:NotePayableIssuedNovember292021Member 2025-01-01 2025-09-30 0001864531 vsee:NotePayableIssuedDecember12021Member 2021-12-01 0001864531 vsee:NotePayableIssuedDecember12021Member 2022-02-25 0001864531 vsee:NotePayableIssuedDecember12021Member 2026-09-30 0001864531 vsee:NotePayableIssuedDecember12021Member 2025-12-31 0001864531 vsee:NotePayableIssuedDecember12021Member 2024-01-01 2024-01-01 0001864531 vsee:IdocNoteMember 2026-07-01 2026-09-30 0001864531 vsee:IdocNoteMember 2026-01-01 2026-09-30 0001864531 vsee:IdocNoteMember 2025-07-01 2025-09-30 0001864531 vsee:IdocNoteMember 2025-01-01 2025-09-30 0001864531 vsee:NotePayableIssuedAugust32023Member 2023-08-03 0001864531 vsee:NotePayableIssuedAugust32023Member 2023-08-03 2023-08-03 0001864531 vsee:IssuedDebtOnAugust32023Member 2026-07-01 2026-09-30 0001864531 vsee:IssuedDebtOnAugust32023Member 2026-01-01 2026-09-30 0001864531 vsee:IssuedDebtOnAugust32023Member 2025-07-01 2025-09-30 0001864531 vsee:IssuedDebtOnAugust32023Member 2025-01-01 2025-09-30 0001864531 us-gaap:LineOfCreditMember 2026-09-30 0001864531 us-gaap:LineOfCreditMember 2025-12-31 0001864531 vsee:NotePayableIssuedAugust32023Member 2026-09-30 0001864531 vsee:NotePayableIssuedAugust32023Member 2025-12-31 0001864531 vsee:NotePayableIssuedAugust182023Member 2023-08-18 0001864531 vsee:NotePayableIssuedAugust182023Member 2023-08-18 2023-08-18 0001864531 vsee:NotePayableIssuedAugust182023Member 2026-09-30 0001864531 vsee:NotePayableIssuedAugust182023Member 2025-12-31 0001864531 vsee:NotePayableIssuedAugust182023Member 2026-07-01 2026-09-30 0001864531 vsee:NotePayableIssuedAugust182023Member 2026-01-01 2026-09-30 0001864531 vsee:NotePayableIssuedAugust182023Member 2025-07-01 2025-09-30 0001864531 vsee:NotePayableIssuedAugust182023Member 2025-01-01 2025-09-30 0001864531 srt:MaximumMember vsee:NotePayableIssuedAugust182023Member 2026-09-30 0001864531 srt:MinimumMember vsee:NotePayableIssuedAugust182023Member 2025-12-31 0001864531 vsee:March2025PromissoryNoteMember 2025-03-20 0001864531 vsee:SecuredPromissoryNoteIssuedOnMarch202025Member 2025-03-20 2025-03-20 0001864531 vsee:March2025PromissoryNoteMember 2025-03-20 2025-03-20 0001864531 vsee:OnNovember112025PromissoryNoteMember 2025-11-11 0001864531 vsee:OnNovember112025PromissoryNoteMember 2025-11-11 2025-11-11 0001864531 vsee:OnNovember112025PromissoryNoteMember 2025-07-01 2025-09-30 0001864531 vsee:OnNovember112025PromissoryNoteMember 2025-01-01 2025-09-30 0001864531 vsee:MasterBusinessLoanAgreementMember vsee:InitialMBLANoteMember 2025-09-05 2025-09-05 0001864531 vsee:MasterBusinessLoanAgreementMember vsee:InitialMBLANoteMember us-gaap:DebtInstrumentRedemptionPeriodOneMember 2025-09-05 2025-09-05 0001864531 vsee:MasterBusinessLoanAgreementMember vsee:InitialMBLANoteMember us-gaap:DebtInstrumentRedemptionPeriodTwoMember 2025-09-05 2025-09-05 0001864531 vsee:MasterBusinessLoanAgreementMember vsee:InitialMBLANoteMember 2025-09-05 0001864531 vsee:MasterBusinessLoanAgreementMember srt:MinimumMember vsee:InitialMBLANoteMember 2025-09-05 2025-09-05 0001864531 vsee:September2025PromissoryNoteMember 2026-09-30 0001864531 vsee:September2025PromissoryNoteMember 2025-12-31 0001864531 vsee:September2025PromissoryNoteMember 2026-07-01 2026-09-30 0001864531 vsee:September2025PromissoryNoteMember 2026-01-01 2026-09-30 0001864531 vsee:September2025PromissoryNoteMember 2025-07-01 2025-09-30 0001864531 vsee:September2025PromissoryNoteMember 2025-01-01 2025-09-30 0001864531 vsee:OctoberPromissoryNoteMember 2025-10-09 0001864531 vsee:OctoberPromissoryNoteMember 2025-10-09 2025-10-09 0001864531 srt:MaximumMember vsee:OctoberPromissoryNoteMember 2025-10-09 0001864531 vsee:OctoberPromissoryNoteMember 2025-07-01 2025-09-30 0001864531 vsee:OctoberPromissoryNoteMember 2025-01-01 2025-09-30 0001864531 vsee:OctoberPromissoryNoteTwoMember 2025-10-20 0001864531 vsee:OctoberPromissoryNoteTwoMember 2025-10-20 2025-10-20 0001864531 srt:MaximumMember vsee:OctoberPromissoryNoteTwoMember 2025-10-20 0001864531 vsee:OctoberPromissoryNoteTwoMember 2025-07-01 2025-09-30 0001864531 vsee:OctoberPromissoryNoteTwoMember 2025-01-01 2025-09-30 0001864531 vsee:FirstInsuranceFundingAgreementMember 2026-09-30 0001864531 vsee:FirstInsuranceFundingAgreementMember 2026-01-01 0001864531 vsee:FirstInsuranceFundingAgreementMember 2026-01-01 2026-09-30 0001864531 vsee:FirstInsuranceFundingAgreementMember 2025-12-31 0001864531 us-gaap:LineOfCreditMember 2026-01-15 2026-01-15 0001864531 us-gaap:LineOfCreditMember 2026-01-01 2026-09-30 0001864531 vsee:LineOfCreditIssuedNovember292021Member 2026-07-01 2026-09-30 0001864531 vsee:LineOfCreditIssuedNovember292021Member 2026-01-01 2026-09-30 0001864531 vsee:LineOfCreditIssuedNovember292021Member 2025-07-01 2025-09-30 0001864531 vsee:LineOfCreditIssuedNovember292021Member 2025-01-01 2025-09-30 0001864531 vsee:EncompassSBALoanMember 2026-02-16 2026-02-16 0001864531 vsee:EncompassSBALoanMember 2021-09-25 0001864531 vsee:EncompassSBALoanMember 2026-09-30 0001864531 vsee:EncompassSBALoanMember 2026-07-01 2026-09-30 0001864531 vsee:EncompassSBALoanMember 2026-01-01 2026-09-30 0001864531 vsee:EncompassSBALoanMember 2025-12-31 0001864531 vsee:FirstInsuranceFundingLoanMember 2026-09-30 0001864531 vsee:FirstInsuranceFundingLoanMember 2025-12-31 0001864531 vsee:March2025ConvertibleNoteMember 2025-03-20 0001864531 vsee:March2025ConvertibleNoteMember 2025-03-20 2025-03-20 0001864531 vsee:March2025ConvertibleNoteMember 2025-03-31 0001864531 vsee:March2025ConvertibleNoteMember 2025-01-31 2025-03-31 0001864531 2025-01-31 2025-03-31 0001864531 vsee:March2025ConvertibleNoteMember 2025-01-01 2025-03-31 0001864531 vsee:October212025ConvertibleNoteMember 2025-10-21 0001864531 vsee:October212025ConvertibleNoteMember 2025-10-21 2025-10-21 0001864531 vsee:March2025ConvertibleNoteMember 2025-07-01 2025-09-30 0001864531 vsee:March2025ConvertibleNoteMember 2025-01-01 2025-09-30 0001864531 vsee:April2025PromissoryNoteMember 2025-04-15 0001864531 vsee:April2025PromissoryNoteMember 2025-04-15 2025-04-15 0001864531 vsee:May2025ConvertiblePromissoryNoteMember 2025-05-30 0001864531 vsee:May2025ConvertiblePromissoryNoteMember 2025-05-01 2025-05-31 0001864531 vsee:May2025ConvertiblePromissoryNoteMember 2025-05-31 0001864531 vsee:April2025PromissoryNoteMember 2025-05-31 0001864531 vsee:May2025ConvertibleNoteMember 2025-05-30 0001864531 vsee:April2025PromissoryNoteMember 2025-05-30 0001864531 vsee:May2025ConvertibleNoteMember 2025-05-30 2025-05-30 0001864531 vsee:May2025ConvertibleNoteMember 2025-09-03 0001864531 vsee:May2025ConvertibleNoteMember 2026-02-23 0001864531 vsee:May2025ConvertibleNoteMember 2026-02-23 2026-02-23 0001864531 vsee:May2025ConvertibleNoteMember 2026-07-01 2026-09-30 0001864531 vsee:May2025ConvertibleNoteMember 2026-01-01 2026-09-30 0001864531 vsee:May2025ConvertibleNoteMember 2025-07-01 2025-09-30 0001864531 vsee:May2025ConvertibleNoteMember 2025-01-01 2025-09-30 0001864531 vsee:October2025ConvertibleNoteMember 2025-10-29 0001864531 vsee:October2025ConvertibleNoteMember 2025-10-29 2025-10-29 0001864531 vsee:October2025ConvertibleNoteMember 2025-12-08 2025-12-08 0001864531 vsee:October2025ConvertibleNoteMember 2025-12-08 0001864531 vsee:ExchangeNoteMember vsee:BridgeNotesMember vsee:BridgeSecuritiesPurchaseAgreementMember 2022-10-05 0001864531 vsee:ExchangeNoteMember vsee:BridgeNotesMember vsee:BridgeSecuritiesPurchaseAgreementMember vsee:BridgeInvestorMember 2022-10-05 0001864531 vsee:ExchangeNoteMember vsee:VseeNoteMember 2023-11-21 0001864531 vsee:ExchangeNoteMember vsee:IdocNoteMember 2023-11-21 0001864531 vsee:ExchangeNoteMember vsee:BridgeExchangeAgreementMember vsee:BridgeInvestorMember 2023-11-21 0001864531 vsee:ExchangeNoteMember 2024-06-24 0001864531 vsee:ExchangeNoteMember 2024-06-24 2024-06-24 0001864531 vsee:ExchangeNoteMember 2024-08-08 0001864531 vsee:ExchangeNoteMember 2024-08-08 2024-08-08 0001864531 vsee:ExchangeNoteMember 2024-11-26 0001864531 vsee:ExchangeNoteMember 2024-11-26 2024-11-26 0001864531 vsee:ExchangeNoteMember 2025-09-03 0001864531 vsee:ExchangeNoteMember 2025-09-03 2025-09-03 0001864531 vsee:ExchangeNoteMember 2025-10-31 0001864531 vsee:ExchangeNoteMember 2025-10-31 2025-10-31 0001864531 vsee:ExchangeNoteMember 2025-07-01 2025-09-30 0001864531 vsee:ExchangeNoteMember 2025-01-01 2025-09-30 0001864531 vsee:QuantumNoteMember 2023-11-21 0001864531 vsee:QuantumNoteMember 2024-07-03 2024-07-03 0001864531 vsee:QuantumNoteMember 2024-06-25 0001864531 vsee:QuantumNoteMember 2024-06-25 2024-06-25 0001864531 srt:MinimumMember vsee:QuantumNoteMember 2024-06-25 2024-06-25 0001864531 vsee:QuantumNoteMember 2025-04-04 0001864531 vsee:QuantumNoteMember 2025-08-28 0001864531 vsee:QuantumNoteMember 2025-10-28 0001864531 srt:MinimumMember vsee:QuantumConvertibleNoteMember 2025-08-28 0001864531 srt:MaximumMember vsee:QuantumConvertibleNoteMember 2025-08-28 0001864531 vsee:QuantumConvertibleNoteMember 2025-08-28 0001864531 vsee:October2025QuantumConvertibleNoteMember 2025-10-31 0001864531 vsee:October2025QuantumConvertibleNoteMember 2025-10-31 2025-10-31 0001864531 vsee:May2026QuantumConvertibleNoteMember 2026-05-31 0001864531 vsee:May2026QuantumConvertibleNoteMember 2026-05-31 2026-05-31 0001864531 vsee:QuantumConvertibleNoteMember 2026-09-30 0001864531 vsee:QuantumConvertibleNoteMember 2025-12-31 0001864531 vsee:QuantumConvertibleNoteMember 2026-07-01 2026-09-30 0001864531 vsee:QuantumConvertibleNoteMember 2026-01-01 2026-09-30 0001864531 vsee:QuantumConvertibleNoteMember 2025-07-01 2025-09-30 0001864531 vsee:QuantumConvertibleNoteMember 2025-01-01 2025-09-30 0001864531 vsee:September2024ConvertibleNoteMember 2024-09-30 0001864531 vsee:September2024ConvertibleNoteMember 2024-09-30 2024-09-30 0001864531 vsee:September2024ConvertibleNoteMember us-gaap:DebtInstrumentRedemptionPeriodOneMember 2024-09-30 2024-09-30 0001864531 vsee:September2024ConvertibleNoteMember us-gaap:DebtInstrumentRedemptionPeriodTwoMember 2024-09-30 2024-09-30 0001864531 vsee:September2024ConvertibleNoteMember 2025-10-31 0001864531 vsee:September2024ConvertibleNoteMember 2025-10-31 2025-10-31 0001864531 srt:MinimumMember vsee:September2024ConvertibleNoteMember 2025-10-31 0001864531 srt:MaximumMember vsee:September2024ConvertibleNoteMember 2025-10-31 0001864531 vsee:September2024ConvertibleNoteMember 2026-06-30 2026-06-30 0001864531 us-gaap:CommonStockMember 2026-06-30 2026-06-30 0001864531 vsee:September2024ConvertibleNoteMember 2025-07-01 2025-09-30 0001864531 vsee:September2024ConvertibleNoteMember 2025-01-01 2025-09-30 0001864531 vsee:QuantumNoteMember 2025-07-01 2025-09-30 0001864531 vsee:ADIFundingConvertibleNoteMember 2026-06-08 0001864531 vsee:ADIFundingConvertibleNoteMember 2026-06-08 2026-06-08 0001864531 vsee:ADIFundingConvertibleNoteMember 2026-06-08 0001864531 srt:MaximumMember vsee:ADIFundingConvertibleNoteMember 2026-06-08 2026-06-08 0001864531 vsee:ADIFundingConvertibleNoteMember 2026-06-12 0001864531 vsee:ADIPromissoryNoteMember 2026-06-12 2026-06-12 0001864531 vsee:ADIPromissoryNoteMember 2026-06-12 0001864531 vsee:ADIPromissoryNoteMember 2026-07-01 2026-09-30 0001864531 vsee:ADIPromissoryNoteMember 2026-01-01 2026-09-30 0001864531 vsee:ADIFundingConvertibleNoteMember 2026-07-21 0001864531 vsee:ADIFundingConvertibleNoteMember 2026-07-21 2026-07-21 0001864531 vsee:ADIFundingConvertibleNoteMember 2026-09-30 0001864531 vsee:ADIFundingConvertibleNoteMember 2025-12-31 0001864531 vsee:ADIFundingConvertibleNoteMember 2026-07-01 2026-09-30 0001864531 vsee:ADIFundingConvertibleNoteMember 2026-01-01 2026-09-30 0001864531 vsee:ClearThinkConvertibleNoteMember 2026-06-22 0001864531 vsee:ClearThinkConvertibleNoteMember 2026-06-22 2026-06-22 0001864531 vsee:ClearThinkConvertibleNoteMember 2026-06-22 2026-06-22 0001864531 vsee:ClearThinkConvertibleNoteMember 2026-09-30 0001864531 vsee:ClearThinkConvertibleNoteMember 2025-12-31 0001864531 vsee:ClearThinkConvertibleNoteMember 2026-07-01 2026-09-30 0001864531 vsee:ClearThinkConvertibleNoteMember 2026-01-01 2026-09-30 0001864531 vsee:VanquishFundingConvertibleNoteMember 2026-06-18 0001864531 vsee:VanquishFundingConvertibleNoteMember 2026-06-18 2026-06-18 0001864531 vsee:VanquishFundingConvertibleNoteMember 2026-09-30 0001864531 vsee:VanquishFundingConvertibleNoteMember 2025-12-31 0001864531 vsee:VanquishFundingConvertibleNoteMember 2026-07-01 2026-09-30 0001864531 vsee:VanquishFundingConvertibleNoteTwoMember 2026-09-24 0001864531 vsee:VanquishFundingConvertibleNoteTwoMember us-gaap:SubsequentEventMember 2026-10-01 2026-10-01 0001864531 vsee:LabrysConvertiblePromissoryNoteMember 2026-07-08 0001864531 vsee:ConversionSecuritiesPurchaseAgreementsMember vsee:LabrysConvertiblePromissoryNoteMember 2026-07-08 2026-07-08 0001864531 vsee:LabrysConvertiblePromissoryNoteMember 2026-07-08 2026-07-08 0001864531 vsee:LabrysConvertiblePromissoryNoteMember 2026-09-30 0001864531 vsee:LabrysConvertiblePromissoryNoteMember 2025-12-31 0001864531 vsee:LabrysConvertiblePromissoryNoteMember 2026-07-01 2026-09-30 0001864531 vsee:LabrysConvertiblePromissoryNoteMember 2026-01-01 2026-09-30 0001864531 vsee:ADIPromissoryNoteMember 2026-07-21 0001864531 vsee:ADIPromissoryNoteMember 2026-09-30 0001864531 vsee:ADIPromissoryNoteMember 2025-12-31 0001864531 vsee:M2BPromissoryNoteMember 2026-07-21 0001864531 vsee:M2BPromissoryNoteMember 2026-07-01 2026-09-30 0001864531 vsee:M2BPromissoryNoteMember 2026-01-01 2026-09-30 0001864531 vsee:M2BPromissoryNoteMember 2026-09-30 0001864531 vsee:M2BPromissoryNoteMember 2025-12-31 0001864531 vsee:EquityLineOfCreditMember 2023-11-21 0001864531 vsee:EquityLineOfCreditMember 2023-11-21 2023-11-21 0001864531 vsee:IfStockPriceDropsBelow2DollarsMember vsee:EquityLineOfCreditMember 2023-11-21 0001864531 vsee:EquityLineOfCreditMember 2025-01-01 2025-12-31 0001864531 vsee:StandbyEquityPUrchaseAgreementMember 2026-06-02 2026-06-02 0001864531 2026-06-02 2026-06-02 0001864531 vsee:June2026SEPALiabilityMember 2026-01-01 2026-09-30 0001864531 vsee:StandbyEquityPUrchaseAgreementMember 2026-09-02 0001864531 vsee:StandbyEquityPUrchaseAgreementMember 2026-09-02 2026-09-02 0001864531 vsee:SEPAAgreementMember 2026-01-01 2026-09-30 0001864531 vsee:SEPAAgreementMember 2026-09-30 0001864531 vsee:SEPAAgreementMember 2026-07-01 2026-09-30 0001864531 vsee:ImoAisikuMember srt:ChiefExecutiveOfficerMember 2026-09-30 0001864531 vsee:ImoAisikuMember srt:ChiefExecutiveOfficerMember 2025-12-31 0001864531 vsee:IdocVirtualTelehealthSolutionsIncMember us-gaap:InvestorMember 2023-05-15 0001864531 vsee:IdocVirtualTelehealthSolutionsIncMember us-gaap:InvestorMember 2023-05-15 2023-05-15 0001864531 vsee:IdocVirtualTelehealthSolutionsIncMember srt:MinimumMember us-gaap:InvestorMember 2023-05-15 2023-05-15 0001864531 vsee:IdocVirtualTelehealthSolutionsIncMember srt:MaximumMember us-gaap:InvestorMember 2023-05-15 2023-05-15 0001864531 vsee:IdocVirtualTelehealthSolutionsIncMember srt:ChiefExecutiveOfficerMember 2026-09-30 0001864531 vsee:IdocVirtualTelehealthSolutionsIncMember srt:ChiefExecutiveOfficerMember 2025-12-31 0001864531 vsee:QuantumNoteMember vsee:QuantumInvestorMember 2023-11-21 0001864531 vsee:QuantumInvestorMember vsee:ScsCapitalPartnersLlcMember 2023-11-21 0001864531 vsee:QuantumInvestorMember vsee:ScsCapitalPartnersLlcMember 2026-09-30 0001864531 vsee:QuantumInvestorMember vsee:ScsCapitalPartnersLlcMember 2025-12-31 0001864531 vsee:AffiliateOfSponsorMember 2024-06-21 2024-06-21 0001864531 vsee:AffiliateOfSponsorMember 2024-06-21 0001864531 vsee:AffiliateOfSponsorMember 2026-09-30 0001864531 vsee:SponsorAffiliatesMember vsee:DigitalHealthAcquisitionCorpMember 2024-06-24 2024-06-24 0001864531 vsee:DigitalHealthAcquisitionCorpMember vsee:SponsorAffiliatesMember 2024-06-25 2024-06-25 0001864531 vsee:SponsorAffiliatesMember 2024-01-01 2024-12-31 0001864531 vsee:SponsorAffiliatesMember 2024-06-24 2024-06-24 0001864531 vsee:SponsorAffiliatesMember 2026-09-30 0001864531 vsee:SponsorAffiliatesMember 2025-12-31 0001864531 vsee:VseeLabIncMember vsee:MiltonChenMember srt:ChiefExecutiveOfficerMember 2026-05-31 0001864531 vsee:VseeLabIncMember vsee:EmployeesMember 2022-01-01 2022-12-31 0001864531 vsee:VseeLabIncMember vsee:EmployeesMember 2022-12-31 0001864531 vsee:VseeLabIncMember us-gaap:RelatedPartyMember 2022-12-31 0001864531 vsee:VseeLabIncMember vsee:MiltonChenMember vsee:RelatedPartyPromissoryNoteOneMember srt:ChiefExecutiveOfficerMember 2022-01-01 2022-12-31 0001864531 vsee:VseeLabIncMember vsee:MiltonChenMember vsee:RelatedPartyPromissoryNoteOneMember srt:ChiefExecutiveOfficerMember 2023-03-29 0001864531 vsee:VseeLabIncMember vsee:MiltonChenMember vsee:RelatedPartyPromissoryNoteOneMember srt:ChiefExecutiveOfficerMember 2023-06-27 2023-06-27 0001864531 vsee:VseeLabIncMember vsee:MiltonChenMember vsee:RelatedPartyPromissoryNoteTwoMember srt:ChiefExecutiveOfficerMember 2025-12-31 0001864531 vsee:VseeLabIncMember vsee:MiltonChenMember vsee:RelatedPartyPromissoryNoteTwoMember srt:ChiefExecutiveOfficerMember 2026-07-01 2026-09-30 0001864531 vsee:VseeLabIncMember vsee:MiltonChenMember vsee:RelatedPartyPromissoryNoteOneMember srt:ChiefExecutiveOfficerMember 2026-01-01 2026-09-30 0001864531 vsee:VseeLabIncMember vsee:MiltonChenMember vsee:RelatedPartyPromissoryNoteOneMember srt:ChiefExecutiveOfficerMember 2025-01-01 2025-12-31 0001864531 vsee:VseeLabIncMember vsee:MiltonChenMember vsee:RelatedPartyPromissoryNoteTwoMember srt:ChiefExecutiveOfficerMember 2023-03-29 0001864531 vsee:VseeLabIncMember vsee:MiltonChenMember vsee:RelatedPartyPromissoryNoteTwoMember srt:ChiefExecutiveOfficerMember 2023-06-27 2023-06-27 0001864531 vsee:VseeLabIncMember vsee:MiltonChenMember vsee:RelatedPartyPromissoryNoteTwoMember srt:ChiefExecutiveOfficerMember 2026-01-01 2026-09-30 0001864531 vsee:VseeLabIncMember vsee:MiltonChenMember vsee:RelatedPartyPromissoryNoteTwoMember srt:ChiefExecutiveOfficerMember 2025-01-01 2025-12-31 0001864531 vsee:VseeLabIncMember vsee:MiltonChenMember vsee:RelatedPartyPromissoryNoteThreeMember srt:ChiefExecutiveOfficerMember 2023-12-26 0001864531 vsee:VseeLabIncMember vsee:MiltonChenMember vsee:RelatedPartyPromissoryNoteThreeMember srt:ChiefExecutiveOfficerMember 2024-03-28 2024-03-28 0001864531 vsee:VseeLabIncMember vsee:MiltonChenMember vsee:RelatedPartyPromissoryNoteThreeMember srt:ChiefExecutiveOfficerMember 2023-12-26 2023-12-26 0001864531 vsee:VseeLabIncMember vsee:MiltonChenMember vsee:RelatedPartyPromissoryNoteThreeMember srt:ChiefExecutiveOfficerMember 2025-12-31 0001864531 vsee:VseeLabIncMember vsee:MiltonChenMember vsee:RelatedPartyPromissoryNoteThreeMember srt:ChiefExecutiveOfficerMember 2026-07-01 2026-09-30 0001864531 vsee:VseeLabIncMember vsee:MiltonChenMember vsee:RelatedPartyPromissoryNoteThreeMember srt:ChiefExecutiveOfficerMember 2026-01-01 2026-09-30 0001864531 vsee:VseeLabIncMember vsee:MiltonChenMember vsee:RelatedPartyPromissoryNoteThreeMember srt:ChiefExecutiveOfficerMember 2025-01-01 2025-12-31 0001864531 2026-04-21 2026-04-21 0001864531 vsee:EncompassHealthcareBillingLlcMember vsee:IdocVirtualTelehealthSolutionsIncMember 2022-01-01 0001864531 vsee:EncompassHealthcareBillingLlcMember vsee:IdocVirtualTelehealthSolutionsIncMember 2022-01-01 2022-01-01 0001864531 vsee:EncompassHealthcareBillingLlcMember vsee:IdocVirtualTelehealthSolutionsIncMember 2023-01-09 0001864531 2026-02-16 2026-02-16 0001864531 vsee:EncompassHealthcareBillingLlcMember vsee:IdocVirtualTelehealthSolutionsIncMember 2026-09-30 0001864531 vsee:EncompassHealthcareBillingLlcMember vsee:IdocVirtualTelehealthSolutionsIncMember 2025-12-31 0001864531 vsee:PurchaseAgreementForTelepresenceRobotsMember 2026-01-01 2026-09-30 0001864531 vsee:PurchaseAgreementForTelepresenceRobotsMember 2026-09-30 0001864531 vsee:PurchaseAgreementForTelepresenceRobotsMember 2025-12-31 0001864531 vsee:IdocVirtualTelehealthSolutionsIncMember us-gaap:InvestorMember 2026-09-30 0001864531 us-gaap:InvestorMember 2026-01-01 2026-09-30 0001864531 vsee:IdocVirtualTelehealthSolutionsIncMember us-gaap:InvestorMember 2026-01-01 2026-09-30 0001864531 vsee:IdocVirtualTelehealthSolutionsIncMember srt:MinimumMember us-gaap:InvestorMember 2026-01-01 2026-09-30 0001864531 vsee:IdocVirtualTelehealthSolutionsIncMember srt:MaximumMember us-gaap:InvestorMember 2026-01-01 2026-09-30 0001864531 vsee:PurchaseAgreementForTelepresenceRobotsMember 2023-05-12 2023-05-12 0001864531 vsee:StockPurchaseAgreementWithGoMyRxIncMember 2026-01-16 2026-01-16 0001864531 vsee:StockPurchaseAgreementWithGoMyRxIncMember 2026-01-16 0001864531 vsee:EquityIncentivePlan2024Member 2026-01-01 2026-09-30 0001864531 vsee:EquityIncentivePlan2025Member 2026-01-01 2026-09-30 0001864531 vsee:EquityIncentivePlan2025Member 2026-09-30 0001864531 vsee:EquityIncentivePlan2025OneMember 2026-09-30 0001864531 vsee:EquityIncentivePlan2025TwoMember 2026-09-30 0001864531 vsee:ThreeCustomersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2026-01-01 2026-09-30 0001864531 vsee:ThreeCustomersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-12-31 0001864531 vsee:OneCustomerMember us-gaap:CustomerConcentrationRiskMember 2026-07-01 2026-09-30 0001864531 vsee:OneCustomerMember us-gaap:CustomerConcentrationRiskMember 2026-01-01 2026-09-30 0001864531 vsee:OneCustomerMember us-gaap:CustomerConcentrationRiskMember 2025-07-01 2025-09-30 0001864531 vsee:OneCustomerMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-09-30 0001864531 vsee:AccountsPayableAndAccruedLiabilityMember us-gaap:SupplierConcentrationRiskMember 2026-01-01 2026-09-30 0001864531 vsee:AccountsPayableAndAccruedLiabilityMember us-gaap:SupplierConcentrationRiskMember vsee:OneVendorMember 2025-01-01 2025-12-31 0001864531 vsee:AccountsPayableAndAccruedLiabilityMember us-gaap:SupplierConcentrationRiskMember 2025-01-01 2025-12-31 0001864531 country:US 2026-01-01 2026-09-30 0001864531 country:US 2025-01-01 2025-09-30 0001864531 country:US 2026-07-01 2026-09-30 0001864531 country:US 2025-07-01 2025-09-30 0001864531 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2026-09-30 0001864531 us-gaap:PreferredStockMember 2026-09-30 0001864531 us-gaap:PreferredStockMember 2025-12-31 0001864531 us-gaap:SeriesAPreferredStockMember 2026-01-01 2026-09-30 0001864531 srt:MaximumMember 2026-01-01 2026-09-30 0001864531 us-gaap:PrivatePlacementMember 2026-01-01 2026-09-30 0001864531 us-gaap:SeriesBPreferredStockMember us-gaap:PrivatePlacementMember 2026-01-01 2026-09-30 0001864531 us-gaap:SeriesBPreferredStockMember 2026-01-01 2026-09-30 0001864531 vsee:EquityIncentivePlan2024Member 2026-09-30 0001864531 vsee:EquityIncentivePlan2025Member 2025-12-30 0001864531 vsee:EquityIncentivePlan2025Member 2026-01-01 0001864531 vsee:EquityIncentivePlan2025Member 2026-01-01 2026-01-01 0001864531 vsee:StockOptionsMember 2026-07-01 2026-09-30 0001864531 us-gaap:EmployeeStockOptionMember 2025-07-01 2025-09-30 0001864531 vsee:StockOptionsMember 2026-01-01 2026-09-30 0001864531 vsee:StockOptionsMember 2025-01-01 2025-09-30 0001864531 vsee:IdocVirtualTelehealthSolutionsIncMember 2024-06-24 2024-06-24 0001864531 vsee:IdocVirtualTelehealthSolutionsIncMember 2024-06-24 0001864531 vsee:IdocVirtualTelehealthSolutionsIncMember 2026-09-30 0001864531 vsee:IdocVirtualTelehealthSolutionsIncMember 2025-12-31 0001864531 vsee:IdocVirtualTelehealthSolutionsIncMember 2026-01-01 2026-09-30 0001864531 vsee:IdocVirtualTelehealthSolutionsIncMember 2025-01-01 2025-09-30 0001864531 vsee:IdocVirtualTelehealthSolutionsIncMember 2026-07-01 2026-09-30 0001864531 vsee:IdocVirtualTelehealthSolutionsIncMember 2025-07-01 2025-09-30 0001864531 vsee:PublicAndPrivateWarrantsMember 2026-09-30 0001864531 vsee:PublicAndPrivateWarrantsMember 2025-12-31 0001864531 vsee:PublicAndPrivateWarrantsMember 2026-01-01 2026-09-30 0001864531 vsee:PrivatePlacementWarrantsMember 2026-01-01 2026-09-30 0001864531 vsee:BridgeWarrantsMember 2022-10-06 0001864531 vsee:ExtensionWarrantsMember 2023-05-05 2023-05-05 0001864531 vsee:ExtensionWarrantsMember 2023-05-05 0001864531 vsee:September2024NoteWarrantsMember 2024-09-30 2024-09-30 0001864531 vsee:September2024NoteWarrantsMember 2024-09-30 0001864531 vsee:WarrantExchangeAgreementMember 2025-10-29 0001864531 vsee:AltaMember vsee:WarrantExchangeAgreementMember us-gaap:CommonStockMember 2025-10-29 0001864531 vsee:WarrantExchangeAgreementMember 2025-10-29 2025-10-29 0001864531 vsee:WarrantExchangeAgreementMember vsee:AltaWarrantsExercisableCommonStockMember 2025-10-29 0001864531 vsee:WarrantExchangeAgreementMember vsee:AltaWarrantsExercisableCommonStockMember us-gaap:CommonStockMember 2025-10-29 0001864531 vsee:PrivatePlacementWithArmisticeMember 2025-11-25 0001864531 vsee:PrivatePlacementWithArmisticeMember vsee:CommonStockWarrantsMember vsee:PurchaseAgreementMember 2025-11-25 0001864531 vsee:PrivatePlacementWithArmisticeMember vsee:CommonStockWarrantsMember 2025-11-25 2025-11-25 0001864531 vsee:PrivatePlacementWithArmisticeMember 2025-11-25 2025-11-25 0001864531 vsee:PrivatePlacementWithArmisticeMember 2026-01-01 2026-09-30 0001864531 vsee:DHACAssumedWarrantsMember 2026-09-30 0001864531 vsee:DHACAssumedWarrantsMember 2026-01-01 2026-09-30 0001864531 vsee:PublicWarrantsMember 2024-03-31 0001864531 vsee:PrivateWarrantsMember 2024-03-31 0001864531 vsee:BridgeWarrantsMember 2024-03-31 0001864531 vsee:ExtensionWarrantsMember 2024-03-31 0001864531 vsee:September2024WarrantsMember 2023-12-31 0001864531 vsee:PreFundedWarrantMember 2024-03-31 0001864531 vsee:CommonStockWarrantsMember 2024-03-31 0001864531 2024-03-31 0001864531 vsee:PublicWarrantsMember 2024-04-01 2024-12-31 0001864531 vsee:PrivateWarrantsMember 2024-04-01 2024-12-31 0001864531 vsee:BridgeWarrantsMember 2024-04-01 2024-12-31 0001864531 vsee:ExtensionWarrantsMember 2024-04-01 2024-12-31 0001864531 vsee:September2024WarrantsMember 2024-01-01 2024-09-30 0001864531 vsee:PreFundedWarrantMember 2024-04-01 2024-12-31 0001864531 vsee:CommonStockWarrantsMember 2024-04-01 2024-12-31 0001864531 2024-04-01 2024-12-31 0001864531 vsee:PublicWarrantsMember 2024-12-31 0001864531 vsee:PrivateWarrantsMember 2024-12-31 0001864531 vsee:BridgeWarrantsMember 2024-12-31 0001864531 vsee:ExtensionWarrantsMember 2024-12-31 0001864531 vsee:September2024WarrantsMember 2024-09-30 0001864531 vsee:PreFundedWarrantMember 2024-12-31 0001864531 vsee:CommonStockWarrantsMember 2024-12-31 0001864531 us-gaap:OperatingSegmentsMember vsee:PatientFeesMember 2026-07-01 2026-09-30 0001864531 us-gaap:OperatingSegmentsMember vsee:PatientFeesMember 2025-07-01 2025-09-30 0001864531 us-gaap:OperatingSegmentsMember vsee:PatientFeesMember 2026-01-01 2026-09-30 0001864531 us-gaap:OperatingSegmentsMember vsee:PatientFeesMember 2025-01-01 2025-09-30 0001864531 us-gaap:OperatingSegmentsMember vsee:TelehealthFeesMember 2026-07-01 2026-09-30 0001864531 us-gaap:OperatingSegmentsMember vsee:TelehealthFeesMember 2025-07-01 2025-09-30 0001864531 us-gaap:OperatingSegmentsMember vsee:TelehealthFeesMember 2026-01-01 2026-09-30 0001864531 us-gaap:OperatingSegmentsMember vsee:TelehealthFeesMember 2025-01-01 2025-09-30 0001864531 us-gaap:OperatingSegmentsMember vsee:InstitutionalFeesMember 2026-07-01 2026-09-30 0001864531 us-gaap:OperatingSegmentsMember vsee:InstitutionalFeesMember 2025-07-01 2025-09-30 0001864531 us-gaap:OperatingSegmentsMember vsee:InstitutionalFeesMember 2026-01-01 2026-09-30 0001864531 us-gaap:OperatingSegmentsMember vsee:InstitutionalFeesMember 2025-01-01 2025-09-30 0001864531 us-gaap:OperatingSegmentsMember 2026-07-01 2026-09-30 0001864531 us-gaap:OperatingSegmentsMember 2025-07-01 2025-09-30 0001864531 us-gaap:OperatingSegmentsMember 2026-01-01 2026-09-30 0001864531 us-gaap:OperatingSegmentsMember 2025-01-01 2025-09-30 0001864531 us-gaap:CorporateNonSegmentMember 2026-07-01 2026-09-30 0001864531 us-gaap:CorporateNonSegmentMember 2025-07-01 2025-09-30 0001864531 us-gaap:CorporateNonSegmentMember 2026-01-01 2026-09-30 0001864531 us-gaap:CorporateNonSegmentMember 2025-01-01 2025-09-30 0001864531 vsee:ADIFundingConvertibleNoteMember 2026-09-30 0001864531 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember vsee:ADIFundingConvertibleNoteMember 2026-09-30 0001864531 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember vsee:ADIFundingConvertibleNoteMember 2026-09-30 0001864531 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember vsee:ADIFundingConvertibleNoteMember 2026-09-30 0001864531 vsee:ClearThinkConvertibleNoteMember 2026-09-30 0001864531 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember vsee:ClearThinkConvertibleNoteMember 2026-09-30 0001864531 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember vsee:ClearThinkConvertibleNoteMember 2026-09-30 0001864531 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember vsee:ClearThinkConvertibleNoteMember 2026-09-30 0001864531 vsee:CommonStockIssuanceObligationMember 2026-09-30 0001864531 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember vsee:CommonStockIssuanceObligationMember 2026-09-30 0001864531 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember vsee:CommonStockIssuanceObligationMember 2026-09-30 0001864531 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember vsee:CommonStockIssuanceObligationMember 2026-09-30 0001864531 vsee:June2026SEPALiabilityMember 2026-09-30 0001864531 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember vsee:June2026SEPALiabilityMember 2026-09-30 0001864531 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember vsee:June2026SEPALiabilityMember 2026-09-30 0001864531 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember vsee:June2026SEPALiabilityMember 2026-09-30 0001864531 vsee:SEPALiabilityMember 2026-09-30 0001864531 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember vsee:SEPALiabilityMember 2026-09-30 0001864531 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember vsee:SEPALiabilityMember 2026-09-30 0001864531 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember vsee:SEPALiabilityMember 2026-09-30 0001864531 vsee:LabrysConvertiblePromissoryNoteMember 2026-09-30 0001864531 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember vsee:LabrysConvertiblePromissoryNoteMember 2026-09-30 0001864531 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember vsee:LabrysConvertiblePromissoryNoteMember 2026-09-30 0001864531 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember vsee:LabrysConvertiblePromissoryNoteMember 2026-09-30 0001864531 vsee:M2BPromissoryNoteMember 2026-09-30 0001864531 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember vsee:M2BPromissoryNoteMember 2026-09-30 0001864531 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember vsee:M2BPromissoryNoteMember 2026-09-30 0001864531 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember vsee:M2BPromissoryNoteMember 2026-09-30 0001864531 vsee:ADIPromissoryNoteMember 2026-09-30 0001864531 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember vsee:ADIPromissoryNoteMember 2026-09-30 0001864531 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember vsee:ADIPromissoryNoteMember 2026-09-30 0001864531 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember vsee:ADIPromissoryNoteMember 2026-09-30 0001864531 vsee:QuantumConvertibleNoteRelatedPartyMember 2025-12-31 0001864531 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember vsee:QuantumConvertibleNoteRelatedPartyMember 2025-12-31 0001864531 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember vsee:QuantumConvertibleNoteRelatedPartyMember 2025-12-31 0001864531 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember vsee:QuantumConvertibleNoteRelatedPartyMember 2025-12-31 0001864531 vsee:CommonStockIssuanceObligationMember 2025-12-31 0001864531 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember vsee:CommonStockIssuanceObligationMember 2025-12-31 0001864531 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember vsee:CommonStockIssuanceObligationMember 2025-12-31 0001864531 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember vsee:CommonStockIssuanceObligationMember 2025-12-31 0001864531 vsee:May2025ConvertibleNoteMember 2025-12-31 0001864531 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember vsee:May2025ConvertibleNoteMember 2025-12-31 0001864531 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember vsee:May2025ConvertibleNoteMember 2025-12-31 0001864531 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember vsee:May2025ConvertibleNoteMember 2025-12-31 0001864531 vsee:QuantumConvertibleNoteMember 2026-01-01 2026-09-30 0001864531 vsee:QuantumConvertibleNoteMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-12-31 0001864531 vsee:QuantumConvertibleNoteMember us-gaap:MeasurementInputExpectedTermMember 2025-12-31 0001864531 vsee:QuantumConvertibleNoteMember us-gaap:MeasurementInputPriceVolatilityMember 2025-12-31 0001864531 vsee:QuantumConvertibleNoteMember us-gaap:MeasurementInputSharePriceMember 2025-12-31 0001864531 vsee:May2025ConvertibleNoteMember 2026-01-01 2026-09-30 0001864531 vsee:May2025ConvertibleNoteMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-12-31 0001864531 vsee:May2025ConvertibleNoteMember us-gaap:MeasurementInputExpectedTermMember 2025-12-31 0001864531 vsee:May2025ConvertibleNoteMember us-gaap:MeasurementInputPriceVolatilityMember 2025-12-31 0001864531 vsee:May2025ConvertibleNoteMember us-gaap:MeasurementInputSharePriceMember 2025-12-31 0001864531 vsee:ADIFundingConvertibleNoteMember 2026-01-01 2026-09-30 0001864531 vsee:ADIFundingLLCConvertibleNoteMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2026-09-30 0001864531 vsee:ADIFundingLLCConvertibleNoteMember us-gaap:MeasurementInputExpectedTermMember 2026-09-30 0001864531 vsee:ADIFundingLLCConvertibleNoteMember us-gaap:MeasurementInputPriceVolatilityMember 2026-09-30 0001864531 vsee:ADIFundingLLCConvertibleNoteMember us-gaap:MeasurementInputSharePriceMember 2026-09-30 0001864531 vsee:ClearThinkConvertibleNoteMember 2026-01-01 2026-09-30 0001864531 vsee:ClearThinkConvertibleNoteMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2026-09-30 0001864531 vsee:ClearThinkConvertibleNoteMember us-gaap:MeasurementInputExpectedTermMember 2026-09-30 0001864531 vsee:ClearThinkConvertibleNoteMember us-gaap:MeasurementInputPriceVolatilityMember 2026-09-30 0001864531 vsee:ClearThinkConvertibleNoteMember us-gaap:MeasurementInputSharePriceMember 2026-09-30 0001864531 vsee:VanquishFundingConvertibleNoteMember 2026-01-01 2026-09-30 0001864531 vsee:VanquishFundingConvertibleNoteMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2026-09-30 0001864531 vsee:VanquishFundingConvertibleNoteMember us-gaap:MeasurementInputExpectedTermMember 2026-09-30 0001864531 vsee:VanquishFundingConvertibleNoteMember us-gaap:MeasurementInputPriceVolatilityMember 2026-09-30 0001864531 vsee:VanquishFundingConvertibleNoteMember us-gaap:MeasurementInputSharePriceMember 2026-09-30 0001864531 vsee:SEPALiabilityMember 2026-01-01 2026-09-30 0001864531 vsee:SEPALiabilityMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2026-09-30 0001864531 vsee:SEPALiabilityMember us-gaap:MeasurementInputExpectedTermMember 2026-09-30 0001864531 vsee:SEPALiabilityMember us-gaap:MeasurementInputPriceVolatilityMember 2026-09-30 0001864531 vsee:SEPALiabilityMember us-gaap:MeasurementInputSharePriceMember 2026-09-30 0001864531 vsee:LabrysConvertiblePromissoryNoteMember 2026-01-01 2026-09-30 0001864531 vsee:LabrysConvertiblePromissoryNoteMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2026-09-30 0001864531 vsee:LabrysConvertiblePromissoryNoteMember us-gaap:MeasurementInputExpectedTermMember 2026-09-30 0001864531 vsee:LabrysConvertiblePromissoryNoteMember us-gaap:MeasurementInputPriceVolatilityMember 2026-09-30 0001864531 vsee:LabrysConvertiblePromissoryNoteMember us-gaap:MeasurementInputSharePriceMember 2026-09-30 0001864531 vsee:M2BPromissoryNoteMember 2026-01-01 2026-09-30 0001864531 vsee:M2BPromissoryNoteMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2026-09-30 0001864531 vsee:M2BPromissoryNoteMember us-gaap:MeasurementInputExpectedTermMember 2026-09-30 0001864531 vsee:M2BPromissoryNoteMember us-gaap:MeasurementInputPriceVolatilityMember 2026-09-30 0001864531 vsee:M2BPromissoryNoteMember us-gaap:MeasurementInputSharePriceMember 2026-09-30 0001864531 vsee:ADIPromissoryNoteMember 2026-01-01 2026-09-30 0001864531 vsee:ADIPromissoryNoteMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2026-09-30 0001864531 vsee:ADIPromissoryNoteMember us-gaap:MeasurementInputExpectedTermMember 2026-09-30 0001864531 vsee:ADIPromissoryNoteMember us-gaap:MeasurementInputPriceVolatilityMember 2026-09-30 0001864531 vsee:ADIPromissoryNoteMember us-gaap:MeasurementInputSharePriceMember 2026-09-30 0001864531 vsee:QuantumConvertibleNoteMember 2025-12-31 0001864531 vsee:ADIFundingConvertibleNoteMember 2025-12-31 0001864531 vsee:ClearThinkConvertibleNoteMember 2025-12-31 0001864531 vsee:VanquishFundingConvertibleNoteMember 2025-12-31 0001864531 vsee:SEPALiabilityMember 2025-12-31 0001864531 vsee:LabrysConvertiblePromissoryNoteMember 2025-12-31 0001864531 vsee:M2BPromissoryNoteMember 2025-12-31 0001864531 vsee:ADIPromissoryNoteMember 2025-12-31 0001864531 vsee:QuantumConvertibleNoteMember 2026-09-30 0001864531 vsee:May2025ConvertibleNoteMember 2026-09-30 0001864531 vsee:VanquishFundingConvertibleNoteMember 2026-09-30 0001864531 vsee:QuantumConvertibleNoteMember 2024-12-31 0001864531 vsee:ExchangeNoteMember 2024-12-31 0001864531 vsee:ELOCMember 2024-12-31 0001864531 vsee:SeptemberConvertibleNoteMember 2024-12-31 0001864531 vsee:March2025ConvertibleNoteMember 2024-12-31 0001864531 vsee:May2025ConvertibleNoteMember 2024-12-31 0001864531 vsee:QuantumConvertibleNoteMember 2025-01-01 2025-09-30 0001864531 vsee:ExchangeNoteMember 2025-01-01 2025-09-30 0001864531 vsee:ELOCMember 2025-01-01 2025-09-30 0001864531 vsee:SeptemberConvertibleNoteMember 2025-01-01 2025-09-30 0001864531 vsee:March2025ConvertibleNoteMember 2025-01-01 2025-09-30 0001864531 vsee:May2025ConvertibleNoteMember 2025-01-01 2025-09-30 0001864531 vsee:QuantumConvertibleNoteMember 2025-09-30 0001864531 vsee:ExchangeNoteMember 2025-09-30 0001864531 vsee:ELOCMember 2025-09-30 0001864531 vsee:SeptemberConvertibleNoteMember 2025-09-30 0001864531 vsee:March2025ConvertibleNoteMember 2025-09-30 0001864531 vsee:May2025ConvertibleNoteMember 2025-09-30 0001864531 vsee:VanquishFundingConvertibleNoteMember us-gaap:SubsequentEventMember 2026-10-01 2026-10-01 0001864531 vsee:VanquishFundingConvertibleNoteMember us-gaap:SubsequentEventMember 2026-10-01 xbrli:shares iso4217:USD iso4217:USD xbrli:shares vsee:segment xbrli:pure vsee:customer vsee:Installment vsee:tradingdays vsee:robot vsee:day vsee:vote

Keep reading